NZ525169A - Spiroheterocyclic nitriles (amidino and guanidino peptidyl compounds) useful as reversible inhibitors of cysteine proteases - Google Patents

Spiroheterocyclic nitriles (amidino and guanidino peptidyl compounds) useful as reversible inhibitors of cysteine proteases

Info

Publication number
NZ525169A
NZ525169A NZ525169A NZ52516901A NZ525169A NZ 525169 A NZ525169 A NZ 525169A NZ 525169 A NZ525169 A NZ 525169A NZ 52516901 A NZ52516901 A NZ 52516901A NZ 525169 A NZ525169 A NZ 525169A
Authority
NZ
New Zealand
Prior art keywords
cyano
piperidin
methyl
cyclohexyl
ylcarbamoyl
Prior art date
Application number
NZ525169A
Inventor
Younes Bekkali
Eugene R Hickey
Usha R Patel
Denice M Spero
Sanxing Sun
David S Thomson
Yancey D Ward
Erick R R Young
Weimin Liu
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of NZ525169A publication Critical patent/NZ525169A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)

Abstract

Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formula (Ia) where R1, R2, R3, R4, R5, R6, Het and X are as described in the specification. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds.

Description

<div class="application article clearfix" id="description"> <p class="printTableText" lang="en">New Zealand Paient Spedficaiion for Paient Number 525169 <br><br> 15 <br><br> 525169 <br><br> WO 02/20485 PCT/USO1/08084 <br><br> SPIROHETEROCVCLIC NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES <br><br> RELATED APPLICATION DATA <br><br> 5 This application is a continuation-in-part of US application serial no. 09/655,351 filed September 8,2000. <br><br> TECHNICAL FIELD OF THE INVENTION <br><br> 10 This invention relates to amidino and guanidino peptidyl compounds active as cysteine protease inhibitors. The compounds are reversible inhibitors of the cysteine protease cathepsin S, K, F, L and B are therefore useful in the treatment of autoimmune and other diseases. The invention also relates to processes for preparing such compounds and pharmaceutical compositions comprising them. <br><br> BACKGROUND OF THE INVENTION <br><br> Cathepsin S and cathepsin K are members of the papain family, within the papain superfamily of cysteine proteases. The papain family is the largest group of cysteine 20 proteases and includes proteases such as cathepsins B, H, K, L, O and S. (AJ. Barrett et al., 1996, Perspectives in Drug Discovery and Design, 6,1). The cysteine proteases have important roles in human biology and diseases including atherosclerosis, emphysema, osteoporosis, chronic inflammation and immune disorders (H.A. Chapman et al., 1997, Ann. Rev. Physiol., 59,63). Cathepsin S plays a key role in regulating antigen 25 presentation and immunity (H.A. Chapman, 1998, Current Opinion in Immunology, 10, 93; R. J. Riese et al., 1998, J. Clin. Invest., 101,2351; R.J. Riese et al., 1996, Immunity, 4, 357). Cathepsin S deficient mice have impaired invariant chain degradation resulting in decreased antigen presentation and germinal center formation, and diminished susceptibility to collagen-induced arthritis indicating the therapeutic potential for a 30 cathepsin S inhibitor (G. Shi et al,, 1999, Immunity, 10,197; T.Y. Nakagawa et al, 1999, Immunity, 10,207) <br><br> 1 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> The specificity of the immune response relies on processing of foreign protein and presentation of antigenic peptide at the cell surface. Antigenic peptide is presented bound to MHC Class II, a heterodimeric glycoprotein expressed in certain antigen presenting 5 cells of hematopoietic lineage, such as B cells, macrophages and dendritic cells. Presentation of antigen to effector cells, such as T-cells, is a fundamental step in recognition of non-self and thus initiation of the immune response. <br><br> Recently MHC Class II heterodimers were shown to associate intracellularly with a third 10 molecule designated invariant chain. Invariant chain facilitates Class II transport to the endosomal compartment and stabilizes the Class II protein prior to loading with antigen. Invariant chain interacts directly with Class II dimers in the antigen-binding groove and therefore must be proteolyzed and removed or antigen cannot be loaded or presented. Current research suggests that invariant chain is selectively proteolyzed by cathepsin S, 15 which is compartmentalized with MHC Class II complexes within the cell. Cathepsin S degrades invariant chain to a small peptide, termed CLIP, which occupies the antigen -binding groove. CLIP is released from MHC Class II by the interaction of MHC Class II with HLA-DM, a MHC-like molecule thus freeing MHC Class II to associate with antigenic peptides. MHC Class II-antigen complexes are then transported to the cell 20 surface for presentation to T-cells, and initiation of the immune response. <br><br> Cathepsin S, through proteolytic degradation of invariant chain to CLIP, provides a fundamental step in generation of an immune response. It follows that inhibition of antigen presentation via prevention of invariant chain degradation by cathepsin S could 25 provide a mechanism for immuno-regulation. Control of antigen-specific immune responses has long been desirable as a useful and safe therapy for autoimmune diseases. Such diseases include Crohn's disease and arthritis, as well as other T-cell-mediated immune responses (C. Janeway and P. Travers, 1996, Immunobiology, The Immune System in Health and Disease, Chapter 12). Furthermore, cathepsin S, which has broad 30 pH specificity, has been implicated in a variety of other diseases involving extracellular proteolysis, such as Alzheimer's disease (U. Muller-Ladner et al., 1996, Perspectives in <br><br> 2 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> Drug Discovery and Design, 6, 87), atherosclerosis (G.K. Sukhova et al., 1998, J. Clin. Invest., 102, 576) and endometriosis (WO 9963115,1999). <br><br> A cathepsin S inhibitor has been found to block the rise in IgE titers and eosinophil 5 infiltration in the lung in a mouse model of pulmonary hypersensitivity, suggesting that cathepsin S may be involved in asthma (RJ. Riese et al., J. Clin. Investigation,1998,101, 2351). <br><br> Another cysteine protease, cathepsin F has been found in macrophages and is also 10 involved in antigen processing. It has been postulated that cathepsin F in stimulated lung macrophages and possibly other antigen presenting cells could play a role in airway inflammation (G.-P. Shi et al., J. Exp. Med., 2000,191,1177). <br><br> Cathepsin K, another cysteine protease has been found to be highly expressed in 15 osteoclasts and to degrade bone collagen and other bone matrix proteins. Inhibitors of cathepsin K have been shown to inhibit bone resorption in mice. Therefore, cathepsin K may play a role in osteoclastic bone resorption and cathepsin K inhibitors may be useful in the treatment of diseases involving bone resoiption such as osteoporosis (F. Lazner et al., Human Molecular Genetics, 1999, 8,1839). <br><br> 20 <br><br> Cysteine proteases are characterized by having a cysteine residue at the active site which serves as a nucleophile. The active site also contains a histidine residue. The imidazole ring on the histidine serves as a base to generate a thiolate anion on the active site cysteine, increasing its nucleophilicity. When a substrate is recognized by the protease, 25 the amide bond to be cleaved is directed to the active site, where the thiolate attacks the carbonyl carbon forming an acyl-enzyme intermediate and cleaving the amide bond, liberating an amine. Subsequently, water cleaves the acyl-enzyme species regenerating the enzyme and liberating the other cleavage product of the substrate, a carboxylic acid. <br><br> 30 Inhibitors of cysteine proteases contain a functionality that can react reversibly or irreversibly with the active site cysteine. Examples of reactive functionalities that have <br><br> 3 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> been described (D. Rasnick, 1996, Perspectives in Drug Discovery and Design, 6,47) on cysteine protease inhibitors include peptidyl diazomethanes, epoxides, <br><br> monofluoroalkanes and acyloxymethanes, which irreversibly alkylate the cysteine thiol. Other irreversible inhibitors include Michael acceptors such as peptidyl vinyl esters and 5 other carboxylic acid derivatives (S. Liu et al., J. Med Chem., 1992, 35, 1067) and vinyl sulfones (J.T. Palmer et al., 1995, J. Med Chem., 38, 3193). <br><br> Reactive functionalities that form reversible complexes with the active site cysteine include peptidyl aldehydes (R.P. Hanzlik et al., 1991, Biochim. Biophys. Acta., 1073, 10 33), which are non-selective, inhibiting both cysteine and serine proteases as well as other nucleophiles. Peptidyl nitriles (R.P. Hanzlik et al., 1990, Biochim. Biophys. Acta., 1035, 62) are less reactive than aldehydes and therefore more selective for the more nucleophilic cysteine proteases. Various reactive ketones have also been reported to be reversible inhibitors of cysteine proteases (D. Rasnick, 1996, ibid). In addition to 15 reacting with the nucleophilic cysteine of the active site, reactive ketones may react with water, forming a hemiketal which may act as a transition state inhibitor. <br><br> Examples of cathepsin S inhibitors have been reported. J.L. Klaus et al. (WO 9640737) described reversible inhibitors of cysteine proteases including cathepsin S, containing an 20 ethylene diamine. In US Patent No. 5,776,718 to Palmer et al. there is disclosed in it's broadest generic aspect a protease inhibitor comprising a targeting group linked through a two carbon atom chain to an electron withdrawing group (EWG). The compounds of the present application are structurally distinct and thus excluded from the 5,776,718 patent with particular embodiments possessing unexpectedly greater activity than the closest 25 compounds of the prior art. Other examples of cathepsin S inhibitors have been reported by E.T. Altmann et al, (WO 9924460,1999) which describes dipeptide nitriles asserted to have activity as inhibitors of Cathepsins B, K, L and S. The WO publication does not disclose any compounds possessing a guanidino or amidino structure at the P3 position. <br><br> 30 Additional peptidyl nitriles have been reported as protease inhibitors. For example, both nitriles and ketoheterocycles are described by B.A. Rowe et al. (US 5,714,471) as <br><br> 4 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> protease inhibitors useful in the treatment of neurodegenerative diseases. Peptidyl nitriles are reported by B. Malcolm et al. (WO 9222570) as inhibitors of picornavirus protease. B J. Gour-Salin (Can. J. Chem., 1991,69,1288) and T.C. Liang (Arch. Biochim. Biophys., 1987,252,626) described peptidyl nitriles as inhibitors of papain <br><br> 5 <br><br> A reversible inhibitor presents a more attractive therapy than irreversible inhibitors. <br><br> Even compounds with high specificity for a particular protease can bind non-target enzymes. An irreversible compound could therefore permanently inactivate a non-target en2yme, increasing the likelihood of toxicity. Furthermore, any toxic effects resulting 10 from inactivation of the target enzyme would be mitigated by reversible inhibitors, and could be easily remedied by modified or lower dosing. Finally, covalent modification of an enzyme by an irreversible inhibitor could potentially generate an antibody response by acting as a hapten. <br><br> 15 In light of the above, there is a clear need for compounds which reversibly and selectively inhibit cysteine proteases such as cathepsin S and cathepsin K for indications in which these proteases exacerbate disease. <br><br> It is therefore an object of this invention to provide novel compounds according to the formulas (la) and (lb) as desrcribed herein which reversibly inhibit the cysteine proteases 25 cathepsin S, K, F, L and B. It is a further object of the invention to provide methods for treating diseases and pathological conditions exacerbated by these cysteine proteases such as, but not limited, to rheumatoid arthritis, multiple sclerosis, asthma and osteoporosis. It is yet a further object of the invention to provide novel processes for preparation of the above-mentioned novel compounds. <br><br> 20 <br><br> BRIEF DESCRIPTION OF THE INVENTION <br><br> 30 <br><br> 5 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> DETAILED DESCRIPTION OF THE INVENTION <br><br> A proposed mechanism of action of the cysteine protease inhibitors of this invention is that the inhibitors contain a functionality that can react (reversibly or irreversibly) with the active site cysteine. The reactive functionality is attached to a peptide or peptide mimic that can be recognized and accommodated by the region of the protease surrounding the active site. The nature of both the reactive functionality and the remaining portion of the inhibitor determine the degree of selectivity and potency toward a particular protease. <br><br> Given the similarity of the active sites in cysteine proteases, it may be anticipated that a given class of inhibitors might have activity against more that one cysteine protease. It may also be expected that due to structural differences between individual cysteine proteases, different compounds of the invention may have different inhibitory potencies against different cysteine proteases. Thus some of the compounds of the invention may also be expected to be most effective in treating diseases mediated by cysteine proteases that they inhibit most potently. The activity of particular compounds disclosed herein against cysteine proteases such as cathepsin S, K, F, L and B may be determined by the screens described in the section entitled "Assessment of Biological Properties." <br><br> Accordingly, in a first generic aspect of the invention, there are provided compounds of formula (la) and (lb): <br><br> f wherein: <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> Het is azepanyl, piperidinyl, pyrrolidinyl, azetidinyl, oxepanyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrofuranyl, oxetanyl, azocanyl, oxocanyl, 1,3-diazocanyl, 1,4-diazocanyl, 1,5-diazocanyl, 1,3-dioxocanyl, 1,4-dioxocanyl, 1,5-dioxocanyl, 1,3-oxazocanyl, 1,4-oxazocanyl, 1,5-oxazocanyl, 1,3-diazepanyl, 1,4-diazepanyl, 1,3-dioxepanyl, 1,4-dioxepanyl, 1,3-oxazepanyl, 1,4-oxazepanyl, l,2-thiazocanyl-l,l-dioxide, 1,2,8-tluadiazocanyl-l, 1-dioxide, 1,2-thiazepanyl-1,1 -dioxide, 1,2,7-thiadiazepany I-1,1-dioxide, tetrahydrothiophenyl, hexahydropyrimidinyl, hexahydropyridazinyl, piperazinyl, 1,4,5,6-tetrahydropyrimidinyl, pyrazolidinyl, dihydro-oxazolyl, dihydrotMazolyl, dihydroiinidazolyl, isoxazolinyl, oxazolidinyl, 1,2-thiazinanyl-1,1 -dioxide, 1,2,6-thiadiazinanyl-1,1 -dioxide, isothiazolidinyl-1,1 -dioxide, imidazolidinyl-2,4-dione, imidazolidinyl, morpholinyl, dioxanyl, tetrahydropyridxnyl, thiomorpholinyl, thiazolidinyl, dihydropyranyl, dithianyl, decahydro-quinolinyl, decahydro-isoquinolinyl, 1,2,3,4-tetrahydro-quinolinyl, indolinyl, octahydro-quinolizinyl, dihydro-indolizinyl, octahydro-indolizinyl, octahydro-indolyl, decahydroquinazolinyl, decahydroquinoxalinyl, 1,2,3,4-tetrahydroquinazolinyl or 1,2,3,4-tetrahydroquinoxalinyl; <br><br> A C6-C10 bridged bicyclo wherein one or more carbon atoms are optionally replaced by a heteroatom chosen from N, O and S; <br><br> each being optionally substituted with one or more Rs; <br><br> Ri is a bond, hydrogen, Cl-10 alkyl, Cl-10 alkoxy, aryloxy, C3-8 cycloalkyl, C3-8 cycloalkyloxy, aryl, benzyl, tetrahydronaphthyl, indenyl, indanyl, Cl-lOalkylsulfonylCl-lOalkyl, C3-8cycloalkylsulfonylCl-10alkyl, arylsulfonylCl-lOalkyl, heterocyclyl selected from azepanyl, azocanyl, pyrrolidinyl, piperidinyl, morpholinyl, <br><br> thiomorpholinyl, piperazinyl, indolinyl, pyranyl, tetrahydropyranyl, tetrahydrothiopyranyl, thiopyranyl, furanyl, tetrahydrofuranyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> tetrazolyl, pyrazolyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, benzisoxazolyl, quinolinyl, tetxahydroquinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, quinazolinyl, tetrahydroquinazolinyl, benzoxazolyl and quinoxalinyl, heterocyclyloxy wherein the heterocyclyl moiety is selected from those herein described in this paragraph, hydroxy or amino; wherein Ri is optionally substituted by one or more R*; <br><br> Ra is a bond, Cl-10 alkyl, C3-8 cycloalkyl, aryl, tetrahydronaphthyl, indenyl, indanyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, indolinyl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, Cl-10 alkoxy, Cl-lOalkanoyl, Cl-lOalkanoyloxy, aryloxy, benzyloxy, Cl-10 alkoxycarbonyl, aryloxycarbonyl, aroyloxy, carbamoyl wherein the nitrogen atom may be independently mono or di-substituted by Cl-10 alkyl, aryl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, indolinyl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, quinolinyl, isoquinolinyl, quinazolinyl or quinoxalinyl, <br><br> or Ra is Cl-10 alkanoylamino, aroylamino, Cl-10 alkylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, arylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, ureido wherein either nitrogen atom may be independently substituted by Cl-10 alkyl, aryl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, indolinyl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, quinolinyl, isoquinolinyl, quinazolinyl or quinoxalinyl, <br><br> or Ra is C1 -10 alkoxycarbonylamino, aryloxycarbonylamino, Cl-10 alkylcarbamoyloxy, arylcarbamoyloxy, Cl-10 alkylsulfonylamino, arylsulfonylamino, Cl-10 alkylaminosulfonyl, arylaminosulfonyl, amino wherein the nitrogen atom may be independently mono or di-substituted by Cl-10 alkyl, <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> aiyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, indolinyl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, quinolinyl, isoquinolinyl, quinazolinyl or quinoxalinyl, <br><br> or Ra is halogen, hydroxy, oxo, carboxy, cyano, nitro, carboxamide, amidino or guanidino, Ra may be further optionally substituted by one or more Rt,; <br><br> with the proviso that Rj and Ra simultaneously cannot be a bond; <br><br> Rb is a CI-6 saturated or unsaturated branched or unbranched carbon chain optionally partially or fully halogenated wherein one or more carbon atoms are optionally replaced by O, N, S(O), S(0)2 or S and wherein said chain is optionally independently substituted with 1-2 oxo groups, -NH2, or one or more CI-4 alkyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, indolinyl, furanyl, thienyl, pyrrolyl, <br><br> oxazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, quinolinyl, isoquinolinyl, quinazolinyl or quinoxalinyl; <br><br> or Rb is C3-6 cycloalkyl, aryl, aryloxy, benzyloxy, halogen, hydroxy, oxo, carboxy, cyano, nitro, mono-C 1-5 alky lamino, di-Cl-5alkylamino, carboxamide, amidino or guanidino; <br><br> R2 is hydrogen or CI-3 alkyl; <br><br> R3 is a bond, hydrogen, Cl-10 alkyl, C2-10alkylene, C3-8 cycloalkyl, arylCl-5alkyl or aryl wherein R3 is optionally substituted by one or more Rc; <br><br> Rc is Cl-10 alkyl, C3-8 cycloalkyl, aryl, indanyl, indenyl, bicyclo[2.2.1]heptanyl, bicyclo[2.2.2]octanyl, bicyclo[4.1.0]heptanyl, bicyclo[3.1.0]hexanyl, bicyclo[l.l.l]pentanyl, cubanyl, 1,2,3,4-tetrahydronaphthyl, decahydronaphthyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, indolinyl, <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> furanyl, tetrahydrofuranyl, pyranyl, tetrahydropyranyl, tetrahydrothiopyranyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, dihydrobenzofuranyl, octohydrobenzofuranyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, tetrahydroquinolinyl, quinolinyl, tetrahydroisoquinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, Cl-10 alkoxy, aryloxy, Cl-10 alkanoyl, aroyl, Cl-10 alkoxycarbonyl, aryloxycarbonyl, Cl-10 alkanoyloxy, aroyloxy, carbamoyl wherein the nitrogen atom may be independently mono or di-substituted by Cl-10 alkyl, aryl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, indolinyl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, quinolinyl, isoquinolinyl, quinazolinyl or quinoxalinyl, <br><br> or Rc is Cl-10 alkanoylamino, aroylamino, Cl-10 alkylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, arylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, ureido wherein either nitrogen atom may be independently substituted by Cl-10 alkyl, aryl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, indolinyl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, ' pyrazinyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, quinolinyl, isoquinolinyl, quinazolinyl or quinoxalinyl, <br><br> or Rc is Cl-10 alkoxycarbonylamino, aryloxycarbonylamino, Cl-10 alkylcarbamoyloxy, arylcarbamoyloxy, Cl-10 alkylsulfonylamino, arylsulfonylamino, Cl-10 alkylaminosulfonyl, arylaminosulfonyl, amino wherein the nitrogen atom may be independently mono or di-substituted by Cl-10 alkyl, aryl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, indolinyl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, quinolinyl, isoquinolinyl, quinazolinyl or quinoxalinyl, <br><br> 10 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> or Rc is halogen, hydroxy, oxo, carboxy, cyano, nitro, amidino or guanidino, Rc may be further optionally substituted by one or more Ra; <br><br> Rd is Cl-5 alkyl, C3-6 cycloalkyl, aryl, arylCl-5alkyl, Cl-5 alkoxy, aryloxy, arylC 1-5 alkoxy, aroyl, amino, halogen, hydroxy, oxo, carboxy, cyano, nitro, amidino or guanidino; <br><br> R2 and R3 together with the carbon they are attached optionally form a nonaromatic 5-7 membered cycloalkyl or heterocyclic ring; <br><br> each R4 is independently hydrogen, hydroxy or CI-3 alkyl; <br><br> R5 is a bond, hydrogen, carbonyl, Cl-10 alkyl, Cl-lOalkoxyCl-lOalkyl, Cl-lOalkylaminoCl-lOalkyl, Cl-lOalkylthioCl-lOalkyl wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, Cl-10 alkoxy, aryloxy, C3-8 cycloalkyl, aryl, benzyl, tetrahydronaphthyl, indenyl, indanyl, C3-7cycloalkylsulfonylCl-5alkyl, arylsulfonylCl-5 alkyl, heterocyclyl selected from pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, indolinyl, pyranyl, tetrahydropyranyl, thiopyranyl, tetrahydrothiopyranyl, furanyl, tetrahydrofuranyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridizinyl, tetrazolyl, triazolyl, pyrazolyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, quinolinyl, tetrahydroquinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, quinazolinyl, tetrahydroquinazolinyl, benzoxazolyl and quinoxalinyl, heterocyclyloxy wherein the heterocyclyl moiety is selected from those herein described in this paragraph, Cl-lOalkanoyl, aroyl, Cl-lOalkanoyloxy, benzyloxy, Cl-lOalkoxycarbonyl, arylCl-Salkoxycarbonyl, aryloxycarbonyl, aroyloxy, carbamoyl wherein the nitrogen atom may be independently mono or di-substituted by Cl-10 alkyl, aryl, pyrrolidinyl, piperidinyl, moipholinyl, thiomorpholinyl, piperazinyl, indolinyl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, quinolinyl, isoquinolinyl, quinazolinyl or quinoxalinyl, <br><br> 11 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> or R5 is Cl-10 alkanoylamino, aroylamino, Cl-10 alkylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, arylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, ureido wherein either nitrogen atom may be independently substituted by Cl-10 alkyl, aryl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, indolinyl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, quinolinyl, isoquinolinyl, quinazolinyl or quinoxalinyl, or R5 is Cl-10 alkoxycarbonylamino, aryloxycarbonylamino, Cl-10 alkylcarbamoyloxy, arylcarbamoyloxy, Cl-10 alkylsulfonylamino, arylsulfonylamino, Cl-10 alkylaminosulfonyl, arylaminosulfonyl, amino wherein the nitrogen atom may be independently mono or di-substituted by Cl-10 alkyl, aryl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, indolinyl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, quinolinyl, isoquinolinyl, quinazolinyl or quinoxalinyl, <br><br> or R5 is halogen, hydroxy, oxy, oxo, carboxy, cyano, nitro, carboxamide, amidino or guanidino, R5 may be further optionally substituted by one or more Re; <br><br> Re is Cl-10 alkyl, Cl-lOalkoxyCl-lOalkyl, C1 -1 OalkylaminoC 1 -1 Oalkyl, Cl-lOalkylthioCl-lOalkyl wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, Cl-10 alkoxy, C3-8 cycloalkyl, aryl, tetrahydronaphthyl, indenyl, indanyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, indolinyl, thiopyranyl, tetrahydrothiopyranyl, pyranyl, tetrahydropyranyl, tetrahydrofixranyl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, Cl-lOalkanoyl, aroyl, Cl-lOalkanoyloxy, aryloxy, benzyloxy, Cl-10 alkoxycarbonyl, arylCl-3alkoxycarbonyl, aryloxycarbonyl, aroyloxy, carbamoyl wherein the nitrogen atom may be independently mono or di-substituted by Cl-10 alkyl, aryl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, indolinyl, <br><br> 12 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, quinolinyl, isoquinolinyl, quinazolinyl or quinoxalinyl, <br><br> or Re is Cl-10 alkanoylamino, aroylamino, Cl-10 alkylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, arylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, ureido wherein either nitrogen atom may be independently substituted by Cl-10 alkyl, aryl, pyrrolidinyl, piperidinyl, morpholinyl, thiomoipholinyl, piperazinyl, indolinyl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, quinolinyl, isoquinolinyl, quinazolinyl or quinoxalinyl, <br><br> or Re is Cl-10 alkoxycarbonylamino, aryloxycarbonylamino, Cl-10 alkylcarbamoyloxy, arylcarbamoyloxy, Cl-10 alkylsulfonylamino, arylsulfonylamino, Cl-10 alkylaminosulfonyl, arylaminosulfonyl, amino wherein the nitrogen atom may be independently mono or di-substituted by Cl-10 alkyl, aryl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, indolinyl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, quinolinyl, isoquinolinyl, quinazolinyl or quinoxalinyl, <br><br> or Re is halogen, hydroxy, oxo, carboxy, cyano, nitro, carboxamide, amidino or guanidino, Re may be further optionally substituted by one or more Rfj <br><br> Rf is Cl-5 alkyl, C3-6 cycloalkyl, tolylsulfonyl, Cl-5 alkoxy, aryl, aryloxy, benzyloxy, halogen, hydroxy, oxo, carboxy, cyano, nitro, carboxamide, amidino or guanidino; <br><br> R6 is hydrogen, hydroxy, nitrile or <br><br> 13 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> a CI-6 saturated or unsaturated branched or unbranched carbon chain optionally partially or fully halogenated wherein one or more C atoms are optionally replaced by O, NH, S(O), S(0)2 or S and wherein said chain is optionally independently substituted with 1-2 oxo groups, -NH2, one or more Cm alkyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, indolinyl, pyranyl, thiopyranyl, furanyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, quinolinyl, isoquinolinyl, quinazolinyl, benzoxazolyl or quinoxalinyl; <br><br> wherein Ri and Re in the formulas (la) or (lb) optionally form a 4 to 8 membered mono-or 7-12 membered polycyclo heteroring system, each aromatic or nonaromatic, wherein each heteroring is optionally substituted by one or more R7; <br><br> each R7 and Rg are independently: <br><br> Cl-5 alkyl chain optionally interrupted by one or two N, O or S(0)m and optionally substituted by 1-2 oxo, amino, hydroxy, halogen, Cl-4alkyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, indolinyl, pyranyl, thiopyranyl, furanyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, quinolinyl, isoquinolinyl, quinazolinyl, benzoxazolyl or quinoxalinyl, <br><br> aryl, aryloxy, aroyl, furanyl, thienyl, pyrrolyl, imidazolyl, pyridinyl, pyrimidinyl, Cl-5 alkanoyl, Cl-5 alkoxycarbonyl, aryloxycarbonyl, benzyloxycarbonyl, Cl-5 alkanoylamino, aroylamino, Cl-5 alkylthio, arylthio Cl-5 alkylsulfonylamino, arylsulfonylamino, Cl-5 alkylaminosulfonyl, arylaminosulfonyl, C3-6 cycloalkyl and benzyloxy each of the aforementioned are optionally halogenated, <br><br> halogen, hydroxy, oxo, carboxy, nitrile, nitro or NH2C(0)-; <br><br> 14 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> m is 0,1 or 2; <br><br> X is =0, =S or =N-Rs wherein Re is as defined above, and pharmaceutical^ acceptable derivatives thereof. <br><br> In another embodiment of the invention, there are provided novel compounds of the formula (la) and formula (lb) as described immediately above, and wherein: <br><br> Het is piperidinyl, pyrrolidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, azetidinyl, azepanyl, oxepanyl, tetrahydrofuranyl, oxetanyl, hexahydropyrimidinyl, hexahydropryidazinyl, piperazinyl, 1,4,5,6-tetrahydropyrimidinyl, octahydro-indolizinyl, octahydro-qumolizinyl, decahydro-quinolinyl, 1,2,3,4-tetrahydro-quinolinyl, dihydro-oxazolyl, 1,2-thiazinanyl-1,1-dioxide, l,2,6-thiadiazinanyl-l,l-dioxide, isothiazolidinyl-1,1-dioxide, imidazolidinyl, pyrazolidinyl or a bridged bicyclo chosen from aza-bicyclo[3.2.1]octane, aza-bicyclo[2.2.1]heptane, aza-bicyclo[2.2.2]octane, aza-bicyclo[3.2.2]nonane, aza-bicyclo[2.1.1]hexane, aza-bicyclo[3.1.1]heptane, aza-bicyclo[3.3.2]decane and 2-oxa or 2-thia-5-aza-bicyclo[2.2.1]heptane; <br><br> each ring being substituted with one or more R5; <br><br> Ri is a bond, hydrogen, Cl-7 alkyl, Cl-7 alkoxy, C3-7 cycloalkyl, aryloxy, phenyl, benzyl, naphthyl, tetrahydronaphthyl, Cl-7alkylsulfonylCl-7alkyl, C3-7cycloaIkylsulfonylCl-7alkyl, arylsulfonylCl-7alkyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, indolinyl, pyranyl, thiopyranyl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, isoxazolyl, pyrimidinyl, pyrazinyl, pyridazinyl, indolyl, quinolinyl, benzofuranyl, benzthienyl, benzimidazolyl, benzthiazolyl, benzoisoxazolyl, benzoxazolyl or amino; wherein Ri is optionally substituted by one or more Ra; <br><br> Ra is a bond Cl-7 alkyl, C3-6 cycloalkyl, phenyl, naphthyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, furanyl, thienyl, oxazolyl, <br><br> 15 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> thiazolyl, imidazolyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, Cl-7 alkoxy, Cl-7alkanoyl, Cl-7alkanoyloxy, aryloxy, benzyloxy, Cl-7 alkoxycarbonyl, aryloxycarbonyl, aroyloxy, carbamoyl wherein the nitrogen atom may be independently mono or di-substituted by Cl-7 alkyl, aryl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, quinolinyl, isoquinolinyl, quinazolinyl or quinoxalinyl, <br><br> or Ra is Cl-7 alkanoylamino, aroylamino, Cl-7 alkylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, arylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, ureido wherein either nitrogen atom may be independently substituted by Cl-7 alkyl, aryl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, quinolinyl, isoquinolinyl, quinazolinyl or quinoxalinyl, <br><br> or Ra is Cl-7 alkoxycarbonylamino, aryloxycarbonylamino, Cl-7 alkylcarbamoyloxy, arylcarbamoyloxy, Cl-7 alkylsulfonylamino, arylsulfonylamino, Cl-7 alkylaminosulfonyl, arylaminosulfonyl, amino wherein the nitrogen atom may be independently mono or di-substituted by Cl-7 alkyl, aryl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, quinolinyl, isoquinolinyl, quinazolinyl or quinoxalinyl, <br><br> or Ra is halogen, hydroxy, oxo, carboxy, cyano, nitro, carboxamide, amidino or guanidino, Ra may be further optionally substituted by one or more Rb; <br><br> 16 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> Rb is Cl-5 alkyl, C3-6 cycloalkyl, aryl, Cl-5 alkoxy, aryloxy, benzyloxy, halogen, hydroxy, oxo, carboxy, cyano, nitro, carboxamide, amidino or guanidino; <br><br> R2 is hydrogen or methyl or ethyl; <br><br> R3 is a bond, hydrogen, Cl-5 alkyl, C2-5alkylene, C3-7 cycloalkyl, arylCl-3alkyl or aryl wherein R3 is optionally substituted by one or more Rc; <br><br> Rc is Cl-5 alkyl, C3-7 cycloalkyl, aryl, indanyl, indenyl, bicyclo[2.2.1]heptanyl, bicyclo[2.2.2]octanyl, bicyclo[4.1.0]heptanyl, bicyclo[3.1.0]hexanyl, bicyclo[l.l.l]pentanyl, cubanyl, 1,2,3,4-tetrahydronaphthyI, pyrrolidinyl, piperidinyl, morpholinyl, thiomoipholinyl, piperazinyl, indolinyl, furanyl, tetrahydrofuranyl, pyranyl, tetrahydropyranyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, Cl-5 alkoxy, aryloxy, Cl-5 alkanoyl, aroyl, Cl-5 alkoxycarbonyl, aryloxycarbonyl, Cl-5 alkanoyloxy, aroyloxy, carbamoyl wherein the nitrogen atom may be independently mono or di-substituted by Cl-5 alkyl, aryl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, indolinyl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, quinolinyl, isoquinolinyl, quinazolinyl or quinoxalinyl, <br><br> or Rc is Cl-5 alkanoylamino, aroylamino, Cl-5 alkylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, arylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, ureido wherein either nitrogen atom may be independently substituted by Cl-5 alkyl, aryl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, indolinyl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, <br><br> 17- <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> pyrazinyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, quinolinyl, isoquinolinyl, quinazolinyl or quinoxalinyl, <br><br> or Rc is Cl-5 alkoxycarbonylamino, aryloxycarbonylamino, Cl-5 alkylcarbamoyloxy, arylcarbamoyloxy, Cl-5 alkylsulfonylamino, arylsulfonylamino, Cl-5 alkylaminosulfonyl, aiylaminosulfonyl, amino wherein the nitrogen atom may be independently mono or di-substituted by Cl-5 alkyl, aryl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, indolinyl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, quinolinyl, isoquinolinyl, quinazolinyl or quinoxalinyl, <br><br> or Rc is halogen, hydroxy, oxo, carboxy, cyano, nitro, amidino or guanidino, Rc may be further optionally substituted by one or more <br><br> R&lt;j is Cl-5 alkyl, C3-6 cycloalkyl, aryl, arylCl-4 <br><br> alkyl, Cl-5 alkoxy, aryloxy, arylC 1-5alkoxy, aroyl, halogen, hydroxy, oxo or cyano; <br><br> R4 is hydrogen or methyl; <br><br> Rs is a bond, hydrogen, carbonyl, Cl-8 alkyl, Cl-8alkoxyCl-8alkyl, Cl-8alkylaminoCl-8alkyl, Cl-8alkylthioCl-8alkyl wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, Cl-8 alkoxy,, aryloxy, C3-7 cycloalkyl, aryl, benzyl, tetrahydronaphthyl, <br><br> indanyl, heterocyclyl selected from pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, indolinyl, pyranyl, tetrahydropyranyl, thiopyranyl, tetrahydrothiopyranyl, furanyl, tetrahydrofuranyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, tetrazolyl, triazolyl, pyrazolyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, quinolinyl, isoquinolinyl, quinazolinyl, benzoxazolyl and quinoxalinyl, heterocyclyloxy wherein the heterocyclyl moiety is selected from those herein described in this paragraph, Cl-7alkanoyl, aroyl, Cl-7alkanoyloxy, benzyloxy, Cl-7 alkoxycarbonyl, aiylCl-4alkoxycarbonyl, <br><br> 18 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> aryloxycarbonyl, aroyloxy, carbamoyl wherein the nitrogen atom may be independently mono or di-substituted by Cl-7 alkyl, aryl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, quinolinyl, isoquinolinyl, quinazolinyl or quinoxalinyl, <br><br> or R5 is Cl-7 alkanoylamino, aroylamino, Cl-7 alkylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, arylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, ureido wherein either nitrogen atom may be independently substituted by Cl-7 alkyl, aryl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, quinolinyl, isoquinolinyl, quinazolinyl or quinoxalinyl, <br><br> or R5 is Cl-7 alkoxycarbonylamino, aryloxycarbonylamino, Cl-7 alkylcarbamoyloxy, arylcarbamoyloxy, Cl-7 alkylsulfonylamino, arylsulfonylamino, Cl-7 alkylaminosulfonyl, arylaminosulfonyl, amino wherein the nitrogen atom may be independently mono or di-substituted by Cl-7 alkyl, aryl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, quinolinyl, isoquinolinyl, quinazolinyl or quinoxalinyl, or R5 is halogen, hydroxy, oxy, oxo, carboxy, cyano, nitro or carboxamide, R5 may be further optionally substituted by one or more Re; <br><br> Re is Cl-7 alkyl, Cl-7alkoxyCl-7alkyl, Cl-7alkylaminoCl-7alkyl, Cl-7alkylthioCl-7alkyl wherein the sulfur atom may be oxidized to a sulfoxide or ' sulfone, Cl-7 alkoxy, C3-7 cycloalkyl, aryl, tetrahydronaphthyl, indanyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, thiopyranyl, tetrahydrothiopyranyl, tetrahydropyranyl, tetrahydrofuranyl, furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, Cl-5 alkanoyl, aroyl, Cl- <br><br> 19 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> 5alkanoyloxy, aryloxy, benzyloxy, Cl-5 alkoxycarbonyl, aryloxycarbonyl, aroyloxy, carbamoyl wherein the nitrogen atom may be independently mono or di-substituted by Cl-5 alkyl, aryl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, quinolinyl, isoquinolinyl, quinazolinyl or quinoxalinyl, <br><br> or Re is Cl-5 alkanoylamino, aroylamino, Cl-5 alkylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, arylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, ureido wherein either nitrogen atom may be independently substituted by Cl-5 alkyl, aryl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, quinolinyl, isoquinolinyl, quinazolinyl or quinoxalinyl, <br><br> or Re is Cl-5 alkoxycarbonylamino, aryloxycarbonylamino, Cl-5 alkylcarbamoyloxy, arylcarbamoyloxy, Cl-5 alkylsulfonylamino, arylsulfonylamino, Cl-5 alkylaminosulfonyl, arylaminosulfonyl, amino wherein the nitrogen atom may be independently mono or di-substituted by Cl-5 alkyl, aryl, pyrrolidinyl, piperidinyl, moipholinyl, thiomorpholinyl, piperazinyl, furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, quinolinyl, isoquinolinyl, quinazolinyl or quinoxalinyl, <br><br> or R&lt;&gt; is halogen, hydroxy, oxo, carboxy, cyano, nitro, carboxamide, amidino or guanidino, Re may be further optionally substituted by one or more Rf; <br><br> Rf is methyl, ethyl, t-butyl, tolylsulfonyl, CI-3 alkoxy, cyclopropyl, cyclohexyl, phenyl, <br><br> naphthyl, phenoxy, benzyloxy, fhioro, chloro, bromo, hydroxy, oxo, carboxy, cyano, <br><br> f" <br><br> nitro or carboxamide; <br><br> Re is <br><br> 20 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> hydrogen, hydroxy, nitrile or a CI-6 saturated or unsaturated branched or unbranched carbon chain optionally partially or fully halogenated wherein one or more C atoms are optionally replaced by O, NH, S(O), S(0)2 or S and wherein said chain is optionally independently substituted with 1-2 oxo groups, -NH2, one or more Cl-4 alkyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, indolinyl, pyranyl, thiopyranyl, furanyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, quinolinyl, isoquinolinyl, quinazolinyl, benzoxazolyl or quinoxalinyl; <br><br> Ri and R^ of the formula (la) or formula (lb) form a monocyclic 5,6 or 7 membered aromatic or nonaromatic heterocyclic ring optionally substituted by R7; <br><br> or a bicyclic ring having one 5,6 or 7 membered aromatic or nonaromatic heterocyclic ring fused to a second 5-7 membered aromatic or nonaromatic heterocyclic or carbocyclic ring wherein each ring is optionally independently substituted by one or more R7; <br><br> R7 and Rg are independently Cl-5 alkyl, C3-6 cycloalkyl, aryl, Cl-5 alkoxy, aryloxy, benzyloxy each of the aforementioned are optionally halogenated or Rx is halogen, hydroxy, oxo, carboxy, nitrile, nitro or NH2C(0)-; <br><br> m is 0,1 or 2 and <br><br> X is O or S. <br><br> In yet another embodiment of the invention, there are provided novel compounds of the formulas (la) and (lb) as described immediately above, and wherein: <br><br> 21 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> Het is piperidinyl, pyrrolidinyl, azetidinyl, azepanyl, oxepanyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrofuranyl, oxetanyl, octahydro-indolizinyl, octahydro-quinolizinyl or aza-bicyclo[3.2.1]octanyl, each ring being optionally substituted with one or more R5; <br><br> Ri is a bond, Cl-5 alkyl, Cl-5 alkoxy, C3-6 cycloalkyl, aryloxy, phenyl, benzyl, naphthyl, Cl-3alkylsulfonylCl-3alkyl, C3-6cycloalkylsulfonylC 1 -3 alkyl, arylsulfonylCl-3alkyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, isoxazolyl, pyrimidinyl, pyrazinyl, pyridazinyl, indolyl, quinolinyl, benzofuranyl, benzthienyl, benzimidazolyl, benzthiazolyl, benzoxazolyl or amino; wherein Ri is optionally substituted by one or more Ra; <br><br> Ra is a bond, CI-3 alkyl, cyclopropyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, benzimidazolyl, benzthiazolyl, benzoxazolyl, Cl-3 alkoxy, Cl-3alkanoyl, Cl-3aIkanoyloxy, aryloxy, benzyloxy, Cl-3 alkoxycarbonyl, aryloxycarbonyl, aroyloxy, carbamoyl wherein the nitrogen atom may be independently mono or di-substituted by Cl-3 alkyl, aryl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, benzimidazolyl or benzthiazolyl, <br><br> or Ra is Cl-3 alkanoylamino, aroylamino, Cl-3 alkylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, arylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, ureido wherein either nitrogen atom may be independently substituted by Cl-3 alkyl, ajryl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl, <br><br> or Ra is Cl-3 alkoxycarbonylamino, aryloxycarbonylamino, Cl-3 alkylcarbamoyloxy, aiylcarbamoyloxy, Cl-3 alkylsulfonylamino, arylsulfonylamino, Cl-3 alkylaminosulfonyl, arylaminosulfonyl, amino wherein <br><br> 22 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> the nitrogen atom may be independently mono or di-substituted by Cl-3 alkyl, aryl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl, <br><br> or Ra is halogen, hydroxy, oxo, carboxy, cyano, nitro, carboxamide, amidino or guanidino, Ra may be further optionally substituted by one or more Rb; <br><br> Rb is Cl-3 alkyl, C3-6 cycloalkyl, aryl, Cl-3 alkoxy, aryloxy, benzyloxy, halogen, hydroxy, oxo, carboxy, cyano, nitro, carboxamide, amidino or guanidino; <br><br> R2 is hydrogen or methyl; <br><br> R3 is a bond, hydrogen, Cl-5 alkyl, C2-5alkylene, C4-6 cycloalkyl or arylCl-2alkyl wherein R3 is optionally substituted by one or more R^; <br><br> Rc is CI-4 alkyl, C5-6 cycloalkyl, phenyl, naphthyl, indanyl, bicyclo[2.2.1]heptanyl, bicyclo[2.2.2]octanyl, bicyclo[4.1 .0]heptanyl, bicyclo[3.1.0]hexanyl, bicyclo[l.l.l]pentanyl, cubanyl, 1,2,3,4-tetrahydronaphthyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, indolinyl, furanyl, tetrahydrofuranyl, pyranyl, tetrahydropyranyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, CI-4 alkoxy, phenoxy, naphthyloxy, Cl-3 alkanoyl, benzoyl, Cl-3 alkoxycarbonyl, phenoxycarbonyl, Cl-3 alkanoyloxy, benzoyloxy, carbamoyl wherein the nitrogen atom may be independently mono or di-substituted by Cl-5 alkyl or aryl, <br><br> or Rc is Cl-3 alkanoylamino, benzoylamino, Cl-3 alkylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, phenylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, ureido wherein either nitrogen atom may be independently substituted by Cl-5 alkyl or aryl, <br><br> or Rc is Cl-3 alkoxycarbonylamino, aryloxycarbonylamino, Cl-3 alkylcarbamoyloxy, arylcarbamoyloxy, Cl-3 alkylsulfonylamino, <br><br> 23 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> aiylsulfonylamino, Cl-3 alkylaminosulfonyl, arylaminosulfonyl, amino wherein the nitrogen atom may be independently mono or di-substituted by Cl-5 alkyl or aryl, <br><br> or Rc is halogen, hydroxy, oxo, carboxy, cyano, nitro, amidino or guanidino, Rc may be further optionally substituted by one or more Rd; <br><br> Rd is Cl-3 alkyl, C3-6 cycloalkyl, phenyl, benzyl, Cl-3 alkoxy, phenoxy, phenylCl-3alkoxy, benzoyl, halogen, hydroxy, oxo or cyano; <br><br> R4 is hydrogen; <br><br> R5 is a bond, hydrogen, carbonyl, Cl-6 alkyl, Cl-6alkoxyCl-6alkyl, Cl-6alkylaminoCl-6alkyl, Cl-6alkylthioCl-6alkyl wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, Cl-6 alkoxy,, phenoxy, naphthyloxy, C3-6 cycloalkyl, phenyl, naphthyl, benzyl, indanyl, heterocyclyl selected from pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, tetrahydropyranyl, tetrahydrothiopyranyl, furanyl, tetrahydrofuranyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, quinolinyl, isoquinolinyl and benzoxazolyl, heterocyclyloxy wherein the heterocyclyl moiety is selected from those herein described in this paragraph, Cl-3alkanoyl, benzoyl, naphthoyl, Cl-4alkanoyloxy, benzyloxy, Cl-4 alkoxycarbonyl, arylCl-2alkoxycarbonyl, phenoxycarbonyl, benzoyloxy, carbamoyl wherein the nitrogen atom may be independently mono or di-substituted by Cl-3 alkyl, phenyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl or pyrimidinyl, or R5 is Cl-4 alkanoylamino, aroylamino, Cl-4 alkylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, arylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, ureido wherein either nitrogen atom may be independently substituted by Cl-3 alkyl, phenyl, naphthyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl or benzthiazolyl, <br><br> 24 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> or R5 is Cl-4 alkoxycarbonylamino, phenoxycarbonylarnino, Cl-4 alkylcarbamoyloxy, phenylcarbamoyloxy, Cl-4 alkylsulfonylamino, phenylsulfonylamino, Cl-3 alkylaminosulfonyl, phenylaminosulfonyl, amino wherein the nitrogen atom may be independently mono or di-substituted by Cl-4 alkyl, aiyl, pyrrolidinyl, piperidinyl, morpholinyl, thiombrpholinyl, piperazinyl, furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, benzimidazolyl or benzthiazolyl, <br><br> or R5 is halogen, hydroxy, oxo, carboxy, cyano, nitro or carboxamide, R5 may be further optionally substituted by one or more Re; <br><br> Re is Cl-4 alkyl, Cl-4 alkoxy, C3-7 cycloalkyl, phenyl, naphthyl, indanyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, tetrahydrothiopyranyl, tetrahydropyranyl, tetrahydrofuranyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, benzimidazolyl, benzthiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, Cl-4 alkanoyl, aroyl, Cl-4alkanoyloxy, phenoxy, naphthyloxy, benzyloxy, Cl-4 alkoxycarbonyl, phenoxycarbonyl, benzoyloxy, carbamoyl wherein the nitrogen atom may be independently mono or di-substituted by Cl-3 alkyl, phenyl, naphthyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, benzimidazolyl, or benzthiazolyl, <br><br> or Re is Cl-4 alkanoylamino, benzoylamino, Cl-4 alkylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, phenylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, ureido wherein either nitrogen atom may be independently substituted by Cl-3 alkyl, phenyl, naphthyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, benzimidazolyl or benzthiazolyl, <br><br> or Re is Cl-4 alkoxycarbonylamino, phenoxycarbonylarnino, Cl-4 alkylcarbamoyloxy, phenylcarbamoyloxy, Cl-4 alkylsulfonylamino, phenylsulfonylamino, Cl-4 alkylaminosulfonyl, phenylaminosulfonyl, amino wherein the nitrogen atom may be independently mono or di-substituted by Cl-3 <br><br> 25 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> alkyl, phenyl, naphthyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, benzimidazolyl or benzthiazolyl, <br><br> or Re is halogen, hydroxy, oxo, carboxy, cyano, nitro or carboxamide, Re may be further optionally substituted by one or more Rf; <br><br> Rf is methyl, ethyl, t-butyl, tolylsulfonyl, methoxy, cyclopropyl, phenyl, phenoxy, benzyloxy, fluoro, chloro, bromo, hydroxy, oxo, carboxy or carboxamide. <br><br> Ri and Re of the formula (la) or Formula (lb) optionally form a monocyclic 5 or 6 membered aromatic or nonaromatic heterocyclic ring optionally substituted by R7; <br><br> or a bicyclic ring having one 5, 6 or 7 membered aromatic or nonaromatic heterocyclic ring fused to a second 5-6 membered aromatic or nonaromatic heterocyclic or carbocyclic ring wherein each ring is optionally independently substituted by one or more R7; <br><br> R7 and Rg are independently Cl-4 alkyl, C5-6 cycloalkyl, Cl-4 alkoxy, halogen, hydroxy, oxo, carboxy, nitrile, nitro or NH2C(0)-; <br><br> and X is O. <br><br> In yet still another embodiment of the invention, there are provided novel compounds of the formulas (la) and (lb) as described immediately above, and wherein: <br><br> Het is piperidinyl, pyrrolidinyl, azetidinyl, azepanyl, oxepanyl, tetrahydropyranyl, <br><br> oxetanyl or tetrahydrothiopyranyl each ring being optionally substituted with one or more R5; <br><br> 26 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> Ri is a bond, Cl-5 alkyl, Cl-5 alkoxy, C3-6 cycloalkyl, aryloxy, phenyl, benzyl, <br><br> naphthyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, indolyl, quinolinyl, benzofuranyl, benzthienyl, benzimidazolyl, benzthiazolyl, benzoxazolyl or amino; wherein Ri is optionally substituted by one or more Ra; <br><br> Ra is a bond, Cl-3 alkyl, cyclopropyl, cyclohexyl, phenyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, thienyl, imidazolyl, Cl-3 alkoxy, Cl-3alkanoyl, Cl-3aIkanoyloxy, aryloxy, benzyloxy, Cl-3 alkoxycarbonyl, aryloxycarbonyl, aroyloxy, carbamoyl wherein the nitrogen atom may be independently mono or di-substituted by Cl-3 alkyl, aryl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl, <br><br> or Ra is Cl-3 alkanoylamino, aroylamino, Cl-3 alkylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, arylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, ureido wherein either nitrogen atom may be independently substituted by Cl-3 alkyl, aryl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl, <br><br> or Ra is Cl-3 alkoxycarbonylamino, aryloxycarbonylamino, Cl-3 alkylcarbamoyloxy, arylcarbamoyloxy, Cl-3 alkylsulfonylamino, arylsulfonylamino, Cl-3 alkylaminosulfonyl, arylaminosulfonyl, amino wherein the nitrogen atom may be independently mono or di-substituted by Cl-3 alkyl, aryl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl, <br><br> or Ra is halogen, hydroxy, oxo, carboxy, cyano, nitro, carboxamide, amidino or guanidino, Ra may be further optionally substituted by one or more Rb; <br><br> Rb is methyl, ethyl, n-propyl, i-propyl, cyclopropyl, cyclopentyl, cyclohexyl, phenyl, methoxy, ethoxy, n-propoxy, i-propoxy, phenoxy, benzyloxy, fluoro, chloro, bromo, iodo, hydroxy, oxo, carboxy, cyano, nitro or carboxamide; <br><br> R2 is hydrogen; <br><br> 27 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> R3 is a bond, Cl-3 alkyl, C2-4alkylene, C5-6 cycloalkyl, benzyl or naphthylmethyl wherein R3 is optionally substituted by one or more Rc; <br><br> Rc is Cl-3 alkyl, C5-6 cycloalkyl, phenyl, naphthyl, indanyl, <br><br> bicyclo[2.2. l]heptanyl, bicyclo[2.2.2]octanyl, bicyclo[4.1.0]heptanyl, bicyclo[3.1.0]hexanyl, bicyclo[l.1.ljpentanyl, cubanyl, 1,2,3,4-tetrahydronaphthyl, furanyl, tetrahydropyranyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrimidinyl, indolyl, benzofuranyl, benzothienyl, benzthiazolyl, Cl-3 alkoxy, phenoxy, naphthyloxy, Cl-2 alkanoyl, benzoyl, Cl-2 alkoxycarbonyl, phenoxycarbonyl, Cl-2alkanoyloxy, benzoyloxy, carbamoyl wherein the nitrogen atom may be independently mono or di-substituted by Cl-3 alkyl or aryl, <br><br> or Rc is Cl-2 alkanoylamino, benzoylamino, Cl-2 alkylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, phenylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, ureido wherein either nitrogen atom may be independently substituted by Cl-3 alkyl or aryl, <br><br> or Rc is Cl-2 alkoxycarbonylamino, phenoxycarbonylarnino, Cl-2 alkylcarbamoyloxy, arylcarbamoyloxy, Cl-2 alkylsulfonylamino, phenylsulfonylamino, C1 -2alkylaminosulfonyl, phenylaminosulfonyl, amino wherein the nitrogen atom may be independently mono or di-substituted by Cl-3 alkyl or phenyl, <br><br> or Rc is halogen, hydroxy, oxo, carboxy or cyano, Rc may be further optionally substituted by one or more Rj; <br><br> Rd is methyl, cyclopropyl, cyclohexyl, phenyl, benzyl, methoxy, phenoxy, benzyloxy, benzoyl, fluoro, chloro, oxo or cyano; <br><br> Rs is a bond, hydrogen, carbonyl, Cl-5 alkyl, Cl-5alkoxyC 1 -5alkyl, Cl-5alkylaminoCl-5alkyl, Cl-5alkylthioCl-5alkyl wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, Cl-5 alkoxy, phenoxy, C3-6 cycloalkyl, phenyl, naphthyl, benzyl, indanyl, heterocyclyl selected from pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, <br><br> 28 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> piperazinyl, tetrahydropyranyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, benzimidazolyl and benzthiazolyl, heterocyclyloxy wherein the heterocyclyl moiety is selected from those herein described in this paragraph, CI-3alkanoyl, benzoyl, naphthoyl, Cl-3alkanoyloxy, benzyloxy, Cl-3 alkoxycarbonyl, benzyloxycarbonyl, phenoxycarbonyl, benzoyloxy, carbamoyl wherein the nitrogen atom may be independently mono or di-substituted by Cl-3 alkyl, phenyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl or pyrimidinyl, or R.5 is Cl-3 alkanoylamino, aroylamino, Cl-3 alkylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, phenylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, ureido wherein either nitrogen atom may be independently substituted by Cl-3 alkyl, phenyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, benzofuranyl, benzothienyl, benzimidazolyl or benzthiazolyl, <br><br> or R5 is Cl-3 alkoxycarbonylamino, phenoxycarbonylarnino, Cl-3 alkylcarbamoyloxy, phenylcarbamoyloxy, Cl-3 alkylsulfonylamino, phenylsulfonylamino, Cl-3 alkylaminosulfonyl, phenylaminosulfonyl, amino wherein the nitrogen atom may be independently mono or di-substituted by Cl-3 alkyl, phenyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, benzimidazolyl or benzthiazolyl, <br><br> or R5 is halogen, hydroxy, oxo, carboxy, cyano or carboxamide, R5 may be further optionally substituted by one or more R^; <br><br> Re is Cl-3 alkyl, Cl-3 alkoxy, C3-7 cycloalkyl, phenyl, naphthyl, indanyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, tetrahydropyranyl, indolyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, benzimidazolyl, benzthiazolyl, benzoxazolyl, Cl-3 alkanoyl, aroyl, Cl-3alkanoyloxy, phenoxy, benzyloxy, Cl-3 alkoxycarbonyl, phenoxycarbonyl, benzoyloxy, carbamoyl wherein the nitrogen atom may be independently mono or di-substituted by Cl-3 alkyl, phenyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, benzimidazolyl or benzthiazolyl, <br><br> 29 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> or Re is Cl-3 alkanoylamino, benzoylamino, Cl-3 alkylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, phenylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, ureido wherein either nitrogen atom may be independently substituted by Cl-3 alkyl, phenyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, benzimidazolyl or benzthiazolyl, <br><br> or Re is C1 -3 alkoxycarbonylamino, phenoxycarbonylarnino, Cl-3 alkylcarbamoyloxy, phenylcarbamoyloxy, Cl-3 alkylsulfonylamino, phenylsulfonylamino, Cl-3 alkylaminosulfonyl, phenylaminosulfonyl, amino wherein the nitrogen atom may be independently mono or di-substituted by Cl-3 alkyl, phenyl, naphthyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, benzimidazolyl or benzthiazolyl, <br><br> or Re is halogen, hydroxy, oxo, carboxy, cyano or carboxamide, Re may be further optionally substituted by one or more Rf; <br><br> and <br><br> Rf is methyl, phenyl, tolylsulfonyl, methoxy, phenoxy, benzyloxy, fluoro, chloro, bromo, hydroxy, oxo, carboxy or carboxamide; <br><br> Ri and R^ of the formula (la) or Formula (lb) form a bicyclic ring having one 5 or 6 membered aromatic or nonaromatic heterocyclic ring fused to a second 5-6 membered heteroaryl, heterocycle or phenyl ring; <br><br> wherein each ring is optionally independently substituted by one or two R7. <br><br> In yet a further embodiment of the invention, there are provided novel compounds of the formulas (la) and (lb) as described immediately above, and wherein: <br><br> Het is piperidinyl, pyrrolidinyl, azetidinyl, azepanyl or tetrahydropyranyl each ring being substituted with one or more R5; <br><br> 30 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> Ri is a bond, methyl, ethyl, i-propyl, methoxy, ethoxy, cyclopropyl, cyclopentyl, cyclohexyl, phenoxy, phenyl, benzyl, naphthyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, furanyl, thienyl, thiazolyl, imidazolyl, pyridinyl, pyrazinyl or amino; wherein Ri is optionally substituted by one or more Ra; <br><br> Ra is a bond, methyl, ethyl, cyclopropyl, phenyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, thienyl, imidazolyl, methoxy, acetyl, acetoxy, phenoxy, benzyloxy, methoxycarbonyl, phenoxycarbonyl, benzoyloxy, carbamoyl wherein the nitrogen atom may be independently mono or di-substituted by methyl, ethyl or phenyl, <br><br> or Ra is acetylamino, benzoylamino, methylthio, phenylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, ureido wherein either nitrogen atom may be independently substituted by methyl, ethyl or phenyl, <br><br> or Ra is methoxycarbonylamino, phenoxycarbonylarnino, methylcarbamoyloxy, phenylcarbamoyloxy, methylsulfonylamino, phenylsulfonylamino, methylaminosulfonyl, phenylaminosulfonyl, amino wherein the nitrogen atom may be independently mono or di-substituted by methyl or phenyl, <br><br> or Ra is fluoro, chloro, bromo, iodo, hydroxy, oxo, carboxy, cyano, nitro or carboxamide, Rg may be further optionally substituted by one or more Rb; <br><br> Rt is methyl, cyclopropyl, phenyl, methoxy, phenoxy, benzyloxy, fluoro, chloro, hydroxy, oxo, carboxy or carboxamide; <br><br> R3 is a bond, Cl-3 alkyl, C2-4alkylene, C5-6 cycloalkyl, benzyl or naphthylmethyl wherein R3 is optionally substituted by one or more R&lt;.; <br><br> Rc is methyl, ethyl, n-propyl, i-propyl, C5-6 cycloalkyl, indanyl, <br><br> bicyclo[2.2. l]heptanyls bicyclo[2.2.2]octanyl, bicyclo[4.1.0]heptanyl, bicyclo[3.1.0]hexanyl, bicyclo[l.l.l]pentanyl, cubanyl, 1,2,3,4-tetrahydronaphthyl, thienyl, oxazolyl, thiazolyl, indolyl, benzofuranyl, <br><br> 31 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> benzothienyl, benzthiazolyl, methoxy, ethoxy, phenoxy, acetyl, benzoyl, methoxycarbonyl, phenoxycarbonyl, acetoxy, benzoyloxy, carbamoyl wherein the nitrogen atom may be independently mono or di-substituted by methyl, ethyl or aryl, <br><br> or Rc is acetylamino, benzoylamino, methylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, phenylthio wherein, the sulfur atom may be oxidized to a sulfoxide or sulfone, ureido wherein either nitrogen atom may be independently substituted by methyl, ethyl or aryl, <br><br> or Rc is methoxycarbonylamino, phenoxycarbonylarnino, methylcarbamoyloxy, phenylcarbamoyloxy, methylsulfonylamino, phenylsulfonylamino, methylaminosulfonyl, phenylaminosulfonyl, amino wherein the nitrogen atom may be independently mono or di-substituted by methyl, ethyl or phenyl, <br><br> or Rc is fluoro, chloro or oxo, Rc may be further optionally substituted by one or more R^; <br><br> Rd is methyl, cyclopropyl, phenyl, methoxy, fluoro, chloro or oxo; <br><br> R5 is a bond, hydrogen, carbonyl, Cl-4 alkyl, Cl-4alkoxyCl-4alkyl, Cl-4alkylaminoCl-4allcyl, Cl-4alkylthioCl-4alkyl wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, Cl-4 alkoxy,phenoxy, cyclopropyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, benzyl, indanyl, heterocyclyl selected from pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, tetrahydropyranyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, benzimidazolyl and benzthiazolyl, heterocyclyloxy wherein the heterocyclyl moiety is selected from those herein described in this paragraph, Cl-2alkanoyI, benzoyl, naphthoyl, Cl-2alkanoyloxy, benzyloxy, Cl-2 alkoxycarbonyl, benzyloxycarbonyl, phenoxycarbonyl, benzoyloxy, carbamoyl wherein the nitrogen atom may be independently mono or di-substituted by Cl-2 alkyl, phenyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl or pyrimidinyl, <br><br> or Rs is Cl-2 alkanoylamino, benzoylamino, Cl-2 alkylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, phenylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, ureido wherein either nitrogen atom may be <br><br> 32 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> independently substituted by Cl-2 alkyl, phenyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, benzimidazolyl or benzthiazolyl, <br><br> orRs is Cl-2 alkoxycarbonylamino, phenoxycarbonylarnino, Cl-2 alkylcarbamoyloxy, phenylcarbamoyloxy, Cl-2 alkylsulfonylamino, phenylsulfonylamino, Cl-2 alkylaminosulfonyl, phenylaminosulfonyl, amino wherein the nitrogen atom may be independently mono or di-substituted by Cl-2 alkyl, phenyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl or pyrimidinyl, or R5 is fluoro, chloro, bromo, hydroxy, oxo, carboxy or carboxamide, R5 may be further optionally substituted by one or more R^ <br><br> Re is Cl-3 alkyl, Cl-2 alkoxy, C3-6 cycloalkyl, phenyl, naphthyl, indanyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, tetrahydropyranyl, indolyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, benzimidazolyl, benzthiazolyl, benzoxazolyl, Cl-2 alkanoyl, aroyl, Cl-2alkanoyloxy, phenoxy, benzyloxy, Cl-2 alkoxycarbonyl, phenoxycarbonyl, benzoyloxy, carbamoyl wherein the nitrogen atom may be independently mono or di-substituted by Cl-2 alkyl, phenyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl or pyrimidinyl, <br><br> or Re is Cl-2 alkanoylamino, benzoylamino, Cl-2 alkylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, phenylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, ureido wherein either nitrogen atom may be independently substituted by Cl-2 alkyl, phenyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl or pyrimidinyl, <br><br> or Re is Cl-2 alkoxycarbonylamino, phenoxycarbonylarnino, Cl-2 alkylcarbamoyloxy, phenylcarbamoyloxy, Cl-2 alkylsulfonylamino, phenylsulfonylamino, Cl-2 alkylaminosulfonyl, phenylaminosulfonyl, amino wherein the nitrogen atom may be independently mono or di-substituted by Cl-2 alkyl, phenyl, naphthyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl or pyrimidinyl, <br><br> 33 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> or Re is fluoro, chloro, bromo, hydroxy, oxo, carboxy or carboxamide, Re may be further optionally substituted by one or more Rf; <br><br> Rf is methyl, phenyl, tolylsulfonyl, methoxy, phenoxy, ben2yloxy, fluoro, chloro, hydroxy, oxo, carboxy or carboxamide and <br><br> Ri and Re of the formula (la) or Formula (lb) form a bicyclic ring having one 5-6 membered aromatic or nonaromatic heterocyclic ring fused to a phenyl ring; <br><br> wherein each ring is optionally independently substituted by one or two R7. <br><br> In yet still a further embodiment of the invention, there are provided novel compounds of the formula (la) or formula (lb) as described immediately above, and wherein: <br><br> Het is piperidin-4-yl, piperidin-3-yl, pyrrolidin-3-yl, azetidin-3-yl, azepan-3-yl, azepan-4-yl or tetrahydropyran-4-yl, each ring being optionally substituted with one or more R5; <br><br> Ri is a bond, methyl, ethyl, i-propyl, methoxy, cyclopropyl, cyclohexyl, phenoxy, phenyl, benzyl, naphthyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, furanyl, thienyl, thiazolyl, imidazolyl, pyridinyl, pyrazinyl or amino; wherein Ri is optionally substituted by one or more Ra; <br><br> Ra is methyl, phenyl, thienyl, methoxy, acetyl, acetoxy, phenoxy, benzyloxy, methoxycarbonyl, benzoyloxy, carbamoyl wherein the nitrogen atom may be independently mono or di-substituted by methyl or phenyl, <br><br> or Ra is acetylamino, methylthio, phenylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, ureido wherein either nitrogen atom may be independently substituted by methyl or phenyl, <br><br> 34 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> or Ra is methoxycarbonylaraino, methylcarbamoyloxy, phenylcarbamoyloxy, methylsulfonylamino, phenylsulfonylamino, amino wherein the nitrogen atom may be independently mono or di-substituted by methyl or phenyl, <br><br> or Ra is fluoro, chloro, hydroxy, oxo, carboxy, cyano or carboxamide; <br><br> R3 is a bond, methyl, ethyl, n-propyl, propenyl, butenyl, i-butenyl, cyclohexyl, benzyl or naphthylmethyl wherein R3 is optionally substituted by one or more Rc; <br><br> Rc is methyl, ethyl, n-propyl, i-propyl, cyclohexyl, cyclopentyl, indanyl, bicyclo[2.2. l]heptanyl, bicyclo[2.2.2]octanyl, bicyclo[4.1.0]heptanyl, bicyclo[3.1.0]hexanyl, bicyclo[l.l.l]pentanyl, cubanyl, 1,2,3,4-tetrahydronaphthyl, methoxy, phenoxy, acetyl, benzoyl, methoxycarbonyl, phenoxycarbonyl, acetoxy, benzoyloxy, methylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, phenylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, fluoro, chloro or oxo; <br><br> R5 is a bond, hydrogen, carbonyl, Cl-4 alkyl, Cl-2alkoxyCl-2alkyl, Cl-2alkyIaminoCl-2alkyl, Cl-2alkylthioCl-2alkyl wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, Cl-2 alkoxy, phenoxy, cyclopropyl, cyclopentyl, cyclohexyl, phenyl, benzyl, heterocyclyl selected from pyrrolidinyl, piperidinyl, morpholinyl, tetrahydropyranyl, pyridinyl, and pyrimidinyl, heterocyclyloxy wherein the heterocyclyl moiety is selected from those herein described in this paragraph, acetyl, benzoyl, acetyloxy, benzyloxy, methoxycarbonyl, ethoxycarbonyl, benzyloxycarbonyl, benzoyloxy, carbamoyl wherein the nitrogen atom may be independently mono or di-substituted by methyl, ethyl or phenyl, <br><br> or Rs is acetylamino, benzoylamino, methylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, phenylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, ureido wherein eilher nitrogen atom may be independently substituted by methyl, ethyl or phenyl, <br><br> or R5 is methoxycarbonylamino, ethoxycarbonylamino, phenoxycarbonylarnino, methylcarbamoyloxy, phenylcarbamoyloxy, methylsulfonylamino, phenylsulfonylamino, <br><br> 35 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> methylaminosulfonyl, phenylaminosulfonyl, amino wherein the nitrogen atom may be independently mono or di-substituted by methyl, ethyl or phenyl, <br><br> or Rs is fluoro, chloro, hydroxy, oxo, carboxy or carboxamide, R5 may be further optionally substituted by one or more Re; <br><br> Re is methyl, methoxy, ethoxy, cyclopropyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, indanyl, piperidinyl, morpholinyl, indolyl, thienyl, pyridinyl, acetyl, benzoyl, acetyloxy, phenoxy, benzyloxy, methoxycarbonyl, ethoxycarbonyl, carbamoyl wherein the nitrogen atom may be independently mono or di-substituted by methyl, ethyl or phenyl, <br><br> or Re is acetylamino, benzoylamino, methylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, phenylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, ureido wherein either nitrogen atom may be independently substituted by methyl, ethyl or phenyl, <br><br> or Re is methoxycarbonylamino, ethoxycarbonylamino, phenoxycarbonylarnino, methylcarbamoyloxy, phenylcarbamoyloxy, methylsulfonylamino, phenylsulfonylamino, methylaminosulfonyl, phenylaminosulfonyl, amino wherein the nitrogen atom may be independently mono or di-substituted by methyl, ethyl or phenyl, <br><br> or Re is fluoro, chloro, hydroxy, oxo, carboxy or carboxamide, R^ may be further optionally substituted by one or more Rf; <br><br> and <br><br> Rf is methyl, phenyl, tolylsulfonyl, phenoxy, benzyloxy, fluoro, chloro or oxo; <br><br> Ri and Rg of the formula (la) or Formula (lb) form the bicyclic ring <br><br> 36 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> ; wherein W is -S(0)n-, -O-C(O)- or -N-C(O)-, n is 0,1 or 2 and wherein each ring is optionally independently substituted by one or two R7. <br><br> In a further embodiment of the invention, there are provided novel compounds of the formulas (la) and (lb) as described immediately above, and wherein: <br><br> Het is piperidin-4-yl, piperidin-3-yl, pyrrolidin-3-yl. azetidin-3-yl or tetrahydropyran-4-yl, each ring being substituted with one or more R5; <br><br> Ri is i-propyl, benzyloxy, cyclohexyl, phenyl, 4-(acetylamino)-phenyl, 4-(methanesulfonylamino)-phenyl, 4-methoxyphenyl, 3-phenoxyphenyl, 4-chlorophenyl, 4-fluorophenyl, 2-fluorophenyl, 2-fluoro-4-chlorophenyl, naphthyl, thienylmethyl, piperidinyl, morpholinyl, pyrrolidinyl, piperazinyl, furanyl, thienyl, 5-chlorothienyl, pyridin-4-yl, pyrazinyl, methylamino, ethylamino, dimethylamino or diethylamino; <br><br> R3 is ethyl, n-propyl,propenyl, butenyl, i-butenyl, benzyl or naphthylmethyl wherein R3 is optionally substituted by one or more R^; <br><br> Rc is methyl, cyclohexyl, cyclopentyl, indanyl, 1,2,3,4-tetrahydronaphthyl, methoxy, methylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, fluoro or chloro; <br><br> Rs is a bond, carbonyl, methyl, ethyl, n-propyl, n-butyl, t-butyl, i-propyl, i-butyl, cyclopropyl, cyclopentyl, cyclohexyl, phenyl, benzyl, piperidinyl, tetrahydropyranyl, pyrimidinyl, acetyl, benzoyl, ethoxycarbonyl, benzyloxycarbonyl, methylsulfonylamino, phenylsulfonylamino, methylamino, dimethylamino, fluoro, oxo or carboxy, R5 may be further optionally substituted by one or more Re; <br><br> 37 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> Re is methyl, cyclopropyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, indanyl, thienyl, 5-methylthienyl, methoxy, phenoxy, benzyloxy, piperidinyl, pyridinyl, indolyl, l-(tolyl-sulfonyl)-indolyl, carbamoyl wherein the nitrogen atom may be independently mono or di-substituted by methyl, phenyl or benzyl, <br><br> . or Re is hydroxy, fluoro, chloro, oxo, dimethylamino or trifluoromethyl; <br><br> and nis 2. <br><br> In another embodiment of the invention, there are provided novel compounds of the formulas (la) and (lb) as described for the broadest generic aspect above and wherein: <br><br> Ri and Re remain acyclic, <br><br> Het is piperidinyl, pyrrolidinyl, azetidinyl, azepanyl, oxepanyl, tetrahydropyranyl, oxetanyl or tetrahydrothiopyranyl each ring being optionally substituted with one or more R5; <br><br> Ri is a bond, Cl-5 alkyl, Cl-5 alkoxy, C3-6 cycloalkyl, aiyloxy, phenyl, benzyl, <br><br> naphthyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, indolyl, quinolinyl, benzofuranyl, benzthienyl, benzimidazolyl, benzthiazolyl, benzoxazolyl or amino; wherein Ri is optionally substituted by one or more Raj <br><br> Ra is a bond, Cl-3 alkyl, cyclopropyl, cyclohexyl, phenyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, thienyl, imidazolyl, Cl-3 alkoxy, Cl-3alkanoyl, Cl-3alkanoyloxy, aryloxy, benzyloxy, Cl-3 alkoxycarbonyl, aryloxycarbonyl, aroyloxy, carbamoyl wherein the nitrogen atom <br><br> 38 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> may be independently mono or di-substituted by Cl-3 alkyl, aryl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl, <br><br> or Ra is Cl-3 alkanoylamino, aroylamino, Cl-3 alkylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, arylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, ureido wherein either nitrogen atom may be independently substituted by Cl-3 alkyl, aryl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl, <br><br> or Ra is Cl-3 alkoxycarbonylamino, aryloxycarbonylamino, Cl-3 alkylcarbamoyloxy, arylcarbamoyloxy, Cl-3 alkylsulfonylamino, arylsulfonylamino, Cl-3 alkylaminosulfonyl, arylaminosulfonyl, amino wherein the nitrogen atom may be independently mono or di-substituted by Cl-3 alkyl, aryl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl, <br><br> or Ra is halogen, hydroxy, oxo, carboxy, cyano, nitro, carboxamide, amidino or guanidino, Ra may be further optionally substituted by one or more Rb; <br><br> Rb is methyl, ethyl, n-propyl, i-propyl, cyclopropyl, cyclopentyl, cyclohexyl, phenyl, methoxy, ethoxy, n-propoxy, i-propoxy, phenoxy, benzyloxy, fluoro, chloro, bromo, iodo, hydroxy, oxo, carboxy, cyano, nitro or carboxamide; <br><br> R2 is hydrogen; <br><br> R3 is a bond, Cl-3 alkyl, C2-4alkylene, C5-6 cycloalkyl, benzyl or naphthylmethyl wherein R3 is optionally substituted by one or more Rc; <br><br> Rc is Cl-3 alkyl, C5-6 cycloalkyl, phenyl, naphthyl, indanyl, <br><br> bicyclo[2.2. l]heptanyl, bicyclo[2.2.2]octanyl, bicyclo[4.1.0]heptanyl, bicyclo[3.1.0]hexanyl,bicyclo[l.l.l]pentanyl, cubanyl, 1,2,3,4-tetrahydronaphthyl, furanyl, tetrahydropyranyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrimidinyl, indolyl, benzofuranyl, benzothienyl, benzthiazolyl, Cl-3 alkoxy, phenoxy, naphthyloxy, Cl-2 alkanoyl, benzoyl, Cl-2 alkoxycarbonyl, <br><br> 39 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> phenoxycarbonyl, Cl-2alkanoyloxy, benzoyloxy, carbamoyl wherein the nitrogen atom may be independently mono or di-substituted by Cl-3 alkyl or aiyl, <br><br> or Rc is Cl-2 alkanoylamino, benzoylamino, Cl-2 alkylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, phenylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, ureido wherein either nitrogen atom may be independently substituted by Cl-3 alkyl or aryl, <br><br> or Rc is Cl-2 alkoxycarbonylamino, phenoxycarbonylarnino, Cl-2 alkylcarbamoyloxy, arylcarbamoyloxy, Cl-2 alkylsulfonylamino, phenylsulfonylamino, Cl-2alkylaminosuIfonyl, phenylaminosulfonyl, amino wherein the nitrogen atom may be independently mono or di-substituted by Cl-3 alkyl or phenyl, <br><br> or Rc is halogen, hydroxy, oxo, carboxy or cyano, Rc may be further optionally substituted by one or more R^; <br><br> Rd is methyl, cyclopropyl, cyclohexyl, phenyl, benzyl, methoxy, phenoxy, benzyloxy, benzoyl, fluoro, chloro, oxo or cyano; <br><br> R4 is hydrogen; <br><br> Rs is a bond, hydrogen, carbonyl, Cl-5 alkyl, Cl-5alkoxyCl-5alkyl, Cl-5alkylaminoCl-5alkyl, Cl-5alkylthioCl-5alkyl wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, Cl-5 alkoxy, phenoxy, C3-6 cycloalkyl, phenyl, naphthyl, benzyl, indanyl, heterocyclyl selected from pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, tetrahydropyranyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, benzimidazolyl and benzthiazolyl, heterocyclyloxy wherein the heterocyclyl moiety is selected from those herein described in this paragraph, Cl-3alkanoyl, benzoyl, naphthoyl, Cl-3alkanoyloxy, benzyloxy, Cl-3 alkoxycarbonyl, benzyloxycarbonyl, phenoxycarbonyl, benzoyloxy, carbamoyl wherein the nitrogen atom may be independently mono or di-substituted by Cl-3 alkyl, phenyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl or pyrimidinyl, <br><br> 40 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> or R5 is Cl-3 alkanoylamino, aroylamino, Cl-3 alkylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, phenylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, ureido wherein either nitrogen atom may be independently substituted by Cl-3 alkyl, phenyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, benzofuranyl, benzothienyl, benzimidazolyl or benzthiazolyl, <br><br> or R5 is Cl-3 alkoxycarbonylamino, phenoxycarbonylarnino, Cl-3 alkylcarbamoyloxy, phenylcarbamoyloxy, Cl-3 alkylsulfonylamino, phenylsulfonylamino, Cl-3 alkylaminosulfonyl, phenylaminosulfonyl, amino wherein the nitrogen atom may be independently mono or di-substituted by Cl-3 alkyl, phenyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomoipholinyl, piperazinyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, benzimidazolyl or benzthiazolyl, <br><br> or R5 is halogen, hydroxy, oxo, carboxy, cyano or carboxamide, R5 may be further optionally substituted by one or more Re; <br><br> Re is Cl-3 alkyl, Cl-3 alkoxy, C3-7 cycloalkyl, phenyl, naphthyl, indanyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, tetrahydropyranyl, indolyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, benzimidazolyl, benzthiazolyl, benzoxazolyl, Cl-3 alkanoyl, aroyl, Cl-3alkanoyloxy, phenoxy, benzyloxy, Cl-3 alkoxycarbonyl, phenoxycarbonyl, benzoyloxy, carbamoyl wherein the nitrogen atom may be independently mono or di-substituted by Cl-3 alkyl, phenyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, benzimidazolyl or benzthiazolyl, or Re is Cl-3 alkanoylamino, benzoylamino, Cl-3 alkylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, phenylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, ureido wherein either nitrogen atom may be independently substituted by Cl-3 alkyl, phenyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, benzimidazolyl or benzthiazolyl, <br><br> or Re is Cl-3 alkoxycarbonylamino, phenoxycarbonylarnino, Cl-3 alkylcarbamoyloxy, phenylcarbamoyloxy, Cl-3 alkylsulfonylamino, <br><br> 41 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> phenylsulfonylamino, Cl-3 alkylaminosulfonyl, phenylaminosulfonyl, amino wherein the nitrogen atom may be independently mono or di-substituted by Cl-3 alkyl, phenyl, naphthyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, benzimidazolyl or benzthiazolyl, <br><br> or Re is halogen, hydroxy, oxo, carboxy, cyano or carboxamide, Re may be further optionally substituted by one or more Rf; <br><br> Rf is methyl, phenyl, tolylsulfonyl, melhoxy, phenoxy, benzyloxy, fluoro, chloro, bromo, hydroxy, oxo, carboxy or carboxamide; <br><br> Re is hydroxy, nitrile or a Cl-5 saturated or unsaturated branched or unbranched carbon chain optionally partially or fully halogenated wherein one or more C atoms are optionally replaced by O, NH, or S(0)2 and wherein said chain is optionally independently substituted with 1-2 oxo groups, -NH2, one or more Cl-4 alkyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, indolinyl, pyranyl, thiopyranyl, furanyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, quinolinyl, isoquinolinyl, quinazolinyl, benzoxazolyl or quinoxalinyl; <br><br> and <br><br> X is O. <br><br> In another embodiment of the invention, there are provided novel compounds of the formula (la) and (lb) as described immediately above, and wherein: <br><br> Ri is a bond, methyl, ethyl, i-propyl, methoxy, ethoxy, cyclopropyl, cyclopentyl, cyclohexyl, phenoxy, phenyl, benzyl, naphthyl, pyrrolidinyl, piperidinyl, morpholinyl, <br><br> 42 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> thiomoipliolinyl, piperazinyl, furanyl, thienyl, thiazolyl, imidazolyl, pyridinyl, pyrazinyl or amino; wherein Rj is optionally substituted by one or more Ra; <br><br> Ra is a bond, methyl, ethyl, cyclopropyl, phenyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, thienyl, imidazolyl, methoxy, acetyl, acetoxy, phenoxy, benzyloxy, methoxycarbonyl, phenoxycarbonyl, benzoyloxy, carbamoyl wherein the nitrogen atom may be independently mono or di-substituted by methyl, ethyl or phenyl, <br><br> or Ra is acetylamino, benzoylamino, methylthio, phenylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, ureido wherein either nitrogen atom may be independently substituted by methyl, ethyl or phenyl, <br><br> or Ra is methoxycarbonylamino, phenoxycarbonylarnino, methylcarbamoyloxy, phenylcarbamoyloxy, methylsulfonylamino, phenylsulfonylamino, methylaminosulfonyl, phenylaminosulfonyl, amino wherein the nitrogen atom may be independently mono or di-substituted by methyl or phenyl, <br><br> or Ra is fluoro, chloro, bromo, iodo, hydroxy, oxo, carboxy, cyano, nitro or carboxamide, Ra may be further optionally substituted by one or more Rb", <br><br> Rb is methyl, cyclopropyl, phenyl, methoxy, phenoxy, benzyloxy, fluoro, chloro, hydroxy, oxo, carboxy or carboxamide; <br><br> R3 is a bond, Cl-3 alkyl, C2-4alkylene, C5-6 cycloalkyl, benzyl or naphthylmethyl wherein R3 is optionally substituted by one or more R^ <br><br> Rc is methyl, ethyl, n-propyl, i-propyl, C5-6 cycloalkyl, indanyl, bicyclo[2.2.1]heptanyI, bicyclo[2.2.2]octanyl, bicyclo[4.1 .Ojheptanyl, bicyclo[3.1.0]hexanyl, bicyclo[l.l.l]pentanyl, cubanyl, 1,2,3,4-tetrahydronaphthyl, thienyl, oxazolyl, thiazolyl, indolyl, benzofuranyl, benzothienyl, benzthiazolyl, methoxy, ethoxy, phenoxy, acetyl, benzoyl, methoxycarbonyl, phenoxycarbonyl, acetoxy, benzoyloxy, carbamoyl wherein the nitrogen atom may be independently mono or di-substituted by methyl, ethyl or aryl, <br><br> 43 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> or Rc is acetyl amino, benzoylamino, methylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, phenylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, ureido wherein either nitrogen atom may be independently substituted by methyl, ethyl or aryl, <br><br> or Rc is methoxycarbonylamino, phenoxycarbonylarnino, methylcarbamoyloxy, phenylcarbamoyloxy, methylsulfonylamino, phenylsulfonylamino, methylaminosulfonyl, phenylaminosulfonyl, amino wherein the nitrogen atom may be independently mono or di-substituted by methyl, ethyl or phenyl, <br><br> or Rc is fluoro, chloro or oxo, Rc may be further optionally substituted by one or more R^; <br><br> R&lt;j is methyl, cyclopropyl, phenyl, methoxy, fluoro, chloro or oxo; <br><br> R5 is a bond, hydrogen, carbonyl, Cl-4 alkyl, Cl-4alkoxyCl-4alkyl, Cl-4alkylaminoCl-4alkyl, C1 -4alkylthioC 1 -4alkyl wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, Cl-4 alkoxy,phenoxy, cyclopropyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, benzyl, indanyl, heterocyclyl selected from pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, tetrahydropyranyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, benzimidazolyl and benzthiazolyl, heterocyclyloxy wherein the heterocyclyl moiety is selected from those herein described in this paragraph, Cl-2alkanoyl, benzoyl, naphthoyl, Cl-2alkanoyloxy, benzyloxy, Cl-2 alkoxycarbonyl, benzyloxycarbonyl, phenoxycarbonyl, benzoyloxy, carbamoyl wherein the nitrogen atom may be independently mono or di-substituted by Cl-2 alkyl, phenyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl or pyrimidinyl, or R5 is Cl-2 alkanoylamino, benzoylamino, Cl-2 alkylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, phenylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, ureido wherein either nitrogen atom may be independently substituted by Cl-2 alkyl, phenyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, benzimidazolyl or benzthiazolyl, <br><br> 44 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> or R5 is Cl-2 alkoxycarbonylamino, phenoxycarbonylarnino, Cl-2 alkylcarbamoyloxy, phenylcarbamoyloxy, Cl-2 alkylsulfonylamino, phenylsulfonylamino, Cl-2 alkylaminosulfonyl, phenylaminosulfonyl, amino wherein the nitrogen atom may be independently mono or di-substituted by Cl-2 alkyl, phenyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl or pyrimidinyl, or R5 is fluoro, chloro, bromo, hydroxy, oxo, carboxy or carboxamide, Rs may be further optionally substituted by one or more R«; <br><br> Re is Cl-3 alkyl, Cl-2 alkoxy, C3-6 cycloalkyl, phenyl, naphthyl, indanyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, tetrahydropyranyl, indolyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, benzimidazolyl, benzthiazolyl, benzoxazolyl, Cl-2 alkanoyl, aroyl, Cl-2alkanoyloxy, phenoxy, benzyloxy, Cl-2 alkoxycarbonyl, phenoxycarbonyl, benzoyloxy, carbamoyl wherein the nitrogen atom may be independently mono or di-substituted by Cl-2 alkyl, phenyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl or pyrimidinyl, <br><br> or Re is Cl-2 alkanoylamino, benzoylamino, Cl-2 alkylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, phenylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, ureido wherein either nitrogen atom may be independently substituted by Cl-2 alkyl, phenyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl or pyrimidinyl, <br><br> or Re is Cl-2 alkoxycarbonylamino, phenoxycarbonylarnino, Cl-2 alkylcarbamoyloxy, phenylcarbamoyloxy, Cl-2 alkylsulfonylamino, phenylsulfonylamino, Cl-2 alkylaminosulfonyl, phenylaminosulfonyl, amino wherein the nitrogen atom may be independently mono or di-substituted by Cl-2 alkyl, phenyl, naphthyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl or pyrimidinyl, <br><br> or Re is fluoro, chloro, bromo, hydroxy, oxo, carboxy or carboxamide, Re may be further optionally substituted by one or more Rf; <br><br> 45 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> Rf is methyl, phenyl, tolylsulfonyl, methoxy, phenoxy, benzyloxy, fluoro, chloro, hydroxy, oxo, carboxy or carboxamide and <br><br> R« is nitrile or a Cl-5 saturated or unsaturated branched or unbranched carbon chain optionally partially or fully halogenated wherein one or more C atoms are optionally replaced by O, NH, or S(0)2 and wherein said chain is optionally independently substituted with oxo, -NH2, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, pyridinyl, pyrimidinyl or pyrazinyl. <br><br> In yet another embodiment of the invention, there are provided novel compounds of the formula (la) or formula (lb) as described immediately above, and wherein: <br><br> Het is piperidin-4-yl, piperidin-3-yl, pyrrolidin-3-yl, azetidin-3-yl, azepan-3-yl, azepan-4-yl or tetrahydropyran-4-yl, each ring being optionally substituted with one or more R5; <br><br> Ri is a bond, methyl, ethyl, i-propyl, methoxy, cyclopropyl, cyclohexyl, phenoxy, phenyl, benzyl, naphthyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, furanyl, thienyl, thiazolyl, imidazolyl, pyridinyl, pyrazinyl or amino; wherein Ri is optionally substituted by one or more Ra; <br><br> Ra is methyl, phenyl, thienyl, methoxy, acetyl, acetoxy, phenoxy, benzyloxy, methoxycarbonyl, benzoyloxy, carbamoyl wherein the nitrogen atom may be independently mono or di-substituted by methyl or phenyl, <br><br> or Ra is acetylamino, methylthio, phenylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, ureido wherein either nitrogen atom may be independently substituted by methyl or phenyl, <br><br> 46 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> or Ra is methoxycarbonylamino, methylcarbamoyloxy, phenylcarbamoyloxy, methylsulfonylamino, phenylsulfonylamino, amino wherein the nitrogen atom may be independently mono or di-substituted by methyl or phenyl, <br><br> or Ra is fluoro, chloro, hydroxy, oxo, carboxy, cyano or carboxamide; <br><br> R3 is a bond, methyl, ethyl, n-propyl, propenyl, butenyl, i-butenyl, cyclohexyl, benzyl or naphthyhnethyl wherein R3 is optionally substituted by one or more R^; <br><br> Rc is methyl, ethyl, n-propyl, i-propyl, cyclohexyl, cyclopentyl, indanyl, bicyclo[2.2.l]heptanyl, bicyclo[2.2.2]octanyl, bicyclo[4.1.0]heptanyl, bicyclo[3.1.0]hexanyl, bicyclo[ 1.1. l]pentanyl, cubanyl, 1,2,3,4-tetrahydronaphthyl, methoxy, phenoxy, acetyl, benzoyl, methoxycarbonyl, phenoxycarbonyl, acetoxy, benzoyloxy, methylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, phenylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, fluoro, chloro or oxo; <br><br> and wherein the configuration at the stereocenter defined by R2 and R3 when they are different and the carbon they are attached to is defined as L; and <br><br> R5 is a bond, hydrogen, carbonyl, Cl-4 alkyl, Cl-2alkoxyCl-2alkyl, Cl-2alkylaminoCl-2alkyl, Cl-2alkylthioCl-2alkyl wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, Cl-2 alkoxy, phenoxy, cyclopropyl, cyclopentyl, cyclohexyl, phenyl, benzyl, heterocyclyl selected from pyrrolidinyl, piperidinyl, morpholinyl, tetrahydropyranyl, pyridinyl, and pyrimidinyl, heterocyclyloxy wherein the heterocyclyl moiety is selected from those herein described in this paragraph, acetyl, benzoyl, acetyloxy, benzyloxy, methoxycarbonyl, ethoxycarbonyl, benzyloxycarbonyl, benzoyloxy, carbamoyl wherein the nitrogen atom may be independently mono or di-substituted by methyl, ethyl or phenyl, <br><br> or R5 is acetylamino, benzoylamino, methylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, phenylthio wherein the sulfur atom may be oxidized to a <br><br> 47 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> sulfoxide or sulfone, ureido wherein either nitrogen atom may be independently substituted by methyl, ethyl or phenyl, <br><br> or R5 is methoxycarbonylamino, ethoxycarbonylamino, phenoxycarbonylarnino, methylcarbamoyloxy, phenylcarbamoyloxy, methylsulfonylamino, phenylsulfonylamino, methylaminosulfonyl, phenylaminosulfonyl, amino wherein the nitrogen atom may be independently mono or di-substituted by methyl, ethyl or phenyl, <br><br> or R5 is fluoro, chloro, hydroxy, oxo, carboxy or carboxamide, R5 may be further optionally substituted by one or more Re', <br><br> Re is methyl, methoxy, ethoxy, cyclopropyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, indanyl, piperidinyl, morpholinyl, indolyl, thienyl, pyridinyl, acetyl, benzoyl, acetyloxy, phenoxy, benzyloxy, methoxycarbonyl, ethoxycarbonyl, carbamoyl wherein the nitrogen atom may be independently mono or di-substituted by methyl, ethyl or phenyl, <br><br> or Re is acetylamino, benzoylamino, methylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, phenylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, ureido wherein either nitrogen atom may be independently substituted by methyl, ethyl or phenyl, <br><br> or Re is methoxycarbonylamino, ethoxycarbonylamino, phenoxycarbonylarnino, methylcarbamoyloxy, phenylcarbamoyloxy, methylsulfonylamino, phenylsulfonylamino, methylaminosulfonyl, phenylaminosulfonyl, amino wherein the nitrogen atom may be independently mono or di-substituted by methyl, ethyl or phenyl, <br><br> or Re is fluoro, chloro, hydroxy, oxo, carboxy or carboxamide, Re may be further optionally substituted by one or more Rf; <br><br> Rf is methyl, phenyl, tolylsulfonyl, phenoxy, benzyloxy, fluoro, chloro or oxo; <br><br> R« is nitrile or a Cl-5 saturated or unsaturated branched or unbranched carbon chain optionally partially or fully halogenated wherein one or more C atoms are optionally replaced by O, NH, or <br><br> 48 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> S(0)2 and wherein said chain is optionally independently substituted with oxo, -NH2, morpholinyl or piperazinyl. <br><br> In yet still another embodiment of the invention, there are provided novel compounds of the formulas (la) and (lb) as described immediately above, and wherein: <br><br> Het is piperidin-4-y1, piperidin-3-yl, pyrroIidin-3-yl, azetidin-3-yl or tetrahydropyran-4-yl, each ring being substituted with one or more R5; <br><br> Ri is i-propyl, benzyloxy, cyclohexyl, phenyl, 4-(acetylarnino)-phenyl, 4-(methanesulfonylamino)-phenyl, 4-methoxyphenyl, 3-phenoxyphenyl, 4-chlorophenyl, 4-fluorophenyl, 2-fluorophenyl, 2-fluoro-4-chlorophenyl, naphthyl, thienylmethyl, piperidinyl, morpholinyl, pyrrolidinyl, piperazinyl, furanyl, thienyl, 5-chlorothienyl, pyridin-4-yl, pyrazinyl, methylamino, ethylamino, dimethylamino or diethylamino; <br><br> R3 is ethyl, n-propyl,propenyl, butenyl, i-butenyl, benzyl or naphthylmethyl wherein R3 is optionally substituted by one or more Rc; <br><br> Rc is methyl, cyclohexyl, cyclopentyl, indanyl, 1,2,3,4-tetrahydronaphthyl, methoxy, methylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, fluoro or chloro; <br><br> R5 is a bond, carbonyl, methyl, ethyl, n-propyl, n-butyl, t-butyl, i-propyl, i-butyl, cyclopropyl, cyclopentyl, cyclohexyl, phenyl, benzyl, piperidinyl, tetrahydropyranyl, pyrimidinyl, acetyl, benzoyl, ethoxycarbonyl, benzyloxycarbonyl, methylsulfonylamino, phenylsulfonylamino, methylamino, dimethylamino, fluoro, oxo or carboxy, R5 may be further optionally substituted by one or more Re; <br><br> Re is methyl, cyclopropyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, indanyl, thienyl, 5-methylthienyl, methoxy, phenoxy, benzyloxy, piperidinyl, pyridinyl, <br><br> 49 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> indolyl, l-(tolyl-sulfonyl)-indolyl, carbamoyl wherein the nitrogen atom may be independently mono or di-substituted by methyl, phenyl or benzyl, <br><br> or Re is hydroxy, fluoro, chloro, oxo, dimethylamino or trifluoromethyl; <br><br> and <br><br> R6 is acetyl, Cl-3alkylaminocarbonyl or Cl-3alkoxycarbonyl. <br><br> In yet a further embodiment of the invention, there are provided novel compounds of the formulas (la) and (lb) as described immediately above, and wherein: <br><br> Het is piperidin-4-yl or pyrrolidin-3-yl; <br><br> Ri is morpholin-4-yl, p-fluorophenyl or p-methoxyphenyl; <br><br> R5 is methyl, propyl, n-pentyl or cyclohexyl and <br><br> Rfi is acetyl, ethylaminocarbonyl or ethoxycarbonyl. <br><br> The activity of particular compounds disclosed herein against cathepsin K may be determined without undue experimentation by one of ordinary skill in the art in view of the art, the guidance provided throughout this specification and by the screens described in the section entitled "Assessment of Biological Properties." <br><br> The following subgeneric aspect of the compounds of the formulas (la) and (lb) is postulated to possess Cathepsin K activity: <br><br> The broadest embodiment of the formula (la) and (lb) as described hereinabove and wherein <br><br> 50 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> Het is piperidinyl, pyrrolidinyl, azetidinyl, azepanyl, oxepanyl, tetrahydropyranyl, oxetanyl or tetrahydrothiopyranyl each ring being optionally substituted with one or more Rs; <br><br> Ri is a bond, Cl-4 alkyl, Cl-4 alkoxy, cyclopropyl, cyclohexyl, phenoxy, naphthyloxy, phenyl, benzyl, naphthyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, indolyl, quinolinyl, benzofuranyl, benzthienyl, benzimidazolyl, benzthiazolyl, benzoxazolyl or amino; wherein Ri is optionally substituted by one or more Ra; <br><br> Ra is methyl, ethyl, propyl, i-propyl, cyclopropyl, cyclohexyl, phenyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, thienyl, imidazolyl, methoxy, ethoxy, acetyl, acetoxy, phenoxy, naphthyloxy, benzyloxy, methoxycarbonyl, ethoxycarbonyl, phenoxycarbonyl, naphthyloxycarbonyl, benzoyloxy, carbamoyl wherein the nitrogen atom may be independently mono or di-substituted by methyl, ethyl, phenyl, naphthyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl, <br><br> or Ra is acetylamino, benzoylamino, methylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, ethylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, phenylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, ureido wherein either nitrogen atom may be independently substituted by methyl, ethyl, phenyl, naphthyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl, <br><br> or Ra is methoxycarbonylamino, ethoxycarbonylamino, phenoxycarbonylarnino, Cl-2 alkylcarbamoyloxy, phenylcarbamoyloxy, naphthylcarbamoyloxy, Cl-2 alkylsulfonylamino, phenylsulfonylamino, naphthylsulfonylamino, Cl-2 alkylaminosulfonyl, phenylaminosulfonyl, naphthylaminosulfonyl, amino wherein the nitrogen atom may be independently mono or di-substituted by methyl, ethyl, phenyl, naphthyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl, <br><br> 51 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> or Ra is halogen, hydroxy, oxo, carboxy, cyano, nitro, carboxamide, amidino or guanidino, Ra may be further optionally substituted by one or more Rb; <br><br> Rb is methyl, ethyl, cyclopropyl, cyclohexyl, phenyl, methoxy, ethoxy, phenoxy, benzyloxy, fluoro, chloro, bromo, hydroxy, oxo, carboxy, cyano, nitro or carboxamide; <br><br> R2 is hydrogen or methyl; <br><br> R3 is a bond, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, n-pentyl, propenyl, i-butenyl, cyclohexyl, benzyl or naphthylmethyl wherein R3 is optionally substituted by one or more Rc; <br><br> Rc is methyl, ethyl, cyclohexyl, cyclopentyl, phenyl, naphthyl, bicyclo[3.1.0]hexany], bicyclof 1.1. ljpentanyl, cubanyl, furanyl, tetrahydropyranyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrimidinyl, methoxy, ethoxy, phenoxy, acetyl, benzoyl, methoxycarbonyl, phenoxycarbonyl, acetoxy, benzoyloxy, carbamoyl wherein the nitrogen atom may be independently mono or di-substituted by methyl or phenyl, <br><br> or Rc is acetylamino, benzoylamino, methylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, phenylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, ureido wherein either nitrogen atom may be independently substituted by methyl or phenyl, <br><br> or Rc is methoxycarbonylamino, phenoxycarbonylarnino, methylcarbamoyloxy, phenylcarbamoyloxy, methylsulfonylamino, phenylsulfonylamino, methylaminosulfonyl, phenylaminosulfonyl, amino wherein the nitrogen atom may be independently mono or di-substituted by methyl or phenyl, <br><br> or Rc is chloro, fluoro, hydroxy, oxo, carboxy or cyano; <br><br> R2 and R3 together with the carbon they are attached optionally form a ring selected from cyclopentyl, cyclohexyl, cycloheptyl, tetrahydropyranyl, tetrahydrothiopyranyl, <br><br> 52 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl or tetrahydrothiophenyl; <br><br> R4 is hydrogen; <br><br> Rs is a bond, hydrogen, carbonyl, Cl-5 alkyl, Cl-5alkoxyCl-5alkyl, Cl-5alkylaminoCl-5alkyl, Cl-5alkylthioCl-5alkyl wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, Cl-5 alkoxy, phenoxy, naphthyloxy, cyclopropyl, cyclopentyl, cyclohexyl, phenyl, benzyl, heterocyclyl selected from pyrrolidinyl, piperidinyl, morpholinyl, tetrahydropyranyl, pyridinyl, and pyrimidinyl, heterocyclyloxy wherein the heterocyclyl moiety is selected from those herein described in this paragraph, acetyl, benzoyl, acetyloxy, benzyloxy, methoxycarbonyl, ethoxycarbonyl, benzyloxycarbonyl, benzoyloxy, carbamoyl wherein the nitrogen atom may be independently mono or di-substituted by methyl, ethyl or phenyl, <br><br> or R5 is acetylamino, benzoylamino, phenylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, ureido wherein either nitrogen atom may be independently substituted by methyl, ethyl or phenyl, <br><br> or Rg is methoxycarbonylamino, ethoxycarbonylamino, phenoxycarbonylarnino, methylcarbamoyloxy, phenylcarbamoyloxy, phenylsulfonylamino, phenylaminosulfonyl, amino wherein the nitrogen atom may be independently mono or di-substituted by methyl, ethyl or phenyl, <br><br> or R5 is fluoro, chloro, hydroxy, oxo, carboxy or carboxamide, R5 may be further optionally substituted by one or more Re; <br><br> R« is methyl ethyl, methoxy, ethoxy, cyclopropyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, indanyl, piperidinyl, morpholinyl, indolyl, thienyl, pyridinyl, methoxy, ethoxy, acetyl, benzoyl, acetyloxy, phenoxy, benzyloxy, methoxycarbonyl, ethoxycarbonyl, carbamoyl wherein the nitrogen atom may be independently mono or di-substituted by methyl, ethyl or phenyl, <br><br> or R« is acetylamino, benzoylamino, methylthio wherein the sulfur atom may be oxidized to a sulfoxide or sulfone, phenylthio methylthio wherein the sulfur atom <br><br> 53 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> may be oxidized to a sulfoxide or sulfone, ureido wherein either nitrogen atom may be independently substituted by methyl, ethyl or phenyl, <br><br> or Re is methoxycarbonylamino, ethoxycarbonylamino, phenoxycarbonylarnino, methylcarbamoyloxy, phenylcarbamoyloxy, methylsulfonylamino, phenylsulfonylamino, methylaminosulfonyl, phenylaminosulfonyl, amino wherein the nitrogen atom may be independently mono or di-substituted by methyl, ethyl or phenyl, <br><br> or Re is fluoro, chloro, hydroxy, oxo, carboxy or carboxamide, Re may be further optionally substituted by one or more Rf; <br><br> Rf is methyl, phenyl, tolylsulfonyl, phenoxy, benzyloxy, fluoro, chloro or oxo. <br><br> Preferred cathepsin K inhibitors are those as described immediately above and wherein: <br><br> Ri is a bond, methyl, ethyl, n-propyl, i-propyl, methoxy, ethoxy, benzyloxy, cyclopropyl, cyclohexyl, phenoxy, naphthyloxy, phenyl, benzyl, naphthyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, indolyl, quinolinyl, benzofuranyl, benzthienyl, benzimidazolyl, benzthiazolyl, benzoxazolyl or amino; wherein R) is optionally substituted by one or more Ra; <br><br> Ra is methyl, cyclopropyl, phenyl, halogen, hydroxy, oxo, carboxy, cyano, nitro or carboxamide; <br><br> R3 is a bond, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, n-pentyl, propenyl, i-butenyl, benzyl or naphthylmethyl wherein R3 is optionally substituted by one or more Rc; <br><br> Rc is methyl, ethyl, cyclohexyl, cyclopentyl, phenyl, furanyl, tetrahydropyranyl, thienyl, oxazolyl, thiazolyl, methoxy, phenoxy, acetyl, benzoyl, methoxycarbonyl, <br><br> 54 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> carbamoyl wherein the nitrogen atom may be independently mono or di-substituted by methyl or phenyl, <br><br> or Rc is acetylamino, benzoylamino, methylthio, methoxycarbonylamino, methylcarbamoyloxy, methylsulfonylamino, methylaminosulfonyl, amino wherein the nitrogen atom may be independently mono or di-substituted by methyl, <br><br> or Rc is fluoro or oxo; <br><br> R2 and R3 together with the carbon they are attached optionally form a ring selected from cyclopentyl, cyclohexyl, cycloheptyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrofuranyl, pyrrolidinyl or piperidinyl; <br><br> Rs is methyl, ethyl, n-propyl, n-butyl, n-pentyl, 2-pentyl, 3-pentyl, phenethyl, <br><br> phenpropyl, 2,2-dimethylpropyl, t-butyl, i-propyl, i-butyl, cyclopropyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl, phenyl, benzyl, 2-methylbenzyl, 3-methylbenzyl, 4-methylbenzyl, 2,6-dimethylbenzyl, 2,5-dimethylbenzyl, 2,4-dimethylbenzyl, 2,3-dimethylbenzyl, 3,4-dimethylbenzyl, 3,5-dimethylbenzyl, 2,4,6-trimethylbenzyl, 2-methoxybenzyl, 3-methoxybenzyl, 4-methoxybenzyl, 2-phenoxybenzyl, 3-phenoxybenzyl, 4-phenoxybenzyl, 2-benzyloxybenzyl,3-benzyloxybenzyl, 4-benzyloxybenzyl, 2-fluorobenzyl, 3-fluorobenzyl, 4-fluorobenzyl, 2,6-difluorobenzyl, 2,5-difluorobenzyl, 2,4-difluorobenzyl, 2,3-difluorobenzyl, 3,4-difluorobenzyl, 3,5-difluorobenzyl, 2,4,6-triflurobenzyl, 2-trifluoromethylben2yl, 3-trifluoromethylbenzyl, 4-trifluoromethyIbenzyl, naphthylmethyl, indanylmethyl, pyridinylmethyl, indolylmethyl, thienylmethyl, 5-methylthienylmethyl, piperidinyl, piperidinylcarbonyl, pyridinylcarbonyl, tetrahydropyranyl, pyrimidinyl, acetyl, benzoyl, ethoxycarbonyl, benzyloxyearbonyl, t-butoxycarbonyl, methylcarbamoyl, phenylcarbamoyl, benzylcarbamoyl, methylsulfonylamino, phenylsulfonylamino, methylamino, dimethylamino, fluoro, oxo or carboxy. <br><br> Most preferred cathepsin K inhibitors are those as described immediately above and wherein: <br><br> 55 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> Ri is methoxy, benzyloxy, cyclohexyl, phenoxy, naphthyloxy, phenyl, benzyl, naphthyl, pyrrolidinyl, piperidinyl, moipholinyl, thiomoipholinyl, piperazinyl, furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, quinolinyl, benzofuranyl, benzthienyl, benzimidazolyl, benzthiazolyl, benzoxazolyl or amino; wherein Ri is optionally substituted by one or more Ra; <br><br> Ra is methyl, phenyl, fluoro, chloro, hydroxy, oxo, carboxy or carboxamide; <br><br> R3 is a bond, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, n-pentyl, propenyl, i-butenyl or benzyl wherein R3 is optionally substituted by one or more Rc; <br><br> Rc is methyl, ethyl, cyclohexyl, cyclopentyl, phenyl, furanyl, tetrahydropyranyl, thienyl, oxazolyl, thiazolyl, methoxy, phenoxy, acetyl, benzoyl, methoxycarbonyl, acetylamino, methylthio, methylsulfonylamino or fluoro; <br><br> R2 and R3 together with the carbon they are attached optionally form, a ring selected from cyclopentyl, cyclohexyl, cycloheptyl, tetrahydropyranyl, tetrahydrothiopyranyl or tetrahydrofuranyl; <br><br> R5 is methyl, ethyl, n-propyl, n-butyl, phenethyl, phenpropyl, t-butyl, i-propyl, i-butyl, cyclopropyl, cyclohexyl, cyclopropylmethyl, cyclohexylmethyl, phenyl, benzyl, 2-methoxybenzyl, 3-methoxybenzyl, 4-methoxybenzyl 4-fluorobenzyl, 3,5-difluorobenzyl, 4-trifluoromethylbenzyl, naphthylmethyl, pyridinylmethyl, indolylmethyl, thienylmethyl, acetyl, benzoyl, ethoxycarbonyl, benzyloxycarbonyl, t-butoxycarbonyl, <br><br> phenylcarbamoyl, phenylsulfonylamino or fluoro. <br><br> Most preferred cathepsin K inhibitors are those as described immediately above and wherein: <br><br> Het is pyrrolidinyl, piperidinyl or tetrahydropyranyl; <br><br> 56 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> Ri is benzyloxy, phenoxy, naphthyloxy, phenyl, naphthyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomoipholinyl, piperazinyl, pyridinyl, indolyl, quinolinyl, benzofuranyl, benzthienyl, benzimidazolyl, benzthiazolyl, benzoxazolyl or phenylamino; <br><br> R3 is n-propyl, i-butyl, propenyl, i-butenyl or 2,2-dimethylpropyl; <br><br> R2 and R3 together with the carbon they are attached optionally form a ring selected from cyclopentyl, cyclohexyl, or cycloheptyl; <br><br> R5 is methyl, ethyl, n-propyl, phenethyl, t-butyl, i-propyl, i-butyl, cyclohexyl, cyclohexylmethyl, benzyl, 4-fluorobenzyl, naphthylmethyl, acetyl, benzoyl or benzyloxycarbonyl. <br><br> Further compounds of Formula (la), made up of components A, B, and C are provided in the following Table I. Any and all combinations of A, B, and C components within the structural limitations of Formula (la), comprise a compound of the invention, and their pharmaceutically acceptable derivatives. These compounds can be synthesized by the General schemes, methods described in the experimental section of this document and analogous methods known to those skilled in the art without undue experimentation. Preferred compounds will possess desirable inhibition activity of Cathepsin S in a cell based assay as described in Riese, R.J. et al., Immunity, 1996,4, 357-366, incorporated herein by reference. <br><br> FORMULA (la) <br><br> 57 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> TABLE I <br><br> A <br><br> R6X <br><br> 4 <br><br> B <br><br> R2 R3 R4 X <br><br> C <br><br> R4 I <br><br> Al <br><br> A <br><br> &gt; <br><br> B1 <br><br> H 0 <br><br> CI <br><br> 7 <br><br> &gt; <br><br> A2 <br><br> X <br><br> &amp;■. <br><br> i <br><br> B2 <br><br> H 0 . <br><br> 9 <br><br> C2 <br><br> i. <br><br> &gt; <br><br> A3 <br><br> H-^"° &lt;A. <br><br> °\X^ <br><br> B3 <br><br> H O <br><br> j <br><br> C3 <br><br> » H ^.N <br><br> tf <br><br> &gt; <br><br> A4 <br><br> o <br><br> MeCL ^0 A. I ° N <br><br> j <br><br> B4 <br><br> Me fj-u. <br><br> w <br><br> H 0 <br><br> C4 <br><br> , H ^.N <br><br> tf <br><br> W <br><br> &gt; <br><br> A5 <br><br> 0 o <br><br> 1 JL <br><br> H3C"Ts| O N <br><br> 9 <br><br> B5 <br><br> _ <br><br> Xf"" <br><br> H 0 <br><br> 5 <br><br> C5 <br><br> K" <br><br> 9 <br><br> 58 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> A6 <br><br> X X <br><br> MeO O N <br><br> &gt; <br><br> B6 <br><br> jCf" <br><br> H 0 <br><br> j <br><br> C6 <br><br> i H xSjN <br><br> t) <br><br> j <br><br> A7 <br><br> 0 <br><br> H,CV 3 N^N <br><br> 6* <br><br> j <br><br> B7 <br><br> Me <br><br> MeJT */* <br><br> H 0 <br><br> 9 <br><br> C7 <br><br> , H <br><br> &gt; <br><br> A8 <br><br> H,Cn ^0 <br><br> 6*. <br><br> j <br><br> B8 <br><br> Me <br><br> A <br><br> H O <br><br> C8 <br><br> tr <br><br> &gt; <br><br> A9 <br><br> MeO—c#5'(-) 0 <br><br> V* <br><br> 6*. <br><br> 9 <br><br> B9 <br><br> Me <br><br> ^&lt;ir- <br><br> H O <br><br> 9 <br><br> C9 <br><br> f <br><br> AlO <br><br> 9 <br><br> H3c|xi O N N <br><br> 6*. <br><br> j <br><br> BIO <br><br> -o <br><br> H O <br><br> i <br><br> CIO <br><br> , H ^j-N <br><br> W&gt;. <br><br> 9 <br><br> All <br><br> I <br><br> MeO^i 0 <br><br> V, <br><br> 6*. <br><br> Bll <br><br> Me <br><br> VS* <br><br> H O <br><br> t <br><br> Cll <br><br> 9 <br><br> A12 <br><br> o y^N <br><br> v. <br><br> 9 <br><br> B12 <br><br> Me <br><br> Tj, <br><br> | pme <br><br> A^Me <br><br> Vt4- <br><br> H O <br><br> 9 <br><br> C12 <br><br> *K <br><br> o <br><br> &gt; <br><br> 59 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> A13 <br><br> .V^IAN <br><br> V <br><br> &gt; <br><br> B13 <br><br> &amp; <br><br> Vr- <br><br> HO <br><br> C13 <br><br> tf <br><br> &gt; <br><br> A14 <br><br> o <br><br> °6* <br><br> 3 <br><br> B14 <br><br> Me^e Me <br><br> H 0 <br><br> » <br><br> C14 <br><br> HSN&gt;&lt;^ <br><br> xLo. <br><br> * <br><br> A15 <br><br> yrz <br><br> B15 <br><br> H O <br><br> * <br><br> C15 <br><br> h2N^ <br><br> t <br><br> A16 <br><br> 0 <br><br> 9 <br><br> B16 <br><br> H 0 <br><br> ♦ <br><br> C16 <br><br> ^■N H2N^^ <br><br> 9 <br><br> &gt; <br><br> A17 <br><br> o <br><br> V. <br><br> J <br><br> B17 <br><br> &amp; <br><br> Vyt <br><br> H 0 <br><br> J <br><br> C17 <br><br> O <br><br> ? <br><br> A18 <br><br> 0 <br><br> V^CAN <br><br> v. <br><br> » <br><br> B18 <br><br> H 0 <br><br> 9 <br><br> C18 <br><br> 1^-^nh2 0 <br><br> i <br><br> A19 <br><br> cA <br><br> &gt; <br><br> B19 <br><br> /p <br><br> ^vV <br><br> H O <br><br> » <br><br> C19 <br><br> . H -4S-N <br><br> tT <br><br> 6; <br><br> 60 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> A20 <br><br> ax <br><br> 9 <br><br> B20 <br><br> r"^[jr'x)Et H O <br><br> J <br><br> C20 <br><br> , H <br><br> A21 <br><br> Xi. <br><br> O4 <br><br> 5 <br><br> B21 <br><br> ^Me <br><br> X) <br><br> ^M-V <br><br> H 0 <br><br> 5 <br><br> C21 <br><br> ft" <br><br> Cr^a1^* . <br><br> 5 <br><br> A22 <br><br> Cr^ <br><br> t <br><br> B22 <br><br> Me <br><br> X&gt; <br><br> ^N-V <br><br> H O <br><br> j <br><br> C22 <br><br> ¥ <br><br> o <br><br> 'A-&gt; o 0 <br><br> A23 <br><br> 9 o <br><br> X v. X <br><br> h3c O^N <br><br> I L <br><br> 9 <br><br> B23 <br><br> Me x&gt; <br><br> vs* <br><br> H 0 <br><br> s <br><br> C23 <br><br> iH <br><br> N H <br><br> 3 <br><br> A24 <br><br> if, <br><br> O^J <br><br> ) <br><br> B24 <br><br> ,J9" <br><br> VV* <br><br> H 0 <br><br> C24 <br><br> tr <br><br> V <br><br> OH <br><br> j <br><br> A25 <br><br> XK <br><br> JL <br><br> °^J <br><br> J <br><br> B25 <br><br> HO. <br><br> j <br><br> C25 <br><br> „ H <br><br> *c&lt; <br><br> '—N H <br><br> 9 <br><br> A26 <br><br> a0xr <br><br> 0 <br><br> » <br><br> B26 <br><br> H 0 <br><br> C26 <br><br> , H ^.N <br><br> xg- <br><br> '—Nx <br><br> "OH . <br><br> j <br><br> 61 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> A27 <br><br> o <br><br> 9 <br><br> B27 <br><br> Me <br><br> W <br><br> H 0 <br><br> » <br><br> C27 <br><br> 9 <br><br> A28 <br><br> &gt;r°\ <br><br> 5 <br><br> B28 <br><br> J3tmb <br><br> ^-VMe <br><br> H 0 <br><br> 5 <br><br> C28 <br><br> Lv. &gt; <br><br> A29 <br><br> oXi j <br><br> B29 <br><br> H O <br><br> j <br><br> C29 <br><br> V <br><br> N\x\ <br><br> 9 <br><br> A30 <br><br> rc\ <br><br> oS <br><br> j <br><br> B30 <br><br> H O <br><br> 1 <br><br> C30 <br><br> 5 <br><br> A31 <br><br> 0 <br><br> c"oJx <br><br> 5 <br><br> B31 <br><br> v1? <br><br> H O <br><br> 1 <br><br> C31 <br><br> , H ^5-N <br><br> 9 <br><br> A32 <br><br> 0=/ z—V <br><br> ,°o s <br><br> o \ <br><br> B32 <br><br> £ <br><br> H O <br><br> 5 <br><br> C32 <br><br> b <br><br> 9 <br><br> A33 <br><br> 1 p <br><br> H&gt;^cAn r^n-^- <br><br> 9 <br><br> B33 <br><br> H 0 . <br><br> 5 <br><br> C33 <br><br> ClO. <br><br> 9 <br><br> A34 <br><br> 0 <br><br> CT'" i f "n"^- <br><br> °sJ <br><br> B34 <br><br> Vll* <br><br> H O <br><br> j <br><br> C34 <br><br> &gt; H <br><br> V. <br><br> 9 <br><br> 62 <br><br> WO 02/20485 <br><br> PCT/U SO1/08084 <br><br> 63 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> A42 <br><br> 0 <br><br> 1 <br><br> O O N <br><br> 9 <br><br> B42 <br><br> z <br><br> VV£ <br><br> H 0 <br><br> » <br><br> C42 <br><br> !p&lt; <br><br> A43 <br><br> 0 <br><br> u <br><br> 0 0' N <br><br> » <br><br> B43 <br><br> H 0 . <br><br> i <br><br> C43 <br><br> .. H <br><br> "l—'i'nv^~sn. <br><br> 9 <br><br> A44 <br><br> C3 <br><br> / <br><br> B44 <br><br> X <br><br> H 0 <br><br> 9 <br><br> C44 <br><br> *K <br><br> cHp^~~ns^\ <br><br> O <br><br> 9 <br><br> A45 <br><br> 0 <br><br> -cr^ <br><br> 9 <br><br> B45 <br><br> vv <br><br> H 0 <br><br> 9 <br><br> C45 <br><br> V <br><br> Nv-\ <br><br> o <br><br> 9 <br><br> A46 <br><br> z^-7 <br><br> io <br><br> / <br><br> 1 <br><br> B46 <br><br> VS* <br><br> HO. <br><br> j <br><br> C46 <br><br> '—N H <br><br> 9 <br><br> A47 <br><br> \ <br><br> N. <br><br> / ^ 0 <br><br> N N <br><br> 6*. <br><br> 9 <br><br> B47 <br><br> H 0 . <br><br> » <br><br> C47 <br><br> &gt;*&amp; <br><br> v*\ <br><br> i <br><br> A48 <br><br> ■ I x <br><br> Sl^N <br><br> 6* <br><br> 9 <br><br> B48 <br><br> VS* <br><br> H 0 . <br><br> 1 <br><br> C48 <br><br> r . <br><br> i <br><br> 64 <br><br> WO 02/20485 PCT/USO1/08084 <br><br> A49 <br><br> Ck 0 <br><br> 6* <br><br> » <br><br> B49 <br><br> h o <br><br> ) <br><br> A50 <br><br> o n n <br><br> 6* <br><br> &gt; <br><br> A51 <br><br> cru. <br><br> 6* <br><br> j <br><br> A52 <br><br> ctxjl o n r^vn'^ <br><br> O <br><br> A53 <br><br> O \Ar <br><br> 1 <br><br> A54 <br><br> o^n <br><br> JL <br><br> O <br><br> 5 <br><br> A55 <br><br> \ <br><br> / &gt; o o n <br><br> JL <br><br> or* <br><br> &gt; <br><br> A56 <br><br> CX „ <br><br> u <br><br> JL <br><br> 65 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> A57 <br><br> 2Q <br><br> O <br><br> / <br><br> and the pharmaceutically acceptable derivates thereof. <br><br> In another embodiment of the invention there are provided the following compounds of the Formulas (la) and (lb) which have been synthesized using the General schemes, methods described in the experimental section of this document and analogous methods known to those skilled in the art without undue experimentation. The compound possess desirable inhibition activity of Cathepsin S in the cell based assay referenced above. <br><br> {[ 1 -(3-cyano-1 -isobutyl-piperdin-3-yl carbamoyl)-3,3-dimethyl-butylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester; MS: 493 (M+l) <br><br> ylamino)-propionamide; MS: 498 (M+l) <br><br> 66 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> {[ 1 -3 -Cyano-1 -methyl-piperidin-3 -ylcarbamoyl)-3,3-dimethyl-butylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester; MS: 451 (M+l) <br><br> {[l-(2-cyano-octahydro-quinolizin-2-ylcarbamoyl)-333-dimethyl-butylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester; MS: 491 (M+l) <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> {[l-(4-cyano-l-cyclohexyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morphohn-4-yl-methylene}-carbamic acid ethyl ester; MS: 545 (M+l) <br><br> {[l-(4-cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid cyclohexybnethyl ester; MS: 545 (M+l) <br><br> {[-l-(4-cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid cyclobutyl ester; MS: 503 (M+l) <br><br> 68 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> {[ 1 -(4-cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid allyl ester; MS: 489 (M+l) <br><br> {[1 -(4-cyano-1 -propyl-piperidin-4-ylcarbamoyl)-3 -cyclohexyl-propylaminoj-morpholin-4-yl-methylene}-carbamic acid ester; MS: 519 (M+l) <br><br> 69 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> {[ 1-(4-cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpb.olin-4-yl-methylene}-carbamic acid tetrahydro-furan-3yImethyI ester; MS: 533 (M+l) <br><br> {[1 -(4-cyano-1 -methy-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethyl amino] -morpholin-4-yl-methylene}-carbamic acid tetrahydro-furan-2-yImethyl ester; MS: 533 (M+l) <br><br> JV-(4-Cyano-1 -methyl-piperidin-4-yl)-3 -cy clohexyl-2-(5,6-difluoro-3-oxo-2,3 -dihydro-isoindol-l-ylideneamino)-propionamide; MS: 458 (M+l) <br><br> 70 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> 2-(5,6-Difluoro-3-oxo-2,3-dihydro-isoindol-l-ylideneamino)-4,4-dimethyl-pentanoic acid (4-cyano-l-propyl-piperidm-4-yl)-amide; MS: 460 (M+l) <br><br> 2-(6-Fluoro-3-oxo-2,3-dihydro-isomdol-l-ylideneamino)-4,4-dimethyl-pentanoic acid (4-cyano-l-propyl-piperidin-4-yl)-amide; MS: 442 (M+l) <br><br> A^-(4-Cyano-l-methyl-piperidin-4-yl)-3-cyclohexyl-2-(6-fluoro-3-oxo-2,3-dihydro-isoindol-1 -ylideneamino)-propionamide; MS: 440 (M+l) <br><br> 71 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> O <br><br> CH, <br><br> ■vsVrT <br><br> ryn* <br><br> &lt;x J o <br><br> {[1 -(4-Cyano-1 -propyl-piperidin-4-ylcarbamoyl)-3,3-dimetliyl-butylixnino]-morpholin-4-yl-methyl}-carbamic acid methyl ester; MS: 465 (M+l) <br><br> O <br><br> h,Cn A. <br><br> 3 ONH <br><br> {[1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-naethyl}-carbamic acid methyl ester; MS: 463 (M+l) <br><br> O <br><br> hM/^0Anh <br><br> CH <br><br> O <br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid 2,2-dimethyl-propyl ester; MS: 519 (M+l) <br><br> 72 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-3,3-dimethyl-butylimino]-morpholin-4-yl-methyl}-carbamic acid methyl ester; MS: 437 (M+l) <br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid benzyl ester; MS: 539 (M+l) <br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethyhmino]-moipholin-4-yl-methyl}-carbamic acid isobutyl ester; MS: 505 (M+l) <br><br> 73 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid propyl ester; MS: 491 (M+l) <br><br> \L J? <br><br> {[ 1 -(4-Cyano-1 -methyl~piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimiELo]-morpholin-4-yI-methyl}-carbamic acid hexyl ester; MS: 533 (M+l) <br><br> .JL X) <br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-moipholin-4-yl-methyl}-carbamic acid cyclobulylmetliyl ester; MS: 517 (M+l) <br><br> 74 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> o <br><br> &lt;Ah fY <br><br> :.n n' <br><br> ch3 <br><br> {[1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-moipholin-4-yl-methyl}-carbamic acid 3,3,3-trifluoro-propyl ester; MS: 545 (M+l) <br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid 2-methoxy-ethyl ester; MS: 507 (M+l) <br><br> 5,5-Dimethyl-2-(2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-hexanoic acid (4-cyano-l-propyl-piperidin-4-yl)-amide; MS: 454 (M+l) <br><br> 75 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> h3c o nh <br><br> {[ 1-(4-Cyano-1 -propyl-piperidin-4-ylcarbamoyl)-4,4-dimethyl-pentylimino]-morpholin-4-yl-methyl}-carbamic acid ethyl ester; MS: 493 (M+l) <br><br> H3C^ ^CH <br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cy clohexyl-ethylimino] -morpholin-4-yl-methyl}-carbamic acid 2-isopropoxy-ethyl ester; MS: 534 (M+l) <br><br> h,c <br><br> {[1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid 3-methoxy-butyl ester; MS: 534 (M+l) <br><br> 76 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid 2-isobutoxy-ethyl ester; MS: 549 (M+l) <br><br> {[ 1 -(4-Cyano-1 -propyl-piperidm-4-ylcarbamoyl)-3,3 -dimethyl-butylimino]-moipholin-4-yl-methyl}-carbamic acid 2-methoxy-ethyl ester; MS: 509 (M+l) <br><br> N-(4-Cyano-l-methyl-piperidin-4-yl)-4-cyclohexyl-2-(6-methoxy-2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-butyraniide; MS: 468 (M+l) <br><br> 77 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> N-(4-Cyano-l-methyl-piperidin-4-yl)-4~cyclohexyl-2-(6-fluoro-2-oxo-2.,3-dihydro-benzo[e][l53]oxazin-4-ylideneaimno)-butyramide; MS: 456 (M+l) <br><br> N-(4-Cyano-l-methyl-piperidm-4-yl)-4-cyclohexyl-2-(7-fluoro-2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-butyramide; MS: 456 (M+l) <br><br> 2-(7-Fluoro-2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-yldeneamino)-5,5-dimethyl-hexanoic acid(4-cyano-l-propyl-piperidin-4-yl)-amide; MS: 458 (M+l) <br><br> 78 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> TM-(4-Cyano-l-methyl-piperidin-4-yl)-4-cyclohexyl-2-(7-methoxy-2-oxo-2,3-dihydro-benzo[e][I,3]oxazin-4-yIideneamino)-butyr amide; MS: 468 (M+l) <br><br> 2-(7-Methoxy-2-oxo-2,3-dihydro-benzo[e][ls3]oxazin-4-yldeneamino)-5,5-dimethyl-hexanoic acid(4-cyano-l-propyl-piperidin-4-yl)-amide; MS: 470 (M+l) <br><br> {[ 1 -(4-Cyano-1 -propyl-piperidin-4-ylcarbamoyl)-5-methyl-hexylimino] -morpholin-4-yl-methyl}-carbamic acid ethyl ester; MS: 479 (M+l) <br><br> 79 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> 2-[(iV-Benzyl-moipholine-4-carboximidoyl)-amino]-iV"-(4-cyano-l-methyl-piperidin-4-yl)-3-cyclohexyl-propionamide; MS: 495 (M+l). <br><br> iVK4-Cyano-l-methyl-piperidin.-4-yl)-3-cyclohexyl-2-(2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-propionamide; MS: 438 (M+l). <br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-pyrrolidin-l-yl-methyl}-carbamic acid ethyl ester; MS: 461 (M+l). <br><br> 80 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-piperidin-1 -yl-methyl}-carbamic acid ethyl ester; MS: 475 (M+l). <br><br> {Azepan-1 -yl-[ 1 -(4-cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-methyl}-carbamic acid ethyl ester; MS: 489 (M+l). <br><br> {Azocan-1 -yl-[ 1 -(4-cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino] -methyl}-carbamic acid ethyl ester; MS: 503 (M+l). <br><br> 81 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> 1 - {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-ethoxycarbonylamino-methyl}-piperidine-4-carboxylic acid ethyl ester; MS: 547 (M+l). <br><br> 1 - {[ 1 -(4-Cyano-l -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-ethoxycarbonylamino-methyl}-piperidine-3-carboxylic acid ethyl ester; MS: 547 (M+I). <br><br> 82 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> [[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino] -(4-pyrrolidin-l-yl-piperidin-l-yl)-methyl]-carbamic acid ethyl ester; MS: 544 (M+l). <br><br> {[1,4']Bipiperidinyl-1 '-yl-[ 1 -(4-cyano-l -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-methyl}-carbamic acid ethyl ester; MS: 558 (M+l). <br><br> [[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-(4-phenyl-piperazin-l-yl)-methyl]-carbamic acid ethyl ester; MS: 552 (M+l). <br><br> 83 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> [[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-(4-ethyl-piperazin-1 -yl)-methyl]-carbamic acid ethyl ester; MS: 504 (M+l). <br><br> {(4-Acetyl-piperazin-1 -yl)-[ 1 -(4-cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-methyl}-carbamic acid ethyl ester; MS: 518 (M+l). <br><br> 4-{[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-ethoxycarbonylamino-methyl}-piperazine-l-carboxylic acid ethyl ester; MS: 548 (M+l). <br><br> 84 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> [[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-(3,3,5-trimethyl-6-aza-bicyclo[3.2.1]oct-6-yl)-methyl]-carbamic acid ethyl ester; MS: 543 (M+l). <br><br> {(3 -Acetylamino-pyrrolidin-1 -yl)-[ 1 -(4-cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-methyl}-carbamic acid ethyl ester; MS: 518 (M+l). <br><br> 85 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> {(3-Acetylamino-pyrrolidin- l-yl)-[l-(4-cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-methyl}-carbamic acid ethyl ester; MS: 518 (M+l). <br><br> {(3-Azapent-3 -yl)-[ 1 -(4-cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethy!imino]-methyl}-carbamic acid ethyl ester; MS: 463 (M+l). <br><br> 10 {(1 -Methoxy-3 -azapent-3-yl)-[ 1 -(4-cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-methyl}-carbamic acid ethyl ester; MS: 493 (M+l). <br><br> 86 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> [[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-(3-oxo-piperazin-l-yl)-methyl]-carbamic acid ethyl ester; MS: 490 (M+l). <br><br> {(1,5-Dimethoxy-3 -azapent-3-yl)-[l -(4-cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-methyl}-carbamic acid ethyl ester; MS: 523 (M+l). <br><br> 87 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> {(4-Carbamoyl-piperidin-1 -yl)-[ 1 -(4-cyano-l -m ethyl -piperi din-4-ylcarbamoyl) -2-cyclohexyl-ethylimino]-methyl}-carbamic acid ethyl ester; MS: 518 (M+l) <br><br> [[1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-(2-methoxymethyl-morpholin-4-yl)-methyl]-carbamic acid ethyl ester; MS: 521 (M+l) <br><br> (4- {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino] -ethoxycarbonylamino-methyl}-piperazin-l-yl)-acetic acid ethyl ester; MS: 562 (M+l) <br><br> 88 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> [[ 1 -(4-Cyano-1 -methyI-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-(2,6-dimethyl-morpholin-4-yl)-methyl]-carbamic acid ethyl ester; MS; 505 (M+l) <br><br> [[1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-(2,6-dimethyl-moipholin-4-yl)-methyl]-carbamic acid ethyl ester; MS: 505 (M+l) <br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-thiomorpholin-4-yl-methyl}-carbamic acid ethyl ester; MS: 493 (M+l) <br><br> 89 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> 4,4-Dimethyl-2-(6-methyl-2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-pentanoic acid (4-cyano-l-propyl-piperidin-4-yl)-amide; MS: 454 (M+l) <br><br> 2-(6-Chloro-2-oxo-2,3-dihydro-benzo[e] [1,3] oxazin-4-ylideneamino)-4,4-dimetliyl-pentanoic acid (4-cyano-l-propyl-piperidin-4-yl)-amide; MS: 475 (M+l) <br><br> 4,4-Dimethyl-2-(2-oxo-2,3-dihydro-lH-quinazolin-4-ylideneamino)-pentanoic acid (4-cyano-l-propyl-piperidin-4-yl)-amide; MS: 439 (M+l) <br><br> 90 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> 1 H3VCHs <br><br> CI' <br><br> 2-(7-Chloro-2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-4,4-dimethyl-pentanoic acid (4-cyano-l-propyl-piperidin-4-yl)-amide; MS: 475 (M+l) <br><br> 5-Methyl-2-(2-oxo-2,3-dih.ydro-benzo[e] [ 1,3]oxazin-4-ylideneamino)-hexanoic acid (4-cyano-l-propyl-piperidin-4-yl)-amide; MS: 440 (M+l) <br><br> H,Cv 1 <br><br> O <br><br> n n <br><br> A" <br><br> h H <br><br> o h3c <br><br> V <br><br> N <br><br> 4,4-Dimethyl-2-(l-methyl-2-oxo-l,2-dihydro-qmnazolin-4-ylamino)-pentanoic acid (4-cyano-l-propyl-piperidin-4-yl)-amide; MS: 453 (M+l) <br><br> 91 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> 3-terZ-Butylsulfanyl-iV-(4-cyano-1 -propyl-piperidin-4-yl)-2-(2-oxo-2,3 -dihydro-benzo[e][l,3]oxazm-4-ylideneamino)-propionamide; MS: 472 (M+l) <br><br> {[2-tert-Butylsulfanyl-1 -(4-cyano-1 -propyl-piperidin-4-ylcarbamoyl)-ethylimino] -morpholin-4-yl-methyl)-carbamic acid ethyl ester; MS: 511 (M+l) <br><br> 3-Ben2ylsulfanyl-iV-(4-cyano-l-propyl-piperidin-4-yl)-2-(2-oxo-2,3-dIhydro-benzo[e][l,3]oxazin-4-ylideneamino)-propionamide; MS: 506 (M+l) <br><br> 92 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> {[2-Benzylsulfanyl-1 -(4-cyano-1 -propyl-piperidin-4-ylcarbamoyl)-ethylimino]-morpholin-4-yl-methyl}-carbamic acid ethyl ester; MS: 545 (M+l) <br><br> iV-(4-Cyano-l-propyl-piperidin-4-yl)-3-cyclooctyl-2-(2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-propionaxnide; MS: 494 (M+l) <br><br> 93 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> iV-(4-Cy ano-1 -propyl-piperidin-4-yl)-3 -cycioheptyl-2-(2-oxo-2,3-dihydro-benzo[e][l;3]oxazm-4-ylideneamino)-propionamide; MS: 480 (M+l) <br><br> h3c&gt; <br><br> {[1 -(4-Cyano-1 -propyI-piperidin-4-ylcarbamoyl)-2-cycloheptyl-ethylimino]-moipholin-4-yl-methyl}-carbamic acid ethyl ester; MS: 519 (M+l) <br><br> {[l-(4-Cyano-l-propyl-piperidin-4-ylcarbamoyl)-2-cyclooctyl-ethylimino]-Tnorpholin-4-yl-methyl}-carbamic acid ethyl ester; MS: 533 (M+l) <br><br> {[ 1 -(4-Cyano-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid isobutyl ester; MS: 491 (M+l) <br><br> 94 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> ({l-[4-Cyano-l-(2-morpholin-4-yl-ethyl)-piperidin-4-ylcarbamoyl]-2-cyclohexyl-ethylamino}-morpholin-4-yl-methylene)-carbamic acid isobutyl ester; MS: 604 (M+l) <br><br> ({1 -[1 -2-Carbamoyl-ethyl)-4-cyano-piperidin-4-ylcarbamoyl]-2-cyclohexyl-ethylamino}-morpholin-4-yl-methylene)-carbamic acid isobutyl ester; MS: 562 (M+l) <br><br> [(l-{4-Cyano-l-[2-(2-methoxyl-ethoxy)-ethyl]-piperidin-4-yicarbamoyl}-2-cyclohexyl-ethylainino)-morpholin-4-yl-methylene]-carbamic acid isobutyl ester; MS: 593 (M+l) <br><br> 95 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> [(1 - {4-Cyano-1 - [3-(2-methoxyl-ethoxy)-propyI]-piperidin-4-ylcarbamoyl}-2-cyclohexyl-ethylamino)-morpholin-4-yl-methyIene]-carbamic acid isobutyl ester; MS: 607 (M+l) <br><br> {[2-tert-Butoxy-l-(4-cyano-l-propyl-piperidin-4-ylcarbamoly)-ethylamino]-moipholin-4-yl-methylene}-carbamic acid ethyl ester; MS: 495 (M+l) <br><br> N-(4-Cyano-l-methyl-piperidin-4-yl)-3-cyclohexyl-2-{[diethyl-carbamoylimino)-moipholin-4-yl-methyl]--amino}-propionamide; MS: 504 (M+l) <br><br> 96 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> h3c. ch3 <br><br> ch3 0 <br><br> LA <br><br> o nh <br><br> O <br><br> N N <br><br> {[ 1 -(4-Cyan.o-1 -ptopy l-piperidin-4-ylcarbamoyl)-2-( 3,3,5,5-tetramethyl-cyclohexy 1)-ethylamino]-morpholin-4-yl-methy lene}-carbamic acid ethyl ester; MS: 561 (M+l) <br><br> CH3 O <br><br> LA <br><br> ^O^NH <br><br> N N <br><br> {[l-(4-Cyano-l-propyl-piperidin-4-ylcarbamoyl)-2-(4,4-dipropyl-cyclohexyl)-ethylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester; MS: 589 (M+l) <br><br> h3c o nh h3c xh3 <br><br> {[l-(4-Cyano-l-isopropyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester; MS: 505 (M+l) <br><br> 97 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> {[1 -(4-Cyano-1 -ethyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester; MS: 491 (M+l) <br><br> {[ 1 -(1 -Benzyl-4-cyano-piperidin-4-ylcarbamoyI)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester; MS: 553 (M+l) <br><br> 98 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> 4-Cyano-4-{3-cyclohexyl-2-[(ethoxycarbonylimino-morpholin-4-yl-meth.yl)-amino]-propionylamiao}-piperidine-l-carboxy lie acid benzyl ester; MS: 597 (M+l) <br><br> {[ 1 -(1 -Benzyl-4-cyano-piperidin-4-ylcarbamoyl)-3,3-dimethyl-butylammo]-morpholm-4-yl-methylene}-carbamic acid ethyl ester; MS: 527 (M+l) <br><br> 99 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> {[l-(4-cyano-l-phenethyl-piperidin-4-ylcarbamoyl)-3,3-dimethyl-butylamino]-morphoUn-4-yl-methylene}-carbamic acid ethyl ester; MS: 541 (M+l) <br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-pentanoic acid (1-benzyl-4-cyano-piperidin-4-yl)-amide; MS: 488 (M+l) <br><br> 100 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][l,3]oxaziii-4-ylamino)-pen.tanoic acid [4-cyano-1-(4-fluoro~benzyl)-piperidin-4-yl]-amide; MS: 506 (M+l) <br><br> x h5A <br><br> O NH ( <br><br> N <br><br> CH3 <br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylamiiio)-pentanoic acid (4-cyano-l-ethyl-piperidin-4-yl)-amide; MS: 426 (M+l) <br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e] [ 1,3 Joxazin-4-ylamino)-pentanoic acid (4-cyano-l-methyl-piperidin-4-yl)-amide; MS: 412 (M+l) <br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-pentanoic acid (4-cyano-piperidin-4-yl)-amide; MS: 398 (M+l) <br><br> 101 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-peatanoic acid (4-cyano-l-phenethyl-piperidin-4-yl)-amide; MS: 502 (M+l) <br><br> ft H3°VCH3 <br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][l ,3]oxazin-4-ylamino)-pentanoic acid [4-cyano-1-(2,2-dimethyl-propyl)-piperidin-4-yl]-amide; MS: 468 (M+l) <br><br> o h3c rh jj k 3 <br><br> O^NH | ^ <br><br> v h <br><br> \X <br><br> N .CH. <br><br> ch, <br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][l ,3]oxazin-4-ylamino)-pentanoic acid [4-cyano-1-(3,3-dimethyl-butyl)-piperidin-4-yl]-amide; MS: 482 (M+l) <br><br> 102 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e] [ 1,3]oxazin-4-ylamino)-pentanoic acid (4-cyano-1 -pentyl-piperidin-4-yl)-amide; MS: 468 (M+l) <br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][ 1,3]oxazin-4-ylarnino)-pentanoic acid (1 -butyl-4-cyano-piperidin-4-yI)-arnide; MS: 454(M+1) <br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e] [ 1,3]oxazin-4-ylamino)-pentanoic acid [4-cyano-1 -(3,3,3-trifluoro-propyl)-piperidin-4-yl]-amide; MS: 494 (M+l) <br><br> 103 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> 4}4-Dimethyl-2-(2-oxo-2H-benzo[e][ 1,3] oxazin-4-ylamino)-pentanoic acid (4-cyano-1 -cyclohexylmethyl-piperidin-4-yl)-amide; MS: 494 (M+l) <br><br> N-(4-Cyano-l-propyl-piperidin-4-yl)-3-(4:4-dimethyl-cyclohexyl)-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-propionamide; MS: 494 (M+l) <br><br> 104 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> 2H-benzo[e][l,3]oxazin-4-ylamino)-propionamide; MS: 550 (M+l) <br><br> N-(4-Cyano-l-propyl-piperidin-4-yl)-3-(4-tert-biityl-cyclohexyl)-2-(2-oxo-2H-benzo[e][ 1,3]oxazin-4-ylamino)-propionamide; MS: 522 (M+l) <br><br> N-(4-Cyano-l-propyl-piperidin-4-yl)-3-(3,3J5,5-tetramethyl-cyclohexyl)-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-propionaxnide; MS: 522 (M+l) <br><br> 105 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> {[ 1 -(3-Cyano-1 -ethyl-pyrrolidin-3 -ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester. MS: 477 (M+l). <br><br> 2-[(Methanesulfonylimino-moipholm-4-yl-methyl)-amino]-4,4-dimethyl-pentanoic acid (4-cyano-l-propyl-piperidin-4-yl)-amide. MS: 485 (M+l). <br><br> {[ 1 -(3 -Cyano-1 -propyl-pyrrolidin-3-ylcarbamoyl)-3,3 -dimethyl-butylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester. MS: 465 (M+l). <br><br> 106 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> ch3 <br><br> ({l-[3-Cyano-l-(4,4-dimethyl-cyclohexyl)-pyrrolidin-3-ylcarbamoyl]-3,3-dimethyl-butylamino}-morpholin-4-yl-methylene)-carbamic acid ethyl ester. MS: 533 (M+l). <br><br> {[l-(3-Cyano-l-ethyl-5,5-dimethyl-pyrrolidin-3-ylcarbamoyl)-353-dimethyl-butylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester. MS: 479 (M+l). <br><br> 107 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> N-(4-Cyano-l-methyl-piperidin-4-yl)-3-cyclohexyl-2-(7,8-difluoro-2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-propionamide; MS: 474 (M+l) <br><br> morpholin-4-y 1-methylene}-carbamic acid ethyl ester; MS: 559 (M+l) <br><br> 108 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> 3-Cyano-3-[4,4-dimeth.yl-2-(2-oxo-2H"-benzo[e][l,3]oxazin-4-ylamino)-pentanoylamino]-azepane-l-carboxylic acid benzyl ester; MS: 546 (M+l) <br><br> 0 CH, <br><br> II HX^UCH <br><br> ? 1H i " <br><br> cy-v <br><br> 4,4-DimethyI-2-(2-oxo-2//-benzo[e] [ 1,3]oxazin-4-ylamino)-pentanoic acid (3-cyano-1 -propyl-azepan-3-yl)-amide; MS: 454 (M+l) <br><br> -N <br><br> O CH, <br><br> X HgC-J-CHg O W f H <br><br> CH, <br><br> 4,4-Dimethyl-2-(2-oxo-2i?-benzo[e][l,3]oxazin-4-ylaniino)-pentanoic acid (4-cyano-l-propyl-azepan-4-yl)-amide; MS; 454 (M+l) <br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid 4-methoxy-cyclohexylmethyl ester; MS: 575 (M+l) <br><br> 109 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> {[1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid cyclohexyl ester; MS: 531 (M+l) <br><br> {[1 -(4-Cyano-l -propyl-piperidin-4-ylcarbamoyl)-3,3 -dimethyl-butylamino]-phenyl-methylene}-carbamic acid ethyl ester; MS: 470 (M+l) <br><br> h3c <br><br> N <br><br> I <br><br> CH3 <br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-eth.ylamino]-phenyl-methylene}-carbamic acid ethyl ester; MS: 468 (M+l) <br><br> 110 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> 2-{[N-(4-Cyano-phenyl)-moipholine-4-carboximidoyl]-amino}-4,4-dimetby]-pentanoic acid (4-cyano-l-propyl-piperidin-4-yl)-amide; MS: 508 (M+l) <br><br> 4,4-Dimethyl-2-{[N-(4-trifluoromethyl-phenyl)-morpholine-4-carboximidoyl]-amino}-pentanoic acid (4-cyano-l-propyl-piperidin-4-yl)-amide; MS: 551 (M+l) <br><br> ill <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> The following are preferred compounds of the Formulas (la) and (lb): <br><br> {[ 1 -(3-cyano-1 -isobutyl-piperdin-3 -yl carbamoyl)-3,3-dimethyl-butylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester; MS: 493 (M+l) <br><br> {[1 -(4-cyano-1 -cyclohexyI-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino] -moipholin-4-yl-methylene}-carbamic acid ethyl ester; MS: 545 (M+l) <br><br> 112 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> {[l-(4-cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino] -morpholin-4-yl-methylene}-carbamic acid cyclohexylmethyl ester; MS: 545 (M+l) <br><br> {[-1 -(4-cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid cyclobutyl ester; MS: 503 (M+l) <br><br> {[l-(4-cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid allyl ester; MS: 489 (M+l) <br><br> 113 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> N-(4-Cyano-l-propyl-piperidin-4-yl)-4-cyclohexyl-2-(2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-butyramide; MS: 480 (M+l) <br><br> {[1 -(4-cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid tetrahydro-furan-3ylmethyl ester; MS: 533 (M+l) <br><br> ch3 <br><br> {[ 1 -(4-cyano-1 -methy-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethyl amino]-morpholin-4-yl-methylene)-carbamic acid tetrahydro-furan-2-ylmethyl ester; MS: 533 (M+l) <br><br> 114 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> iV-(4-Cyano-l-methyl-piperidin-4-yl)-3-cyclohexyl-2-(5s6-difluoro-3-oxo-2,3-dihydro-isoindol-1 -ylideneamino)-propionamide; MS: 458 (M+l) <br><br> 2-(5,6-Difluoro-3-oxo-2,3-dihydro-isoindol-l-ylideneamino)-4,4-dimethyl-pentanoic acid (4-cyano-1 -propyl-piperidin-4-yl)-amide; MS: 460 (M+l) <br><br> 2-(6-Fluoro-3-oxo-2,3 -dihydro-isoindol-1 -ylideneamino)-4,4-dimethyl-pentanoic acid (4- <br><br> cyano-1 -propyl-piperidin-4-yl)-amide; MS: 442 (M+l) <br><br> 115 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> Af-(4-Cyano-l-methyl-piperidin-4-yl)-3-cyclohexyl-2-(6-fluoro-3-oxo-2,3-dihydro-isoindol-l-ylideneamino)-propionamide; MS: 440 (M+l) <br><br> {[l-(4-Cyario-l-propyl-piperidm-4-ylcarbamoyl)-3,3-dimethyl-butylimino]-morpholin.-4-yl-methyl}-carbamic acid methyl ester; MS: 465 (M+l) <br><br> {[ 1 -(4-Cyano-1 -methyl-piperidm-4-ylcarbamoyl)-2-cyclohexyl-ethylimino] -morpholin-4-yl-methyl}-carbamic acid methyl ester; MS: 463 (M+l) <br><br> 116 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> ch3 <br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid 2,2-dimethyl-propyl ester; MS: 519 (M+l) <br><br> ch3 <br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-3,3-dimethyl-butylimino]-morpholin-4-yl-methyl}-carbamic acid methyl ester; MS: 437 (M+l) <br><br> ch3 <br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid benzyl ester; MS: 539 (M+l) <br><br> 117 <br><br> WO 02/20485 <br><br> PCT/U SO1/08084 <br><br> {[l-(4-Cyano-l-methyl-piperidm-4-ylcarbamoyl)-2-cyclohexyl-ethylimmo]-morpholin-4-yl-methyl}-carbamic acid isobutyl ester; MS: 505 (M+l) <br><br> {[l-(4-Cyano~l-methyl-piperidm-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid propyl ester; MS: 491 (M+l) <br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyI-ethylimino]-morpholin- <br><br> 4-yl-methyl}-carbamic acid hexyl ester; MS: 533 (M+l) <br><br> 118 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid cyclobutylmethyl ester; MS: 517 (M+l) <br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid 3,3,3-trifluoro-propyl ester; MS: 545 (M+l) <br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino] -morpholin-4-yl-methyl}-carbamic acid 2-methoxy-ethyl ester; MS: 507 (M+l) <br><br> 119 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> 5,5-Dimethyl-2-(2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-hexanoic acid (4-cyano-l-propyl-piperidin-4-yl)-amide; MS: 454 (M+l) <br><br> {[1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid 2-isopropoxy-ethyl ester; MS: 534 (M+l) <br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimmo]-morpholin- <br><br> 4-yl-methyl}-carbamic acid 3-methoxy-butyl ester; MS: 534 (M+l) <br><br> 120 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethyhmino]-morpholin-4-yl-methyl}-carbamic acid 2-isobutoxy-ethyl ester; MS: 549 (M-fl) <br><br> {[ 1 -(4-Cyano-1 -propyl-piperidin-4-ylcarbamoyl)-3,3 -dimethyl-butylimino]-morpholin-4-yl-methyl}-carbamic acid 2-methoxy-ethyl ester; MS: 509 (M+l) <br><br> N-(4-Cyano-l-methyl-piperidin-4-yl)-4-cyclohexyl-2-(6-methoxy-2-oxo-2,3-dihydro-benzo[e3[l,3]oxazin-4-ylideneamino)-butyramide; MS: 468 (M+l) <br><br> 121 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> N-(4-Cyano-l-methyl-piperidin-4-yl)-4-cyclohexyl-2-(6-fluoro-2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-butyramide; MS: 456 (M+l) <br><br> N-(4-Cyano-l-methyl-piperidin-4-yl)-4-cyclohexyl-2-(7-fluoro-2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-butyramide; MS: 456 (M+l) <br><br> 2-(7-Fluoro-2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-yldeneamino)-5,5-dimethyl- <br><br> hexanoic acid(4-cyano-l-propyl-piperidiri-4-yl)-amide; MS: 458 (M+l) <br><br> 122 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> N-(4-Cyano-l-methyl-piperidin-4-yl)-4-cyclohexyl-2-(7-methoxy-2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-butyramide; MS: 468 (M+l) <br><br> 2-(7-Methoxy-2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-yldeneamino)-5,5-dimethyl-hexanoic acid(4-cyano-l-propyl-piperidin-4-yl)-amide; MS: 470 (M+l) <br><br> iV-(4-Cyano4-methyl-piperidin-4-yl)-3-cyclohexyl-2-(2-oxo-2}3-dihydro- <br><br> benzo[e][l,3]oxazin-4-ylideneammo)-propionamide; MS: 438 (M+l). <br><br> 123 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> {[1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-pyrrolidiii-1 -yl-methyl}-carbamic acid ethyl ester; MS: 461 (M+l). <br><br> {[1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-piperidin-1 -yl-methyl}-carbamic acid ethyl ester; MS: 475 (M+l). <br><br> {Azepan-l-yl-[l-(4-cyano-l-methyl-piperidiii-4-ylcarbamoyl)-2-cyclohexyl-e1hylimino]-methyl}-carbamic acid ethyl ester; MS: 489 (M+l). <br><br> 124 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> {Azocan-1 -yl-[ 1 -(4-cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-methyl}-carbamic acid ethyl ester; MS: 503 (M+l). <br><br> ch3 <br><br> 1 - {[1 -(4-Cyano-1 -methyl-piperidin-4-yIcarbamoyl)-2-cyclohexyl-ethylimino]-ethoxycarbonylamino-methyl}-piperidine-4-carboxylic acid ethyl ester; MS: 547 (M+l). <br><br> 1 - {[ 1 -(4-Cyano- l-methyl-piperidm-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-ethoxycarbonylamino-methyl}-piperidine-3-carboxylic acid ethyl ester; MS: 547 (M+l). <br><br> 125 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> [[1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-(4-phenyl-piperazin-l-yl)-methyl]-carbamic acid ethyl ester; MS: 552 (M+l). <br><br> ch. <br><br> J <br><br> h3C^,N <br><br> CT NH . <br><br> [[1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-(4-ethyl-piperazin-l-yl)-methyl]-carbamic acid ethyl ester; MS: 504 (M+l). <br><br> 126 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> {(4-Acetyl-piperazin-l-yl)-[l-(4-cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-methyl}-carbamic acid ethyl ester; MS: 518 (M+l). <br><br> ch3 <br><br> 4- {[1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino] -ethoxycarbonylamino-methyl}-piperazine-l-carboxylic acid ethyl ester; MS: 548 (M+l). <br><br> [[1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-(3,3,5-trimethyl-6-aza-bicyclo[3.2.1]oct-6-yl)-methyl]-carbamic acid ethyl ester; MS: 543 (M+l). <br><br> 127 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> {(3 -Acetylamino-pyrrolidin-1 -yl)-[ 1 -(4-cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-methyl}-carbamic acid ethyl ester; MS: 518 (M+l). <br><br> {(3-Acetylamino-pyrrolidin- l-yl)-[ 1 -(4-cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-methyl}-carbamic acid ethyl ester; MS: 518 (M+l). <br><br> {(3-Azapent-3-yl)-[l-(4-cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimmo]-methyl}-carbamic acid ethyl ester; MS: 463 (M+l). <br><br> 128 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> {(1 -Methoxv-S-azapent-S-ylVf 1 ~(4-cvano-1 -methvl-rvrnsridin-4-vlcarbainQvP-2- <br><br> ' \ J x J J l \ J v'J ■* f ' J *** '*""(/ v "' <br><br> cyclohexyl-ethylimino]-methyl}-carbamic acid ethyl ester; MS: 493 (M+l). <br><br> [[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino] -(3-oxo-piperazin-l-yl)-methyl]-carbamic acid ethyl ester; MS: 490 (M+l). <br><br> 10 {(l,5-Dimethoxy-3-azapent-3-yl)-[l-(4-cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-methyl}-carbamic acid ethyl ester; MS: 523 (M+l). <br><br> 129 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> 4,4-Dimethyl-2-(2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-pentanoic acid (4-cyano-l-propyl-piperidin-4-yl)-amide; MS: 440 (M+l) <br><br> {(4-Carbamoyl-piperidin-l-yl)-[l-(4-cyatio-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-methyl}-carbamic acid ethyl ester; MS: 518 (M+l) <br><br> [ [ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino] -(2- <br><br> methoxymethyl-morpholin-4-yl)-methyl]-carbamic acid ethyl ester; MS: 521 (M+l) <br><br> 130 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> (4- {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-ethoxycarbonylamino-methyl}-piperazin-l-yl)-acetic acid ethyl ester; MS: 562 (M+l) <br><br> [[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-(2,6-dimethyl-morpholin-4-yl)-methyl]-carbamic acid ethyl ester; MS: 505 (M+l) <br><br> [[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-(2,6-dimethyl-morpholin-4-yl)-methyl]-carbamic acid ethyl ester; MS: 505 (M+l) <br><br> 131 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylirnino]-thiomorpho lin-4-yl-methyl} - carbamic acid ethyl ester; MS: 493 (M+l) <br><br> 4,4-Dimethyl-2-(6-methyl-2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-pentanoic acid (4-cyano-l-propyl-piperidin-4-yl)-amide; MS: 454 (M+l) <br><br> 2-(6-Chloro-2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-4,4-dimethyl- <br><br> pentanoic acid (4-cyano-l-propyl-piperidin-4-yl)-amide; MS: 475 (M+l) <br><br> 132 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> 9 H C ch, <br><br> %-^NH V^CH, <br><br> IiV^Y^ <br><br> n <br><br> O <br><br> h3c <br><br> 4,4-Dimethyl-2-(2-oxo-2)3-dihydro- l/f-quinazolin-4-ylideneamino)-pentanoic acid (4-cyaao-l-propyl-piperidin-4-yl)-amide; MS: 439 (M+l) <br><br> 0 h3c phs h3c. <br><br> 2-(7-ChIoro-2-oxo-2,3-dihydro-benzo[e] [ 153]oxazin-4-ylideneamino)-434-dimethyl-pentanoic acid (4-cyano-l-propyl-piperidin-4-yl)-amide; MS: 475 (M+l) <br><br> 5-Methyl-2-(2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-hexanoic acid (4- <br><br> cyano-l-propyl-piperidin-4-yl)-amide; MS: 440 (M+l) <br><br> 133 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> h3c. <br><br> 4,4-Dimethyl-2-( 1 -methyl-2-oxo-1,2-dihy dro-quinazolin-4-ylamino)-pentanoic acid (4-cyano-1 -propyl-piperidin-4-yl)-amide; MS: 453 (M+l) <br><br> o H3C^( <br><br> ,A„ /* <br><br> w o <br><br> n <br><br> 'n' <br><br> h3c <br><br> 3-/er/-Butylsulfanyl-7Vr-(4-cyano-l-propyl-piperidin-4-yl)-2-(2-oxo-2,3-diliydro-benzo[e][l,3]oxazin-4-ylideneamino)-propionamide; MS: 472 (M+l) <br><br> 3-Benzylsulfanyl-iV-(4-cyano-l-propyl-piperidin-4-yl)-2-(2-oxo-2,3-diliydro-benzo[e][l ,3]oxazin-4-ylideneamino)-propionamide; MS: 506 (M+l) <br><br> 134 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> {[2-Benzylsulfanyl-l-(4-cyano-l-propyl-piperidin-4-ylcarbamoyl)-ethylimino]-morpholin-4-yl-methyl}-carbamic acid ethyl ester; MS: 545 (M+l) <br><br> iV-(4-Cyano-1 -propyl-piperidin-4-yl)-3-cyclooctyl-2-(2-oxo-2,3 -dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-propionamide; MS: 494 (M+l) <br><br> h3c&gt; <br><br> 7V-(4-Cyano-l-propyl-piperidin-4-yl)-3-cycloheptyl-2-(2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-propionamide; MS: 480 (M+l) <br><br> 135 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> h3c. <br><br> {[ 1 -(4-Cyano-1 -propyl-piperidin-4-ylcarbamoyl)-2-cycloheptyl-ethylimmo]-morpholin-4-yl-methyl}-carbamic acid ethyl ester; MS: 519 (M+l) <br><br> {[ 1 -(4-Cyano-1 -propyl-piperidin-4-ylcarbamoyl)-2-cyclooctyl-ethylimino] -morpholin-4-yl-methyl}-carbamic acid ethyl ester; MS: 533 (M+l) <br><br> {[l-(4-Cyano-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid isobutyl ester; MS: 491 (M+l) <br><br> 136 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> ({1 - [4-Cyano-1 -(2-morpholin-4-yl-ethyl)-piperidin-4-ylcarbamoyl] -2-cyclohexyl-ethyIamino}-morpholin-4-yl-methylene)-carbamic acid isobutyl ester; MS: 604 (M+l) <br><br> ({1 -[ 1 -2-Carbamoyl-ethyl)-4-cyano-piperidin-4-ylcarbamoyl] -2-cyclohexyl-ethylamino}-morpholin-4-yl-methylene)-carbamic acid isobutyl ester; MS: 562 (M+l) <br><br> [(1- {4-Cyano-1 -[2-(2-methoxyl-ethoxy)-ethyl]-piperidin-4-ylcarbamoyl} -2-cyclohexyl-ethylamino)-morpholin-4-yl-methylene]-carbamic acid isobutyl ester; MS: 593 (M+l) <br><br> 137 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> [(l-{4-Cyano-l-[3-(2-methoxyl-ethoxy)-propyI]-piperidin-4-ylcarbamoyl}-2-cyclohexyl-ethylamino)-morpholin-4-yl-methylene]-carbamic acid isobutyl ester; MS: 607 (M+l) <br><br> h3c o o <br><br> o <br><br> A <br><br> h3c. <br><br> ch, <br><br> nh <br><br> N" N <br><br> O <br><br> -ch, <br><br> O <br><br> h3c n <br><br> "N' <br><br> {[2-tert-Butoxy-l-(4-cyano-l-propyl-piperidin-4-ylcarbamoly)-ethylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester; MS: 495 (M+l) <br><br> h3c <br><br> N-(4-Cyano-1 -methyl-piperidin-4-yl)-3-cyclohexyl-2- {[diethyl-carbamoylimino)- <br><br> 0iorpholin-4-yl-methyl]-amino}-propionamide; MS: 504 (M+l) <br><br> 138 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> CH3 O <br><br> ^Ah <br><br> N N <br><br> O <br><br> {[l-(4-Cyano-l-propyl-piperidin-4-ylcarbamoyl)-2-(3,3,5,5-tetramethyl-cyclohexyl)-ethylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester; MS: 561 (M+l) <br><br> ch3 0 <br><br> N N <br><br> O <br><br> {[ 1 -(4-Cyano-1 -propyl-piperidin-4-ylcarbamoyl)-2-(4,4-dipropyl-cyclohexyl)-ethylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester; MS: 589 (M+l) <br><br> H3C' ^CH3 <br><br> {[l-(4-Cyano-l-isopropyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester; MS: 505 (M+l) <br><br> 139 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> {[1-(4-Cyano-l-phenethyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbarnic acid ethyl ester; MS: 567 (M+l) <br><br> &lt;?h3 o <br><br> n n <br><br> {[ 1 -(4-Cyano-1 -ethyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester; MS: 491 (M+l) <br><br> ch3 o <br><br> n' <br><br> {[ 1 -(1 -Benzyl-4-cyano-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino] -morpholin-4-yl-methylene}-carbamic acid ethyl ester; MS: 553 (M+l) <br><br> 140 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> 0h3 o <br><br> n n <br><br> J <br><br> 4-Cyano-4-{3-cyclohexyl-2-[(ethoxycarbonylimino-morpholin-4-yl-methyl)-amino]-propionylamino)-piperidine-l-carboxylic acid benzyl ester; MS; 597 (M+l) <br><br> ch3 0 <br><br> ch, <br><br> A-V <br><br> o^J o <br><br> {[l-(l-Benzyl-4-cyano-piperidin-4-ylcarbamoyl)-3,3-dimethyl-butylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester; MS: 527 (M+l) <br><br> 141 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> {[l-(4-cyano-l-phenethyl-piperidin-4-ylcarbamoyl)-3,3-dimethyl-butylamino]-morpholin-4-yl-methylenej-carbamic acid ethyl ester; MS: 541 (M+l) <br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-pentanoic acid (l-benzyl-4-cyano-piperidin-4-yl)-amide; MS: 488 (M+l) <br><br> 142 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> H*CVCH3 <br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][ 1,3]oxazin-4-ylamino)-pentanoic acid [4-cyano-l -(4-fluoro-benzyl)-piperidin-4-yl]-amide; MS: 506 (M+l) <br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e] [ 1,3]oxazin-4-ylamino)-p entanoic acid (4-cyano-1 -ethyl-piperidin-4-yl)-amide; MS: 426 (M+l) <br><br> 0 H,C qu <br><br> X <br><br> O^NH |^gHs <br><br> An o <br><br> 4}4-Dimethyl-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-pentanoic acid (4-cyano-l-methyl-piperidin-4-yl)-amide; MS: 412 (M+l) <br><br> 143 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e](l ,3]oxazin-4-ylamino)-pentaiioic acid (4-cyano-piperidin-4-yl)-amide; MS: 398 (M+l) <br><br> 4;4-Dimethyl-2-(2-oxo-2H-benzo[e] [ 1,3]oxazin-4-ylamino)-pentanoic acid (4-cyano-1 -phenethyl-piperidin-4-yl)-amide; MS: 502 (M+l) <br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-pentanoic acid [4-cyano-l-(2,2-dimethyl-propyl)-piperidin-4-yl]-amide; MS: 468 (M+l) <br><br> 144 <br><br> WO 02/20485 <br><br> PCT/USO1/08084' <br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][ 1,3]oxazin-4-ylamino)-pentanoic acid [4-cyano-1 -(3,3-dimethyl-butyl)-piperidin-4-yl]-amide; MS: 482 (M+l) <br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][ 1,3]oxazin-4-ylamino)-pentanoic acid (1 -butyl-4- <br><br> cyano-piperidin-4-yl)-amide; MS: 454(M+1) <br><br> 145 <br><br> WO 02/20485 <br><br> PCT/USO 1/08084 <br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-pentanoic acid [4-cyano-l-(3,3,3-ti"ifluoro-propyl)-piperidiii-4-yl]-amide; MS: 494 (M+l) <br><br> N-(4-Cyano-1 -propyl-piperidin-4-yl)-3 -(4,4-dimetliyl-cyclohexyl)-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-propionamide; MS: 494 (M+l) <br><br> 146 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> N-(4-Cyano-l-propyl-piperidin-4-yl)-3-(4,4-dipropyl-cyclohexyl)-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-propionamide; MS: 550 (M+l) <br><br> N-(4-Cyano-l-propyl-piperidin-4-yl)-3-(4-tert-butyl-cyclohexyl)-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-propionamide; MS: 522 (M+l) <br><br> 147 <br><br> WO 02/20485 <br><br> PCT/U SO1/08084 <br><br> N-(4-Cyano-1 -propyl-piperidin-4-yl)-3 -(3,3,5,5-tetramethyl-cyclohexyl)-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-propionamide; MS: 522 (M+l) <br><br> {[l-(3-Cyano-l-ethyl-pyrrolidin-3-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methyIene}-carbamic acid ethyl ester. MS: 477 (M+l). <br><br> {[ 1 -(3 -Cyano-1 -propyl-pyrrolidin-3 -ylcarbamoyl)-3,3 -dimethyl-butylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester. MS: 465 (M+l). <br><br> 148 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> ({l-[3-Cyano-l-(4,4-dimethyl-cycIohexyl)-pyrrolidin-3-ylcarbamoyl]-3,3-dimethyl-butylamino}-morpholin-4-yl-methylene)-carbamic acid ethyl ester. MS: 533 (M+l). <br><br> N-(4-Cyano-l-methyl-piperidin-4-yl)-3-cyclohexyl-2-(7,8-difluoro-2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-propionamide; MS: 474 (M+l) <br><br> 149 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> morpholin-4-yl-methylene}-carbamic acid ethyl ester; MS: 559 (M+l) <br><br> 3-Cyano-3 -[434-dimethyl-2-(2~oxo-2i?-benzo[e] [1,3] oxazin-4-ylamino)-pentanoylamino]-azepane-l-carboxylic acid benzyl ester; MS: 546 (M+l) <br><br> 4,4-Dimethyl-2-(2-oxo-2i?-benzo[e] [ 1,3]oxazin-4-ylamino)-pentanoic acid (3-cyano-1 - <br><br> propyl-azepan-3-yl)-amide; MS: 454 (M+l) <br><br> 150 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> o ch„ <br><br> JJ H,C^UCH„ <br><br> crSlH'f^ 3 <br><br> Vxf <br><br> SO <br><br> N^A <br><br> ch3 <br><br> 4,4-Dimethyl-2-(2-oxo-2#-benzo[e][l,3]oxazin-4-yIamino)-pentanoic acid (4-cyano-l-propyl-azepan-4-yl)-amide; MS: 454 (M+l) <br><br> N <br><br> I <br><br> ch3 <br><br> {[l-(4-Cyano-l-methyl-piperidixi-4-yIcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid 4-methoxy-cyclohexylmethyl ester; MS: 575 (M+l) <br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methyIene}-carbamic acid cyclohexyl ester; MS: 531 (M+l) <br><br> 151 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> {[ 1 -(4-Cyano-1 -propyl-piperidin-4-ylcarbamoyl)-3,3-dimethyl-butylamino]-phenyl-methylene}-carbamic acid ethyl ester; MS: 470 (M+l) <br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-phenyl-methylene}-carbamic acid ethyl ester; MS: 468 (M+l) <br><br> 152 <br><br> WO 02/20485 PCT/USO1/08084 <br><br> More preferred compounds of the formulas (la) and (lb) are chosen firom the following: <br><br> {[ 1 -(4-cyano-l -cyclohexy l-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester; MS: 545 (M+l) <br><br> {[l-(4-cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid cyclohexylmethyl ester; MS: 545 (M+l) <br><br> 153 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> {[-l-(4-cyano-l-methyl-piperidm-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid cyclobutyl ester; MS: 503 (M+l) <br><br> O <br><br> o <br><br> N <br><br> I <br><br> ch3 <br><br> {[1 -(4-cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino] -morpholin-4-yl-methylene}-carbamic acid allyl ester; MS: 489 (M+l) <br><br> {[ l-(4-cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid tetrahydro-furan-3ylmethyl ester; MS: 533 (M+l) <br><br> {[ 1 -(4-cyano-1 -methy-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethyl amino]-morpholin-4-yl-methylene}-carbamic acid tetrahydro-furan-2-ylmethyl ester; MS: 533 (M+l) <br><br> 154 <br><br> WO 02/20485 <br><br> PCT/USO 1/08084 <br><br> {[1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid methyl ester; MS: 463 (M+l) <br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid 2,2-dimethyl-propyl ester; MS: 519 (M+l) <br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin- <br><br> 4-yl-methyl}-carbamic acid benzyl ester; MS: 539 (M+l) <br><br> 155 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> {[1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino] -morpholin-4-yl-methyl}-carbamic acid isobutyl ester; MS: 505 (M+l) <br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid propyl ester; MS: 491 (M+l) <br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin- <br><br> 4-yl-methyl}-carbamic acid hexyl ester; MS: 533 (M+l) <br><br> 156 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> ch3 <br><br> {[l-(4-Cyano-l-methyl-piperidm-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholiri-4-yl-methyl}-carbamic acid cyclobutylmethyl ester; MS: 517 (M+l) <br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-moipholin-4-yl-methyl}-carbamic acid 3,3,3-trifluoro-propyl ester; MS: 545 (M+l) <br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid 2-methoxy-ethyl ester; MS: 507 (M+I) <br><br> 157 <br><br> WO 02/20485 <br><br> PCT/USO 1/08084 <br><br> 5,5-Dimethyl-2-(2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-hexanoic acid (4-cyano-1 -propyI-piperidin-4-yl)-amide; MS: 454 (M+1) <br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid 2-isopropoxy-ethyl ester; MS: 534 (M+l) <br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin- <br><br> 4-yl-methyl}-carbamic acid 3-methoxy-butyl ester; MS: 534 (M+l) <br><br> 158 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholiii-4-yl-methyl}-carbamic acid 2-isobutoxy-ethyl ester; MS: 549 (M+l) <br><br> N-(4-Cyano-l-methyl-piperidin-4-yl)-4-cyclohexyl-2-(7-fluoro-2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-butyramide; MS: 456 (M+l) <br><br> 2-(7-Fluoro-2-oxo-253-dihydro-benzo[e][l,3]oxazin-4-yldeneamino)-5,5-dimethyl-hexanoic acid(4-cyano-l-propyl-piperidin-4-yl)-amide; MS: 458 (M+l) <br><br> 159 <br><br> WO 02/20485 PCT7US01/08084 <br><br> N-(4-Cyano-l-methyl-piperidin-4-yl)-4-cyclohexyl-2-(7-methoxy-2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-butyramide; MS: 468 (M+l) <br><br> 2-(7-Metboxy-2-oxo-2,3-dibydro-benzo[e][l,3]oxazin-4-yldeneamino)-5,5-dimethyl-hexanoic acid(4-cyano-l-propyl-piperidin-4-yl)-amide; MS: 470 (M+l) <br><br> jV-(4-Cyano-1 -methyl-piperidin-4-yl)-3 -cyclohexyl-2-(2-oxo-2,3 -dihydro- <br><br> benzo[e][l,3]oxazin-4-ylideneamino)-propionamide; MS: 438 (M+l). <br><br> 160 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> 4,4-Dimethyl-2-(2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamiiio)-pentanoic acid (4-cyano-l-propyl-piperidin-4-yl)-amide; MS: 440 (M+l) <br><br> 4,4-Dimethyl-2-(2-oxo-2,3-dihydro- l#-quinazolin-4-ylideneamino)-pentanoic acid (4-cyano-l-propyl-piperidin-4-yl)-amide; MS: 439 (M+l) <br><br> 2-(7-Chloro-2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-4,4-diinetliyl- <br><br> pentanoic acid (4-cyano-l-propyl-piperidin-4-yl)-amide; MS: 475 (M+l) <br><br> 161 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> 4,4-Dimethyl-2-( 1 -methyl-2-oxo-1,2-dihydro-quinazolin-4-ylamino)-pentanoic acid (4-cyano-l-propyl-piperidin-4-yI)-amide; MS: 453 (M+l) <br><br> JV-(4-Cyano-l-propyl-piperidin-4-yl)-3-cyclooctyl-2-(2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-propionanaide; MS: 494 (M+l) <br><br> 7V-(4-Cyano-l-propyl-piperidin-4-yl)-3-cycloheptyl-2-(2-oxo-2,3-dIhydro-benzo[e][l,3]oxazin-4-ylideneamino)-propionamide; MS: 480 (M+l) <br><br> 162 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> {[l-(4-Cyano-l-propyl-piperidin-4-ylcarbamoyl)-2-cycloheptyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid ethyl ester; MS: 519 (M+l) <br><br> {[l-(4-Cyano-l-propyl-piperidin-4-ylcarbamoyl)-2-cyclooctyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid ethyl ester; MS: 533 (M+l) <br><br> ( {1 -[ 1 -2-Carbamoyl-ethyl)-4-cyano-piperidin-4-ylcarbamoyl]-2-cyclohexyl-ethylamino}-morpholin-4-yl-methylene)-carbamic acid isobutyl ester; MS: 562 (M+l) <br><br> 163 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> [(l-{4-Cyano-l-[3-(2-methoxyl-ethoxy)-propyl]-piperidin-4-ylcarbamoyl}-2-cyclohexyl-ethylammo)-morpholin-4-yl-methylene]-carbamic acid isobutyl ester; MS: 607 (M+l) <br><br> {[ 1 -(4-Cyano-1 -isopropyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]- <br><br> morpholin-4-yl-metliylene}-carbamic acid ethyl ester; MS: 505 (M+l) <br><br> 164 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> {[1 -(4-Cyano-1 -phenethyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester; MS: 567 (M+l) <br><br> {[l-(4-Cyano-l-ethyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene} -carbamic acid ethyl ester; MS: 491 (M+1) <br><br> CH3 O <br><br> o <br><br> N N <br><br> {[l-(l-Benzyl-4-cyano-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester; MS: 553 (M+l) <br><br> 165 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e] [ 1,3]oxazm-4-ylamino)-pentanoic acid (l-benzyl-4-cyano-piperidin-4-yl)-amide; MS: 488 (M+l) <br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-pentanoic acid [4-cyano-l-(4-fluoro-benzyl)-piperidin-4-yl]-amide; MS: 506 (M+l) <br><br> 166 <br><br> WO 02/20485 <br><br> PCT/USO 1/08084 <br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylammo)-pentanoic acid (4-cyano-l-ethyl-piperidin-4-yl)-amide; MS: 426 (M+l) <br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-pentanoic acid (4-cyano-l-methyl-piperidin-4-yl)-amide; MS: 412 (M+l) <br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-pentanoic acid (4-cyano-1- <br><br> phenethyl-piperidin-4-yl)-amide; MS: 502 (M+l) <br><br> 167 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> H3C\ PH. <br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e] [ 1,3]oxazm-4-ylamino)-pentanoic acid [4-cyano-l -(2,2-dimethyl-propyl)-piperidin-4-yl]-amide; MS: 468 (M+l) <br><br> O NH <br><br> v!xf o <br><br> ^ .CH, <br><br> CH, <br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e] [ 1,3 ]oxazin-4-ylamino)-pentanoic acid [4-cyano-1 -(3,3-dimethyl-butyi)-piperidin-4-yl]-amide; MS: 482 (M+l) <br><br> Q H3Cv PM <br><br> u X 3 <br><br> O NH / CH3 <br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e] [ 1,3]oxazin-4-ylamino)-pentanoic acid (4-cyano-1 - <br><br> pentyl-piperidin-4-yl)-amide; MS: 468 (M+l) <br><br> 168 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][l 3]oxazin-4-ylamino)-pentanoic acid (l-butyl-4-cyano-piperidin-4-yl)-amide; MS: 454(M+1) <br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][l,3]oxazm-4-ylamino)-pentanoic acid [4-cyano-l-(3,3,3-trifluoro-propyl)-piperidin-4-yl]-amide; MS: 494 (M+l) <br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e] [ 1 &gt;3]oxazin-4-ylamino)-pentanoic acid (4-cyano-l - <br><br> cyclohexylmethyl-piperidin-4-yl)-amide; MS: 494 (M+l) <br><br> 169 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> N-(4-Cyano-l-propyl-piperidin-4-yl)-3-(4,4-dimethyI-cyclohexyl)-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-propionaxnide; MS: 494 (M+l) <br><br> {[l-(3-Cyano-l-ethyl-pyrrolidin-3-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester. MS: 477 (M+l). <br><br> N-(4-Cyano-1 -methyl-piperidin-4-yl)-3 -cyclohexyl-2-(7,8-difluoro-2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-propionamide; MS: 474 (M+l) <br><br> 170 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> {[l-(4-Cyano-l-cyclohexylmethyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester; MS: 559 (M+l) <br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid 4-methoxy-cyclohexylmethyl ester; MS: 575 (M+l) <br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methyIene}-carbamic acid cyclohexyl ester; MS: 531 (M+l) <br><br> 171 <br><br> J <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> {[1 -(4-Cyano-1 -propyl-piperidin-4-ylcarbamoyl)-3,3 -dimethyl-butylamino] -phenyl-methylene}-carbamic acid ethyl ester; MS: 470 (M+l) <br><br> {[ 1 -(4-Cyano- l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-phenyl-methylene}-carbamic acid ethyl ester; MS; 468 (M+l) <br><br> 172 <br><br> WO 02/20485 PCT/US01/08084 <br><br> Most preferred compounds of the formulas (la) and (lb) are those chosen firom the following: <br><br> {[ 1 -(3 -cyano-1 -isobutyl-piperdin-3-yl carbamoyl)-3,3-dimethyl-butylamino]-morpholin-4-yl-methylene)-carbamic acid ethyl ester; MS: 493 (M+l) <br><br> {[ 1 -(4-cyano-1 -cyclohexyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morphohn-4-yl-methylene}-carbamic acid ethyl ester; MS: 545 (M+l) <br><br> 173 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> {[ 1 -(4-cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid cyclohexylmethyl ester; MS: 545 (M+l) <br><br> {[-l-(4-cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cycIohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid cyclobutyl ester; MS: 503 (M+l) <br><br> {[1 -(4-cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid allyl ester; MS: 489 (M+l) <br><br> 174 <br><br> WO 02/20485 <br><br> PCT/USO 1/08084 <br><br> N-(4-Cyano-l-propyl-piperidin-4-yl)-4-cyclohexyl-2-(2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-butyramide; MS: 480 (M+l) <br><br> {[ 1 -(4-cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acidtetrahydro-furan-3ylmeth.yl ester; MS: 533 (M+l) <br><br> {[ 1 -(4-cyano-1 -methy-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethyl amino]-morpholin-4-yl-methylene}-carbamic acid tetrahydro-furan-2-ylmelJiyl ester; MS: 533 (M+l) <br><br> 175 <br><br> WO 02/20485 <br><br> PCT/USO 1/08084 <br><br> ch3 <br><br> iV"-(4-Cyano-l-methyl-piperidin-4-yl)-3-cyclohexyl-2-(6-fluoro-3-oxo-2,3-dihydro-isoindol-l-ylideneamino)-propionamide; MS: 440 (M+l) <br><br> ch3 <br><br> {[l-(4-Cyano-l-methyI-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid methyl ester; MS: 463 (M+l) <br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimiixo]-morpholin-4-yl-methyl}-carbamic acid 2,2-dimethyl-propyl ester; MS: 519 (M+l) <br><br> 176 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> {[l-(4-Cyano-l-methyl-piperidm-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid benzyl ester; MS: 539 (M+l) <br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid isobutyl ester; MS: 505 (M+l) <br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino] -morpholin-4-yl-methyl}-carbamic acid propyl ester; MS: 491 (M+l) <br><br> 177 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino] -morpholin-4-yl-methyl}-carbamic acid hexyl ester; MS: 533 (M+l) <br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cy clohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid cyclobutylmethyl ester; MS: 517 (M+l) <br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-moipholin-4-yl-methyl}-carbamic acid 3,3,3-trifluoro-propyl ester; MS: 545 (M+l) <br><br> 178 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]~morpholin-4-yl-methyl}-carbamic acid 2-methoxy-ethyl ester; MS: 507 (M+l) <br><br> 5,5-Dimethyl-2-(2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-hexanoic acid (4-cyano-l-propyl-piperidin-4-yl)-amide; MS: 454 (M+l) <br><br> H3CXv/CH3 <br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-moipholin-4-yl-methyl}-carbamic acid 2-isopropoxy-ethyl ester; MS: 534 (M+l) <br><br> 179 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid 3-methoxy-butyl ester; MS: 534 (M+l) <br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid 2-isobutoxy-ethyl ester; MS: 549 (M+l) <br><br> N-(4-Cyano-l-methyl-piperidin-4-yl)-4-cyclohexyl-2-(7-fluoro-2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-butyramide; MS: 456 (M+l) <br><br> 180 <br><br> WO 02/20485 <br><br> PCT/USO 1/08084 <br><br> 2-(7-Fluoro-2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-yldeneamino)-5,5-dimsthyl-hexanoic acid(4-cyano-1 -propyl-piperidin-4-yl)-amide; MS: 458 (M+l) <br><br> N-(4-Cyano-l-methyl-piperidin-4-yl)-4-cyclohexyl-2-(7-methoxy-2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-butyramide; MS: 468 (M+l) <br><br> 2-(7-Methoxy-2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-yldeneamino)-5,5-dimethyl-hexanoic acid(4-cyano-l-propyl-piperidin-4-yl)-amide; MS: 470 (M+l) <br><br> 181 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> A^-(4-Cyano-1 -methyl-piperidin-4-yl)-3-cyclohexyl-2-(2-oxo-2,3 -dihydro-benzo[e][l,3]oxazm-4-ylideneamino)-propionamide; MS: 438 (M+l). <br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino] -pyrrolidin-1 -yl-methyl}-carbamic acid ethyl ester; MS: 461 (M+l). <br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-piperidin-l-yl-methyl}-carbamic acid ethyl ester; MS: 475 (M+l). <br><br> 182 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> {Azepan-1 -yl-[ 1 -(4-cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-methyl}-carbamic acid ethyl ester; MS: 489 (M+l). <br><br> CHq c <br><br> o=&lt;° <br><br> O" <br><br> {Azocan-1 -yl-[ 1 -(4-cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-methyl}-carbamic acid ethyl ester; MS: 503 (M+l). <br><br> [[l-(4-Cyano-l-methyl-piperidin-4-yIcarbamoyl)-2-cyclohexyI-ethylimino]-(4-phenyl-piperazin-l-yl)-methyl]-carbamic acid ethyl ester; MS: 552 (M+l). <br><br> 183 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> {(4-Acetyl-piperazin-1 -yl)-[ 1 -(4-cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl- <br><br> [[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cycIohexyI-ethyIimino]-(3,355-trimethyl-6-aza-bicyclo[3.2.1]oct-6-yl)-methyl]-carbamic acid ethyl ester; MS: 543 (M+l). <br><br> O CH, <br><br> A ACH* <br><br> o nh ( ch, <br><br> N <br><br> h3C^ <br><br> 4,4-Dimethyl-2-(2-oxo-2,3-dihydro-benzo[e][l,3]oxazm-4-ylideneamino)-pentanoic acid (4-cyano-l-propyl-piperidin-4-yl)-amide; MS: 440 (M+l) <br><br> 184 <br><br> WO 02/20485 <br><br> PCT/USO 1/08084 <br><br> [[l-(4-Cyano-l-methyl-piperidm-4-ylcarbamoyl)-2-cyclohexyl-ethylimiiio]-(2-methoxymethyl-morpholin-4-yl)-methyl]-carbamic acid ethyl ester; MS: 521 (M+l) <br><br> [[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethyhmino]-(2,6-dimethyl-morpholin-4-yl)-methyl]-carbamic acid ethyl ester; MS: 505 (M+l) <br><br> [[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-(2,6-dimethyl-morpholin-4-yl)-methyl]-carbamic acid ethyl ester; MS: 505 (M+l) <br><br> 185 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> 2-(7-Chloro-2-oxo-2,3-dihydro-benzo[e][1.3]oxazin-4-ylideneamino)-4,4-dimethyl-pentanoic acid (4-cyano-l-propyl-piperidin-4-yl)-amide; MS: 475 (M+l) <br><br> 5-Methyl-2-(2-oxo-2,3-dihydro-benzo[e] [ 1,3]oxazin-4-ylideneamino)-hexanoic acid (4-cyano-l-propyl-piperidin-4-yl)-amide; MS: 440 (M+l) <br><br> 186 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> 4,4-Dimethyl-2-(l-methyl-2-oxo-l J2-dihydro-quinazolm-4-ylamino)-pexitanoic acid (4-cyano-l-propyl-piperidin-4-yl)-amide; MS: 453 (M+l) <br><br> Af-(4-Cyano-1 -propyl-piperidin-4-yl)-3 -cyclooctyl-2-(2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-propionamide; MS: 494 (M+l) <br><br> iV-(4-Cyano-l-propyl-piperidin-4-yl)-3-cycloheptyl-2-(2-oxo-2,3-dih.ydro-benzo[e][l,3]oxazin-4-ylideneamino)-propionamide; MS: 480 (M+l) <br><br> 187 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> {[1-(4-Cyano-l-propyl-piperidin-4-ylcarbamoyl)-2-cycloheptyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid ethyl ester; MS: 519 (M+l) <br><br> {[ 1 -(4-Cyano-1 -propyl-piperidin-4-ylcarbamoyl)-2-cyclooctyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid ethyl ester; MS: 533 (M+l) <br><br> {[l-(4-Cyano-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylaimno]-morpholin-4-yl-methylene}-carbamic acid isobutyl ester; MS: 491 (M+l) <br><br> 188 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> ({1 -[4-Cyano-1 -(2-morpholm-4-yl-ethyl)-piperidin-4-ylcarbamoyl] -2-cyclohexyl-ethylamino}-morpholin-4-yl-methylene)-carbamic acid isobutyl ester; MS: 604 (M+l) <br><br> ({1 -[1 -2-Carbamoyl-ethyl)-4-cyano-piperidin-4-ylcarbamoyl]-2-cyclohexyl-ethylamino}-moipholin-4-yl-methylene)-carbamic acid isobutyl ester; MS: 562 (M+l) <br><br> 189 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> h=cY^o-^nh , <br><br> i h ^.n <br><br> O <br><br> h3c' <br><br> n <br><br> O <br><br> [(1 - {4-Cyano-1 -[3-(2-methoxyl-ethoxy)-propyl]-piperidin-4-ylcarbamoyl} -2-cyclohexyl-ethylamino)-moipholin-4-yl-methylene]-carbamic acid isobutyl ester; MS: 607 (M+l) <br><br> hx ch3 <br><br> ch3 0 <br><br> N N <br><br> {[l-(4-Cyano-l-propyl-piperidin-4-ylcarbamoyl)-2-(3,3,5,5-tetramethyl-cyclohexyl)-ethylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester; MS: 561 (M+l) <br><br> O <br><br> A. <br><br> h,c' ^0" "nh <br><br> O <br><br> *N' <br><br> O <br><br> h3c ch3 <br><br> {[l-(4-Cyano-l-isopropyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-moipholin-4-yl-methylene}-carbamic acid ethyl ester; MS: 505 (M+l) <br><br> 190 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> {[1 -(4-Cyano-1 -phenethyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino] -morpholin-4-yl-methylene}-carbamic acid ethyl ester; MS: 567 (M+l) <br><br> &lt;?H3 O <br><br> o <br><br> NH <br><br> -W <br><br> N' N <br><br> {[l-(4-Cyano-l-ethyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester; MS: 491 (M+l) <br><br> {[ 1 -(1 -Benzyl-4-cyano-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino] -morpholin-4-yl-methylene}-carbamic acid ethyl ester; MS: 553 (M+l) <br><br> 191 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> {[l-(4-cyano-l-phenethyl-piperidin-4-ylcarbamoyl)-3,3-dimethyl-butylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester; MS: 541 (M+l) <br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-pentanoic acid (l-benzyl-4-cyano-piperidin-4-yl)-amide; MS: 488 (M+l) <br><br> 192 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-pentanoic acid [4-cyano-l-(5-methyl-thiophen-2-ylmethyl)-piperidin-4-yl]-amide; MS: 508 (M+l) <br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e] [1,3]oxazin-4-ylamino)-pentanoic acid [4-cyano-1 -(4-fluoro-benzyl)-piperidin-4-yl]-amide; MS: 506 (M+l) <br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-pentanoic acid (4-cyano-1-ethyl-piperidin-4-yl)-amide; MS: 426 (M+l) <br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][ 1,3]oxazin-4-ylamino)-pentanoic acid (4-cyano-l- <br><br> methyl-piperidin-4-yl)-amide; MS: 412 (M+l) <br><br> 193 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][l33]oxazin-4-ylamino)-pentanoic acid (4-cyano-piperidin-4-yl)-amide; MS: 398 (M+l) <br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylaniino)-pentanoic acid (4-cyano-1-phenethyl-piperidin-4-yl)-amide; MS: 502 (M+l) <br><br> 4,4-Dimethyl-2-(2-oxo-2H-ben2:o[e] [ 1,3]oxazin-4-ylamino)-pentanoic acid [4-cyano-1 -(2,2-dimethyl-propyl)-piperidin-4-yl]-amide; MS: 468 (M+l) <br><br> 194 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][ 1,3]oxazin-4-ylamino)-pentan.oic acid [4-cyano-1 -(3s3-dimethyl-butyl)-piperidin-4-yl]-amide; MS: 482 (M+l) <br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e] [ 1,3]oxazin-4-ylamino)-pentanoic acid (1 -butyl-4- <br><br> cyano-piperidin-4-yl)-amide; MS: 454(M+1) <br><br> 195 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-pentanoic acid [4-cyano-l-(3}3,3-trifluoro-propyl)-piperidin-4-yl]-amide; MS: 494 (M+l) <br><br> cyclohexylmethyl-piperidin-4-yl)-amide; MS: 494 (M+l) <br><br> N-(4-Cyano-l-propyl-piperidin-4-yl)-3-(4,4-dimethyi-cyclohexyl)-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-yIamino)-propionamide; MS: 494 (M+l) <br><br> 196 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> {[ 1 -(3-Cyano-1 -ethyl-pyrrolidin-3 -ylcarbamoyl)-2-cyclohexyl-ethylamino] -moipholin-4-yl-methylene}-carbamic acid ethyl ester. MS: 477 (M+l). <br><br> {[ l-(3-Cyano- l-propyl-pyrrolidin-3-ylcarbamoyl)-3,3 -dimethyl-butylamino]-moipholin-4-yl-methylene}-carbamic acid ethyl ester. MS: 465 (M+l). <br><br> 197 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> ({l-[3-Cyano-l-(4,4-dimethyl-cyclohexyl)-pyrrolidin-3-ylcarbamoyl]-3,3-dimethyl-butylamino}-morpholin-4-yl-methylene)-carbamic acid ethyl ester. MS: 533 (M+l). <br><br> N-(4-Cyano-1 -methyl-piperidin-4-yl)-3 -cyclohexyl-2-(7,8-difluoro-2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-propionamide; MS: 474 (M+l) <br><br> morpholin-4-yl-methylene}-carbamic acid ethyl ester; MS: 559 (M+l) <br><br> 198 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> V <br><br> ch3 <br><br> {[1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid 4-methoxy-cyclohexylmethyl ester; MS: 575 (M+l) <br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino] -morpholin-4-yl-methylene}-carbamic acid cyclohexyl ester; MS: 531 (M+l) <br><br> {[l-(4-Cyano-l-propyl-piperidin-4-ylcarbamoyl)-3,3-dimethyl-butylamino]-phenyl-methylene}-carbamic acid ethyl ester; MS: 470 (M+l) <br><br> 199 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-phenyl-methylene}-carbamic acid ethyl ester; MS: 468 (M+l). <br><br> Any compounds of this invention containing one or more asymmetric carbon atoms may occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. All such isomeric forms of these compounds are expressly included in the present invention. Each stereogenic carbon may be in the R or S configuration unless otherwise specified, or a combination of configurations. <br><br> Some of the compounds of formulas (la) and (lb) can exist in more than one tautomeric form. The invention includes all such tautomers. <br><br> It shall be understood by one of ordinary skill in the art that all compounds of the invention are those which are chemically stable. <br><br> The invention includes pharmaceutically acceptable derivatives of compounds of formula (la) and (lb). A "pharmaceutically acceptable derivative" refers to any pharmaceutically acceptable acid, salt or ester of a compound of this invention, or any other compound which, upon administration to a patient, is capable of providing (directly or indirectly) a compound of this invention, a pharmacologically active metabolite or pharmacologically active residue thereof. <br><br> 200 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> In addition, the compounds of this invention include prodrugs of compounds of the formulas (la) and (lb). Prodrugs include those compounds that, upon simple transformation, are modified to produce the compounds of the invention. Simple chemical transformations include hydrolysis, oxidation and reduction which occur 5 enzymatically, metabolically or otherwise. Specifically, when a prodrug of this invention is administered to a patient, the prodrug may be transformed into a compound of formula (la) and (lb), thereby imparting the desired pharmacological effect. <br><br> In order that the invention herein described may be more fully understood, the following 10 detailed description is set forth. As used herein, the following abbreviations are used: <br><br> BOC or t-BOC is tertiary-butoxycarbonyl; <br><br> t-Bu is tertiary-butyl; <br><br> DMF is dimethylformamide; <br><br> 15 EtOAc is ethyl acetate; <br><br> THF is tetrahydrofuran; <br><br> Ar is argon; <br><br> EDC is l-(3-dimethylaminopropyl)-3-ethylcarbodimide hydrochloride and HOBT is 1-hydroxybenzotriazole. <br><br> 20 <br><br> Also, as used herein, each of the following terms, used alone or in conjunction with other terms, are defined as follows (except where noted to the contrary): <br><br> 25 The term "alkyl" refers to a saturated aliphatic radical containing from one to ten carbon atoms or a mono- or polyunsaturated aliphatic hydrocarbon radical containing from two to twelve carbon atoms. The mono- or polyunsaturated aliphatic hydrocarbon radical containing at least one double or triple bond, respectively. "Alkyl" refers to both branched and unbranched alkyl groups. Examples of "alkyl" include alkyl groups which 30 are straight chain alkyl groups containing from one to eight carbon atoms and branched alkyl groups containing from three to eight carbon atoms. Other examples include lower alkyl groups which are straight chain alkyl groups containing from one to six carbon <br><br> 201 <br><br> WO 02/20485 PCT/USO1/08084 <br><br> atoms and branched alkyl groups containing from three to six carbon atoms. It should be understood that any combination term using an "alk" or "alkyl" prefix refers to analogs according to the above definition of "alkyl". For example, terms such as "alkoxy", "alkythio" refer to alkyl groups linked to a second group via an oxygen or sulfur atom. <br><br> 5 "Alkanoyl" refers to an alkyl group linked to a carbonyl group (OO). Each alkyl or alkyl analog described herein shall be understood to be optionally partially or fully halogenated. <br><br> .The term "cycloalkyl" refers to the cyclic analog of an alkyl group, as defined above. <br><br> 10 Examples of cycloalkyl groups are saturated or unsaturated nonaromatic cycloalkyl groups containing from three to eight carbon atoms, and other examples include cycloalkyl groups having three to six carbon atoms. Each cycloalkyl described herein shall be understood to be optionally partially or fully halogenated. <br><br> 15 The term "aryl" refers to phenyl and naphthyl. <br><br> The term "halo" refers to a halogen radical selected from fluoro, chloro, bromo or iodo. Representative halo groups of the invention are fluoro, chloro and bromo. <br><br> 20 The term "heteroaryl" refers to a stable 5-8 membered (but preferably, 5 or 6 membered) monocyclic or 8-11 membered bicyclic aromatic heterocycle radical. Each heterocycle consists of carbon atoms and from 1 to 4 heteroatoms chosen from nitrogen, oxygen and sulfur. The heterocycle may be attached by any atom of the cycle, which results in the creation of a stable structure. Examples of "heteroaryl" include radicals such as furanyl, <br><br> 25 thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, indolyl, isoindolyl, benzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzthiazolyl, benzoxazolyl, purinyl, quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, <br><br> 30 pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl and phenoxazinyl, <br><br> 202 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> The term "heterocycle" refers to a stable 4-8 membered (but preferably, 5 or 6 membered) monocyclic or 8-11 membered bicyclic heterocycle radical which may be either saturated or unsaturated, and is non-aromatic. Each heterocycle consists of carbon atoms and from 1 to 4 heteroatoms chosen from nitrogen, oxygen and sulfur. The heterocycle may be attached by any atom of the cycle, which results in the creation of a stable structure. Examples of "heterocycle" include radicals such as pyrrolinyl, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, pyranyl, thiopyranyl, piperazinyl, indolinyl, azetidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrofuranyl, hexahydropyrimidinyl, hexahydropyridazinyl, 1,4,5,6-tetrahydropyrimidin-2-ylamine, dihydro-oxazolyl, 1,2-thiazinanyl-1,1 -dioxide, l,2,6-thiadiazinanyl-l,l-dioxide, isothiazolidinyl-1,1-dioxide and imidazolidinyl-2,4-dione. <br><br> The terms "heterocycle", "heteroaryl" or "aryl", when associated with another moiety, unless otherwise specified shall have the same meaning as given above. For example, "aroyl" refers to phenyl or naphthyl linked to a carbonyl group (C=0). <br><br> Each aiyl or heteroaryl unless otherwise specified includes it's partially or fully hydrogenated derivative. For example, quinolinyl may include decahydroquinolinyl and tetrahydroquinolinyl, naphthyl may include it's hydrogenated derivatives such as tetrahydranaphthyl. Other partially or fully hydrogenated derivatives of the aryl and heteroaryl compounds described herein will be apparent to one of ordinary skill in the art. <br><br> The term heterocycle as it pertains to "Het" shall to be understood to mean a stable nonaromatic spiroheterocycle, 4-8 membered (but preferably, 5 or 6 membered) monocyclic, 8-11 membered bicyclic heterocycle radical which may be either saturated or unsaturated or a C6-C10 bridged bicyclo wherein one or more carbon atoms are optionally replaced by a heteroatom. Each heterocycle consists of carbon atoms and from 1 to 4 heteroatoms chosen from nitrogen, oxygen and sulfur. The heterocycle may be attached by any atom of the cycle, which results in the creation of a stable structure. Examples of "Het" include the following heterocycles: azepanyl, piperidinyl, pyrrolidinyl, azetidinyl, oxepanyl, <br><br> 203 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrofuranyl, oxetanyl, azocanyl, <br><br> oxocanyl, 1,3-diazocanyl, 1,4-diazocanyl, 1,5-diazocanyl, 1,3-dioxocanyl, 1,4-dioxocanyl, 1,5-dioxocanyl, 1,3-oxazocanyl, 1,4-oxazocanyl, 1,5-oxazocanyl, 1,3-diazepanyl, 1,4-diazepanyl, 1,3-dioxepanyl, 1,4-dioxepanyl, 1,3-oxazepanyl, 1,4-oxazepanyl, 1,2-thiazocany 1-1,1-dioxide, 1,2,8-thiadiazocanyl-1,1 -dioxide, 1,2-thiazepanyl-1,1-dioxide, 1,2,7-thiadiazepanyl-1,1 -dioxide, tetrahydrothiophenyl, hexahydropyrimidinyl, hexahydropyridazinyl, piperazinyl, 1,4,5,6-tetrahydropyrimidinyl, pyrazolidinyl, dihydro-oxazolyl, dihydrothiazolyl, dihydroimidazolyl, isoxazolinyl, oxazolidinyl, 1,2-thiazinanyl-1,1-dioxide, 1,2,6-thiadiazinanyl-l, 1-dioxide, isothiazolidinyl-1,1-dioxide, imidazolidinyl-2,4-dione, imidazolidinyl, morpholinyl, dioxanyl, tetrahydropyridinyl, thiomorpholinyl, thiazolidinyl, dihydropyranyl, dithianyl, decahydro-quinolinyl, decahydro-isoquinolinyl, 1,2,3,4-tetrahydro-quinolinyl, indolinyl, octahydro-quinolizinyl, dihydro-indolizinyl, octahydro-indolizinyl, octahydro-indolyl, decahydroquinazolinyl, decahydroquinoxalinyl, 1,2,3,4-tetrahydroquinazolinyl or 1,2,3,4-tetrahydroquinoxalinyl, aza-bicyclo[3.2.1]octane, aza-bicyclo[2.2.1]heptane, aza-bicyclo[2.2.2]octane, aza-bicyclo[3.2.2]nonane, aza-bicyclo[2.1.1]hexane, aza-bicyclo[3.1.1]heptane, aza-bicyclo[3.3.2]decane and 2-oxa or 2-thia-5-aza-bicyclo[2.2.1]heptaneeach; heterocyclic ring being substituted with one or more R5. The substituent R5 is defined above. <br><br> As used herein above and throughout this application, "nitrogen" and "sulfur" include any oxidized form of nitrogen and sulfur and the quaternized form of any basic nitrogen. <br><br> In order that this invention be more fully understood, the following examples are set forth. These examples are for the purpose of illustrating preferred embodiments of this invention, and are not to be construed as limiting the scope of the invention in any way. <br><br> The examples which follow are illustrative and, as recognized by one skilled in the art, <br><br> -P <br><br> particular reagents or conditions could be modified as needed for individual compounds. Starting materials used in the scheme below are either commercially available or easily prepared from commercially available materials by those skilled in the art. <br><br> 204 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> GENERAL SYNTHETIC METHODS <br><br> The invention also provides processes of making the present novel compounds of formula 5 (la) and (Ih). Compounds of the invention may be prepared by methods described below, those found in US application serial no. 09/655,351, incorporated herein be reference in it's entirety, and by methods known to those of ordinary skill in the art. <br><br> 10 <br><br> N^^CN <br><br> (la) <br><br> (lb) <br><br> 15 <br><br> A key intermediate in the preparation of compounds of formula (la) and (lb) is the dipeptide nitrile intermediate (III). <br><br> R2. R3 R4 .N. <br><br> HN' <br><br> R4 X <br><br> (III) <br><br> The synthesis of intermediates of formula (HI) is described in US provisional patent 20 application 60/222,900 and outlined below in Schemes I and II. <br><br> Scheme I <br><br> 25 <br><br> 205 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> R, <br><br> IV <br><br> V <br><br> VI: R' = Boc r, <br><br> III: R' = H <br><br> As illustrated in Scheme I, an amino acid bearing a suitable protecting group R' (TV), is reacted with an amino nitrile (V) under suitable coupling conditions. An example of a 5 suitable protecting group is the f-butoxycarbonyl (BOC) group. An example of standard coupling conditions would be combining the starting materials in the presence of a coupling reagent such as l-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) with 1-hydroxybenzotriazole (HOBT), in a suitable solvent such as DMF or methylene chloride. A base such as N-methylmorpholine may be added. This is followed by deprotection to 10 give amino acid nitrile III. <br><br> The intermediate aminonitrile (V) used in Scheme I above may be prepared as outlined in Scheme II. <br><br> 15 Scheme II <br><br> In this method, a ketone bearing "Het" (VII) is reacted with an a primary amine or an ammonium salt, such as ammonium chloride, and a cyanide salt, such as potassium 20 cyanide or sodium cyanide, in a suitable solvent, such as water or a solution of ammonia in methanol, at about room temperature to reflux temperature. <br><br> O <br><br> vii <br><br> V <br><br> 206 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> Compounds having formula (Ta/Ib) may be prepared by Methods A-D, as illustrated in Schemes HE- VI. <br><br> Scheme in (Method A) <br><br> According to Method A, a dipeptide nitrile intermediate (III), or a basic salt thereof, is allowed to react with (VIET) in the presence of a suitable coupling agent to provide the desired product (Ia/Ib). Suitable reaction conditions are known to those skilled in the art and some examples of suitable coupling agents include 2-chloro-l-methylpyridinium iodide (Yong, Y.F. et al., J. Org. Chem. 1997, 62,1540), phosgene or triphosgene (Barton, D.H. et al., J. Chem. Soc. Perkin Trans. 1,1982, 2085), alkyl halides (Brand, E. and Brand, F. C., Org. Synth., 1955, 3, 440) carbodiimides (Poss, M. A. et al., Tetrahedron Lett., 1992,40,5933) and mercury salts (Su, W., Synthetic Comm., 1996, 26, 407 and Wiggall, K. J. and Richardson, S. K. J., Heterocyclic Chem., 1995, 32, 867). <br><br> Compounds having formulas (la) and (lb) may also be prepared by Method B as illustrated in Scheme IV, where R is an alkyl or aryl group. <br><br> Scheme IV (Method B) <br><br> + (HO <br><br> coupling agent base, <br><br> viii <br><br> (iii) <br><br> base <br><br> (la/lb) <br><br> IX <br><br> 207 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> According to Method B a dipeptide nitrile intermediate (HI), or a basic salt thereof, is allowed to react with IX, with or without an added base such as triethylamine, to provide the desired product (Ia/Ib). Suitable reaction conditions are known to those skilled in the art and examples of such amine additions may be found in the chemical literature, for 5 example Haake, M. and Schummelfeder, B., Synthesis, 1991,9,753; Dauwe, C. and Buddrus, J., Synthesis 1995,2,171; Ried, W. and Piechaczek, D., Justus Liebigs Ann. Chem. 1966, 97,696 and Dean, W. D. and Papadopoulos, E. P., J. Heterocyclic Chem., 1982,19,1117. <br><br> 10 The intermediate IX is either commercially available or can be synthesized by methods known to those skilled in the art and described in the literature, for example Francesconi, I. et. al., J. Med. Chem. 1999,42,2260; Kurzer, F., Lawson, A.,Org. Synth. 1963,645, and Gutman, A. D. US 3984410, 1976. <br><br> 15 In a similar reaction, intermediate X having a halogen or other suitable leaving group (X') may be used in place of intermediate IX, as illustrated in Method C, Scheme V. <br><br> Scheme V (Method C) <br><br> base <br><br> (III) (la/lb) <br><br> According to Method C, a dipeptide nitrile intermediate, or a basic salt thereof, is allowed to react with intermediate X, with or without an added base such as triethylamine, to provide the desired product (Ia/Ib). Procedures for accomplishing this reaction are 25 known to those skilled in the art and described in the chemical literature (for example, Dunn, A. D., Org. Prep. Proceed. Int., 1998, 30, 709; Lindstroem, S. et al., Heterocycles, 1994,38, 529; Katritzky, A. R. and Saczewski, F., Synthesis, 1990, 561; Hontz, A. C. <br><br> 208 <br><br> and Wagner, E. C., Org Synth., 1963, IV, 383; Stephen, E. and Stephen, H., J. Chem. Soc., 1957, 490). <br><br> Compounds having formula (Ia/Ib) in which Ri is an amine may also be prepared by Method D as illustrated in Scheme VI. <br><br> Scheme VI (Method D) <br><br> According to Method D, a carbodiimide (XT) derivative of (III) is allowed to react with an amine (Ri) to provide the desired guanidine (Ia/Ib) product. The conversion of amines to carbodiimides is known to those in the art and described in the literature (for example, Pri-Bar, I. and Schwartz, J., J. Chem. Soc. Chem. Commun., 1997, 347; Hirao, T. and Saegusa, T., J. Org. Chem., 1975, 40, 298). The reaction of carbodiimides with amine nucleophiles is also described in the literature (for example, Yoshiizumi, K. et al., Chem. Pharm. Bull., 1997, 45, 2005; Thomas, E. W. etal., J. Med. Chem., 1989, 32, 228; Lawson, A. and Tinkler, R. B., J. Chem. Soc. C, 1971, 1429. <br><br> In a modification of Method D, one may start with the thiourea XH (formed by reaction of the corresponding amine with an isothiocyanate R^N=C=S) and then form the corresponding carbodiimide (XI) in situ by reaction with a suitable desulfurizing agent, such as HgCl2, in a suitable solvent such as DMF or acetonitrile. <br><br> R2 R3 R4 <br><br> XI <br><br> (la/lb) <br><br> 209 <br><br> 1, <br><br> M <br><br> nr i-iz <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> R, <br><br> 6\ <br><br> NH <br><br> R2 R3 R4 <br><br> S <br><br> A <br><br> N <br><br> Compounds of formula (lb), where Ri is an amine may be prepared using a general procedure described by M. Haake and B. Schummfelder (Synthesis, 1991, 753). According to this procedure (Method E, Scheme VII), intermediate XIII bearing two suitable leaving groups Z, such as phenoxy groups, is reacted sequentially with amines Ri and RgRsNH in a suitable solvent such as methanol or isopropanol to provide the desired product. Reaction of the first amine may be carried out at about room temperature and reaction of the second amine is preferentially carried out with heating at the reflux temperature of the solvent. If XHI is allowed to react with a bifunctional nucleophile intermediate XIV, where Y is a nucleophilic heteroatom such as N, O or S, one may obtain the product of formula (lb) where Ri and Rg form a heterocyclic ring. <br><br> Intermediate XIII may be prepared by reaction of III (R4 = H) with dichlorodiphenoxymethane, which in turn, may be prepared by heating diphenyl carbonate with PCI5 (R.L. Webb and C.S. Labow, J. Het. Chem., 1982, 1205). <br><br> Scheme VH (Method E) <br><br> 210 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> Z <br><br> '5 <br><br> 2- RfiRfiNH <br><br> '5 <br><br> XIII <br><br> lb <br><br> VWV" <br><br> x ^Het^-F <br><br> R <br><br> Y XIV <br><br> + XIII <br><br> lb <br><br> In order that this invention be more fully understood, the following examples are set 5 forth. These examples are for the purpose of illustrating embodiments of this invention, and are not to be construed as limiting the scope of the invention in any way. <br><br> The examples which follow are illustrative and, as recognized by one skilled in the art, particular reagents or conditions could be modified as needed for individual compounds 10 without undue experimentation. Starting materials used in the scheme below are either commercially available or easily prepared from commercially available materials by those skilled in the art. <br><br> 15 <br><br> 20 <br><br> 211 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> SYNTHETIC EXAMPLES EXAMPLE 1 <br><br> 2-{[Acetylimino-(4-methoxy-phenyl)-methyl]-amino}-N-(4-cyano-I-methyl-piperidin-4-yl)-3-cyclohexyl-propionamide (Method A). <br><br> (a) N-(4-methoxy-thiobenzoyl)acetamide. <br><br> A solution of acetyl chloride (4.69 g, 59.8 mmol) in acetone (20 mL) was added dropwise to a solution of 4-methoxythiobenzamide (5.00 g, 29.9 mmol) and pyridine (4.76 g, 60.1 mmol) in acetone (30 mL). The reaction mixture was heated to reflux for 30 min then poured onto ice water. The resulting precipitate was isolated via filtration and dried under vacuum overnight to provide a light yellow/orange solid (4.52 g, 72%). *H NMR (400 MHz, CDC13) 5 2.56 (s, 3H), 3.87 (s, 3H), 6.89 (dd, J= 6.9, 2.0 Hz, 2H), 7.77 (dd, J = 6.9, 2.0 Hz, 2H). <br><br> tz. <br><br> (b) 2- {[Acetylimino-(4-methoxy-phenyl)-methyl]-amino} -N-(4-cyano-1 -methyl-piperidin-4-yl)-3-cyclohexyl-propionamide. <br><br> 2-Chloro-N-methylpyridinium iodide (660 mg, 2.58 mmol), was added to a solution of N-(4-methoxy-thiobenzoyl)acetamide (420 mg, 2.01 mmoI), 2-amino-N-(4-cyano- <br><br> 212 <br><br> WO 02/20485 <br><br> PCT/USO 1/08084 <br><br> l-methyl-piperidin-4-yl)-3-cyclohexyl-propionamide bis hydrochloride salt (730 mg, 2.00 mmol), and N,N-diisopropylethyIamine (1.05 mL, 6.02 mmol) in dichloromethane (8.0 mL). The reaction mixture was stirred at room temperature for 2 h, then diluted with dichloromethane (100 mL)and washed with 2x150 mL of 5 saturated sodium bicarbonate. The organic phase was dried (MgSC&gt;4) and concentrated. The resulting residue was chromatographed over 100 g of flash silica first using EtOAc, then dichloromethane/methanol 9:1 as the eluant to provide the desired, product as an off white solid (377 mg, 40%). 1H NMR (400 MHz, DMSO-d6) 8 0.70-0.90 (m, 2H), 1.00-1.30 (m, 4H), 1.35-1.65 (m, 8H), 1.72 (s, 3H), 1.85-2.20 10 (m, 6H), 2.48-2.60 (m, 1H), 3.78 (s, 3H), 4.20-4.35 (m, 1H), 6.95-6.99 (m, 2 H), 7.33 (d,/= 8.4 Hz, 1H), 7.72 (d, J= 8.4 Hz, 1H). MS, m/z 468 = M+l. <br><br> 2-[(Acetylimino-phenyl-methyl)-amino]-N-(4-cyano-1 -methyl-piperidin-4-yl)-3 -cyclohexyl-propionamide. <br><br> 20 (a) Thiobenzoyl acetamide was prepared according to the procedure firom Example 1, step a, starting with thiobenzamide. <br><br> (b) The title compound was prepared starting from thiobenzoyl acetamide and 2-amino-N-(4-cyano-l -methyl-piperidin-4-yl)-3-cyclohexyl-propionamide bis <br><br> EXAMPLE 2 <br><br> 15 <br><br> 213 <br><br> WO 02/20485 <br><br> PCT/USO 1/08084 <br><br> hydrochloride salt according to the procedure from Example 1, step b. MS, m/z 438 = <br><br> 2-{[Acetylimino-(4-fluoro-phenyl)-methyl]-amino}-N-(4-cyano-l-methyl-piperidin-4-yl)-3 -cyclohexyl-propionamide. <br><br> (a) N-(4-Fluoro-thiobenzoyl )acetamide was prepared according to the procedure from Example 1, step a, starting with 4-fluorothiobenzamide. <br><br> (b) The title compound was prepared starting from N-(4-fluoro~thiobenzoyl) <br><br> acetamide and 2-airdno-N-(4-cyano-l-methyl-piperidin-4-yl)-3-cyclohexyl-propionamide bis hydrochloride salt according to the procedure from Example 1, step b. MS, m/z 456 = <br><br> M+l. <br><br> EXAMPLE 3 <br><br> M+l. <br><br> EXAMPLE 4 <br><br> 214 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> 2-[(AcetyUmino-phenyl-methyl)]-amino]-N-[3-cyano-l-(l-ethyl-propyl)-pyrrolidin-3-yl]- <br><br> 3-cyclohexyl-propionamide. <br><br> (a) The title compound was prepared starting from thiobenzoyl acetamide and 2-amino-N-[3-cyano-l-( 1 -ethyl-propyl)-pyrrolidin-3-yl]-3-cyclohexyl-propionamide bis hydrochloride salt according to the procedure from Example 1, step b, except that the compound was purified by HPLC using a 20 x 250 mm CI8 reverse phase column with the method being 20% acetonitrile in water to 90% acetonitrile in water. MS, m/z 480 = <br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylen}-carbamic acid ethyl ester (Method A). <br><br> M+l. <br><br> EXAMPLE 5 <br><br> 215 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> (a) (Morpholine-4-carbothioyl)-carbamic acid ethyl ester. <br><br> Morpholine (7.5 mL, 86.0 mmol) was added dropwise to a solution of ethyl isothiocyanato formate (10.0 mL, 84.8 mmol) in tetrahydrofuran (200 mL). The reaction mixture was stirred at room temperature for 2.5 h, then concentrated and dried under 5 vacuum to provide the desired product as a white solid (16.5 g, 89%). This material was used without further purification. *H NMR (400 MHz, CDCI3) 5 1.28 (t, J = 7.1 Hz, 3H), 3.61-3.97 (m, 8H), 4.16 (q, 7.1 Hz, 2H), 7.44 (br s, 1H). <br><br> (a) {[ 1 -(4-Cyano-1 -methyI-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-10 morpholin-4-yl-methylen}-carbamic acid ethyl ester. <br><br> 2-Chloro-N-methylpyridinium iodide (680 mg, 2.66 mmol), was added to a solution of (morpholine-4-carbothioyl)-carbamic acid ethyl ester (450 mg, 2.06 mmol), 2-amino-N-(4-cyano-l-methyl-piperidin-4-yl)-3-cyclohexyl-propionamide bis hydrochloride salt (745 mg, 2.04 mmol), and N,N-diisopropylethylamine (1.10 mL, 6.3 mmol) in 15 dichloromethane (8.0 mL). The reaction was stirred at room temperature for 2.5 h then taken up in 10% citric acid solution and washed with EtOAc. The aqueous phase was then basified with saturated sodium carbonate and extracted with EtOAc. The organic extract was dried (MgSC&gt;4) and concentrated to provide the desired product as a white solid (250 mg, 26%). This material was further purified by HPLC using a 20x250 mm 20 C]8 reverse phase column with the method being 20% acetonitrile in water to 90% acetonitrile in water. MS, m/z 477 = M+l. <br><br> EXAMPLE 6 <br><br> 216 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> {[ 1 -(4-Cyano-1 -propyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid ethyl ester. <br><br> The title compound was prepared starting from (morpholine-4-carbothioyl)-carbamic acid ethyl ester and 2-amino -N-(-4-cyano-l-propyl-piperidin-4-yl)-3- <br><br> cyclohexylpropionamide bis hydrochloride salt according to the procedure from Example 5, step b, except that the compound was first purified by chromatography over silica gel using 9:1 methylene chloride : methanol as the eluant prior to reverse phase HPLC purification. MS, m/z 505 = M+l. <br><br> {[ 1 -(4-Cyano-1 -propyl-piperidin-4-ylcarbamoyl)-3,3-dimethyl-butylimino]-morpholin-4-yl-methyl}-carbamic acid ethyl ester. <br><br> EXAMPLE 7 <br><br> 217 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> The title compound was prepared starting firom (morphohne-4-carbothioyl)-carbamic acid ' ethyl ester and 2-amino -4,4-dimethyl-pentanoic acid (4-cyano-l-propyl-piperidin-4-yl)amide bis hydrochloride salt according to the procedure from Example 5. MS, m/z <br><br> ( {1 -[3-Cyano-1 -(1 -ethyl-propyl)-pyrrolidin-3-ylcarbamoyl]-2-cyclohexyl-ethylamino} -morpholin-4-yl-methylene)-carbamic acid ethyl ester. <br><br> The title compound was prepared starting firom (morphohne-4-carbothioyl)-carbamic acid ethyl ester and 2-amino-N-[3-cyano-l-(l-ethyl-propyl)-pyrrolidin-3-yl]-3-cyclohexyl-propionamide bis hydrochloride salt according to the procedure from Example 5, step b,. MS, m/z 519 = M+l. <br><br> 460 = M+l. <br><br> EXAMPLE 8 <br><br> EXAMPLE 9 <br><br> 218 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> N-(4-Cyano-l-methyl-piperidin-4-yl)-3-cyclohexyl-2-[(ethylcarbamoylimino-phenyl-methyl)-amino] -propionamide (Method B). <br><br> (a) Benzimidic acid methyl ester. <br><br> Benzimidic acid methyl ester hydrochloride (5 g, 29.1 mmol) was partitioned between saturated sodium carbonate solution (200 mL) and diethyl ether (100 mL). The organic layer was dried (MgSO^ and concentrated to provide the desired product as a colorless liquid (3.20 g} 81%). This material was used without further purification. lH NMR (400 MHz, CDCI3) 5 3.93 (s, 3H), 7.39-7.46 (m, 3H), 7.75 (d, J = 1.1 Hz, 2H). <br><br> (a) 1 -Ethyl-3-(methoxy-phenyl-methylene)-urea. <br><br> A neat mixture of benzimidic acid methyl ester (750 mg, 5.56 mmol) and ethyl isocyanate (808 mg, 11.3 mmol) was stirred at 50 °C for 24 h. Excess isocyanate was removed under vacuum to provide the desired product as a colorless viscous oil (1.09 g, 95%). This material was used without further purification. 'H NMR (400 MHz, CDCI3) 6 1.07 (t, /= 7.3 Hz, 3 H), 3.25 (q, 7.3 Hz, 2 H), 3.87 (s, 3H), 4.97 (br s, 1H), 7.26-7.40 (m, 2H), 7.45 (d, J= 7.4 Hz, 1H), 7.69-7.71 (m, 2H). MS, m/z 207 = M+l. <br><br> (a) N-(4-Cyano-1 -methyl-piperidin-4-yl)-3-cyclohexyl-2-[(ethylcarbamoylimino-phenyl-methyl)-amino]-propionamide. <br><br> 219 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> A solution of l-ethyl-3-(methoxy-phenyl-methylene)-urea (350 mg, 1.70 mmol), 2-amino-N-(4-cyano-l-methyl-piperidin-4-yl)-3-cyclohexyl-propionamide bis hydrochloride salt (512 mg, 1.40 mmol) andN,N-diisopropylethylamine (352 mg, 2.73 mmol) in dry methanol (5.0 mL) was stirred at room temperature for 60 h. The reaction 5 mixture was concentrated and the resulting residue was chromatographed over 50 g of flash silica gel using dichloromethane to 5% methanol in dichloromethane as the eluant. This provided the desired product as a light yellow solid (280 mg, 43%) which was further purified by HPLC using a 20 x 250 mm Qg reverse phase column with the method being 20% acetonitrile in water to 90% acetonitrile in water. MS, m/z 467 = <br><br> EXAMPLE 10 <br><br> 15 N-(4-Cyano-1 -methyl-piperidin-4-yl)-3-cyclohexyl-2-( 1,1 -dioxo-1H-1A,6-benzo[d]isothiazol-3-ylamino)-propionamide (Method C). <br><br> A suspension of 3-chloro-benzo[d]isothiazole 1,1-dioxide (300 mg, 1.49 mmol) and 2-amino -N-(-4-cyano-l-methyl-piperidm-4-yl)-3-cyclohexylpropionamide bis 20 hydrochloride salt (500 mg, 1.37 mmol) was prepared in 5.5 mL of acetonitrile. <br><br> Triethylamine (575 p.L, 4.10 mmol) was added and the reaction mixture was stirred at room temperature for 1 day. The suspension was filtered to remove triethylamine hydrochloride and the filtrate was concentrated. The resulting residue was chromatographed over 50 g of flash silica using dichloromethane/ methanol 9:1 as the 25 eluant to provide the desired product as a light yellow solid (310 mg, 49%). *H NMR (400 MHz, CDC13) S 0.25-0.45 (m, 1H), 0.65-0.85 (m, 2H), 0.95-1.10 (m, 2H), 1.30-1.60 <br><br> 220 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> (m, 7H), 1.75-1.85 (m, 2H), 1.85-2.2 (m, 2H), 2.31 (s, 3H), 2.35-2.50 (m, 3H), 2.65-2.80 (m, 2H), 4.60-4.70 (m, 1H), 7.35-7.50 (m, 2H), 7.58 (t, J = 7.3, 1H), 7.78 (d, J = 7.7 Hz, 1H), 7.81 (br s, 1H), 8.91 (br s, 1H). MS, m/z 458 = M+l. <br><br> N-(4-Cyano-l -propyl-piperidin-4-yl)-3 -cyclohexyl-2-(l, 1 -dioxo-lH-1X6-benzo[d]isothiazol-3-ylamino)-propionamide. <br><br> The title compound was prepared starting from 3-chloro-benzo[d]isothiazole 1,1-dioxide and 2-amino -N-(-4-cyano-l-propyl-piperidin-4-yl)-3-cyclohexylpropionamide bis hydrochloride salt according to the procedure from Example 10, except that the compound was further purified by HPLC using a 20 x 250 mm Cis reverse phase column with the method being 20% acetonitrile in water to acetonitrile. MS, m/z 486 = M+l. <br><br> EXAMPLE 11 <br><br> EXAMPLE 12 <br><br> 221 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> 2-( 1,1 -dioxo-1H-1 ^6-benzo[d]isothiazoI-3-ylamino)-4,4-dimethyl-pentanoic acid(4- <br><br> cyano-1 -propylpiperidin-4-yl)-ainide. <br><br> The title compound was prepared starting from 3-chloro-benzo[d]isothiazole 1,1-dioxide and 2-amino -4,4-dimethyl-pentanoic acid (4-cyano-l-propyl-piperidin-4-yl)amide bis hydrochloride salt according to the procedure from Example 10, except that the compound was further purified by HPLC using a 20 x 250 mm Cig reverse phase column with the method being 20% acetonitrile in water to acetonitrile. MS, m/z 460 = M+l. <br><br> N-[3-Cyano-1 -(1 -ethyl-propyl)-pyrrolidin-3-yl]-3-cyclohexyl-2-(l, 1 -dioxo-\H-\ X6-benzo[d]isothiazol-3-ylamino)-propionarnide. <br><br> EXAMPLE 13 <br><br> 222 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> The title compound was prepared starting firom 3-chloro benzo[d]isothiazole 1,1-dioxide and 2-amino-N- [3 -cyano-1 -(1 -ethyl-propyl)-pyrrolidin-3 -yl]-3-cyclohexyl-propionamide bis hydrochloride salt according to. the procedure firom Example 10, except that the compound was further purified by HPLC using a 20 x 250 mm Cis reverse phase column with the method being 40% acetonitrile in water to acetonitrile. MS, m/z 500 = M+l. <br><br> N-(3-Cyano-1 -cyclohexyl-pyrrolidin-3-yl)-3-cyclohexyl-2-(l, 1 -dioxo-1H-1X6-benzo[d]isothiazol-3-ylamino)-propionamide. <br><br> The title compound was prepared starting from 3-chloro benzo[d]isothiazole 1,1-dioxide and 2-amino-N-(3 -cyano-1 -cyclohexyl-pyrrolidin-3 -yl)-3 -cyclohexyl-propionamide bis hydrochloride salt according to the procedure firom Example 10, except that the compound was further purified by HPLC using a 20 x 250 mm C^ reverse phase column with the method being 40% acetonitrile in water to acetonitrile. MS, m/z 512 = M+l. <br><br> N-(4-Cyano-methyl-piperidin-4-yl)-3-cyclohexyl-2-(3-oxo-3H-isoindol-l-ylamino)-propionamide. <br><br> The title compound was prepared starting from 3-imino-2, 3-dihydro-isoindol-1-one and 2-amino-N-(4-cyano-1 -methyl-piperidin-4-yl)-3-cyclohexyl-propionamide bis <br><br> EXAMPLE 14 <br><br> EXAMPLE 15 <br><br> 223 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> hydrochloride salt according to the procedure from Example 10, except that refluxing THF was used as the solvent. The compound was further purified by HPLC using a 20 x 250 mm Cis reverse phase column with the method being 20% acetonitrile in water to acetonitrile. MS, m/z 422.5 = M+l. <br><br> 4,4-Dimethyl-2-(3-oxo-3H-isoindol-l-ylamino)-pentanoicacid-(4-cyano-l-propyl-piperidin-4-yl)-amide. <br><br> The title compound was prepared from 3-imino-2, 3-dihydro-isomdol-l-one and 2-amino -4,4-dimethyl-pentanoic acid (4-cyano-l-propyl-piperidin-4-yl)amide bis hydrochloride salt according to the procedure from Example 15. MS, m/z 424.5 = M+l. <br><br> EXAMPLE 16 <br><br> EXAMPLE 17 <br><br> 224 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> 15 <br><br> N-(4-cyano-l-methyl-piperidin-4-yl)-3-cyclohexyl-2-(5,6-difluoro-3-oxo-3H-isoindol-l-ylamino) propionamide. <br><br> 5 (a) 2-Chloro-4,5-difluorobenzoic acid methyl ester. <br><br> 2-Chloro-4,5-difluorobenzoic acid (1.93 g, 10 mmol) was dissolved in 20 mL of acetone. Cesium carbonate (5.29 g, 15 mmol) was added followed by iodomethane (1.0 mL, 15 mmol). This reaction mixture was heated under reflux for 1 h and then cooled to room 10 temperature. This suspension was then diluted with 40 mL of ethyl ether. The solid was removed by filtration and washed with ethyl ether. The filtrate was evaporated in vacuo to give the title compound in quantitative yield as a clear oil. <br><br> (b) 2-Cyano-4,5-difluorobenzoic acid methyl ester. <br><br> The above oil (2.06 g, 10 mmol) was dissolved in 10 mL of JV-methyl pyrrolidinone. Copper (I) cyanide (1.79 g, 20 mmol) was added. This mixture was heated at 195 °C under nitrogen for 1 h. After cooling to room temperature, this solution was diluted with 100 mL of water. The resulting solid was collected by filtration. This solid was then 20 suspended in a rapidly stirred solution of potassium cyanide (0.5 g) in 30 mL of water for 1 h. EtOAc (30 mL) was added. The mixture was filtered through diatomaceous earth. The organic phase was separated and the aqueous phase was extracted with EtOAc (20 mL x 2). The combined organic phase was washed with brine and dried over magnesium sulfate. The solvent was removed in vacuo. The residue was crystallized from ethyl 25 ether and petroleum ether to give the title compound as a yellow solid (1.26 g, 64 %). <br><br> (c) 5,6-Difluoro-2,3-dihydro-3-imino-li/-isoindol-l-one. <br><br> The above solid (0.493 g, 2.5 mmol) was dissolved in 20 niL of MeOH. This solution 30 was saturated with ammonia at 0 °C and then stirred in a pressure tube at room <br><br> 225 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> temperature for 3 days. The solid was collected by filtration and washed with ethyl ether to give the title compound as a yellow solid ( 0.363 g, 80 %). <br><br> The title compound was prepared from 5,6-difluoro-2!3-dihydro-3-imino-li/-isoindol-l-one and 2-amino-N-(4-cyano-l-methyl-piperidin-4-yl)-3-cyclohexyl-propionamide bis hydrochloride salt according to the procedure firom Example 15. MS, m/z 458.3 = M+l. <br><br> N-(4-cyano-1 -methyl-piperidin-4-yl)-3-cyclohexyl-2-(2-oxo-2H-benzo[e] [ 1,3] oxazin-4-ylamino)-propionamide. <br><br> The title compound was prepared starting from 4-chloro-benzo[e][l,3] oxazin-2-one (prepared from benzo [e][l,3] oxazin-2,4-dione and PCI5 inrefluxing toluene) and 2-amino-N-(4-cyano-l-methyl-piperidin-4-yl)-3-cyclohexyl-propionamide bis hydrochloride salt according to the procedure from Example 10. MS, m/z 438 = M+l. <br><br> EXAMPLE 18 <br><br> EXAMPLE 19 <br><br> 226 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> N' <br><br> CN <br><br> N-(4-cyano-1 -methyl-piperidin-4-yl)-2-(4-cyano-pyrimidin-2-ylamino)-3 -cyclohexyl-propionaraide (Method C). <br><br> 2-Chloro-4-pyrimidinecarbonitrile (0.3 mmol, Daves, G. D. Jr., O'Brien, D. E., Cheng, C. C, J. Het. Chem, 1964,1,130) and2-amino-iV-(4-cyano-l-methyl-piperidin-4-yl)-3-cyclohexyl-propionaxnide (0.7 mmol) were dissolved in acetonitrile (10 mL) containing A^N-diisopropylethylamine (0.6 mmol). The solution was heated to a gentle reflux for 17 h. The volatiles were evaporated and the residue was subjected to chromatography (silica gel, eluant = EtOAc then MeOH). The methanolic fraction was concentrated to a colorless solid which was rechromatographed (10% MeOH/EtOAc) to afford the title compound as a colorless solid (52%). The material was recrystallized from dichloromethane/petroleum ether. <br><br> N-(4-cyano-l-methyl-piperidin-4-yl)-2-(4-trifluoromethyI-pyrimidin-2-ylamino)-3-cyclohexyl-propionamide. <br><br> EXAMPLE 20 <br><br> 227 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> The title compound was prepared from 2-chloro-4-trifluoromethyl pyrimidine and 2-amino-iV-(4-cyano-l-methyl-piperidin-4-yl)-3-cyclohexyl-propionamide according to the procedure from Example 19. MS, m/z 439.5 = M+l. <br><br> N-(4-cyano-l-methyl-piperidine-4-yl)-3-cyclohexyl-2[N-cyano-morpholine-4-carboximidoyl)-amino]-propionamide (Method D). <br><br> (a) 2-(N-Cyano-iminomethylene-amino)-N-(4-cyano-1 -methyl-piperidine-4-yl)-3 -cyclohexyl-propionamide. <br><br> A solution of diphenylcyanocarbonimidate (455 mg, 1.91 mmol), 2-amino-N-(4-cyano-l-methyl-piperidin-4-yl)-3-cyclohexyl-propionamide bis hydrochloride salt (680 mg, 1.86 mmol) and N,N-diisopropylethylamine (482 mg, 3.73 mmol) in isopropanol (5.0 mL) was stirred overnight at room temperature. The reaction mixture was then filtered to provide the desired carbodiimide as a white powder (140 mg, 22%). This material was used without further purification. 'H NMR (400 MHz, CDCI3) 5 0.80-1.00 (m, 2H), <br><br> 1.05-1.20 (m, IH), 1.20-1.40 (2H), 1.50-1.85 (m, 8H), 2.32 (s, 3H), 2.40-2.50 (m, 2H), 2.55-2.70 (m, 4H), 2.85-2.95 (m, 2H), 4.10-4.20 (m, IH), 8.77 (br s, IH). MS, m/z 343 = <br><br> (b) 2-(N-Cyano-benzimidoyl-amino)-N-(4-cyano-1 -methyl-piperidine-4-yl)-3-cyclohexyl-propionamide. <br><br> EXAMPLE 21 <br><br> M+l. <br><br> 228 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> A suspension of 2-(N-cyano-iminomethylene-amino)-N-(4-cyano-l-methyl-piperidine-4-yl)-3-cyclohexyl-propionamide (120 mg, 0.35 mmol) in tetrahydrofuran (1 mL) was treated with morpholine (4 mL, 45.9 mmol). The reaction mixture was stirred at room temperature for 3 days then concentrated to dryness. The residue was purified by HPLC using a 20 x 250 mm Cis reverse phase column with the method being 20% acetonitrile in water to 90% acetonitrile in water. MS, m/z 430 = M+l. <br><br> N-(4-Cyano-1 -methyl-piperidin-4-yl)-3-cyclohexyl-2- {[(diethyl-carbamoylimino)-morpholin-4-yl-methyl]-amino}-propionamide (Method D). <br><br> (a) N,N-Diethyl carbamoyl thiocyanate. <br><br> A suspension of sodium thiocyanate (3.30 g, 40.7 mmol) in dry acetonitrile (25 mL) at 80°C was treated dropwise with a solution of N,N-diethyl carbamoyl chloride (5.0 g, 36.9 mmol) in dry acetonitrile (15 mL). The reaction mixture was stirred at 80°C for 50 min, cooled to room temperature, then filtered through a fine glass frit. The resulting filtrate was used as a 0.9 M solution of N,N-diethyl carbamoyl thiocyanate in acetonitrile, <br><br> (b) N-(4-Cyano-1 -methyl-piperidin-4-yl)-3-cyclohexyl-2-(3-diethylarnino-carbonyl-thioureido)-propionamide <br><br> EXAMPLE 22 <br><br> 229 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> A solution of 2-amino -N-(-4-cyano-l-propyl-piperidin-4-yl)-3-cyclohexylpropionamide bis hydrochloride salt (560 mg, 1.53 mmol) and triethylamine (500 jjL, 3.59 mmol) in acetonitrile (4 mL) was treated with a solution of N,N-diethyl carbamoyl thiocyanate in acetonitrile (3.0 mL, 2.7 mmol). The reaction mixture was stirred overnight at room temperature and concentrated on a rotary evaporator. The resulting residue was chromatographed (ethyl acetate: hexanes 1:1 then ethyl acetate and finally methanol: methylene chloride 1:9 as the eluant) to provide the desired product as a light yellow solid (340 mg, 49%). MS, m/z 451.3 = M+l. <br><br> The title compound was prepared by treating a solution of the resulting thiourea (340 mg, 0.75 mmol) and triethylamine (230 jaL, 1.65 mmol) in dry acetonitrile (4 mL) with mercury (II) chloride (225 mg, 0.83 mmol) and morpholine (200 (J.L, 2.23 mmol). The reaction mixture was stirred at room temperature for 4 h then filtered through a 0.45 [j,m filter disc. The resulting filtrate was filtered through a column of silica (5% <br><br> methanol/methylene chloride as the eluant) and the resulting crude product was further <br><br> ♦ <br><br> purified by HPLC using a 20 x 250 mm Cig reverse phase column with the method being 20% acetonitrile in water to acetonitrile. MS, m/z 504.6 = M+l. <br><br> The following examples were prepared by Method D in a parallel fashion: <br><br> EXAMPLE 23 <br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino] -pyrrolidin-1-yl-methyl}-carbamic acid ethyl ester. MS, m/z 461 = M+l. <br><br> EXAMPLE 24 <br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-piperidin-l- <br><br> yl-methyl}-carbamic acid ethyl ester. MS, m/z 477 = M+l. <br><br> EXAMPLE 25 <br><br> 230 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> {Azepan-1 -yl-[ 1 -(4-cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-etliylamino] methylene)-carbamic acid ethyl ester. MS, m/z 490 = M+l. <br><br> EXAMPLE 26 <br><br> {Azocan-1 -yl-[ 1 -(4-cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino] methylene}-carbamic acid ethyl ester. MS, m/z 504 = M+l. <br><br> EXAMPLE 27 <br><br> 1 - {[ 1 -(4-Cyano- l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-ethoxycarbonylimino-methyl}-piperidine-4-carboxylic acid ethyl ester. MS, m/z 548 = M+l. <br><br> EXAMPLE 28 <br><br> 1 - {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino] -ethoxycarbonylimino-methyl}-piperidine-3-carboxylie acid ethyl ester. MS, m/z 548 = M+l. <br><br> EXAMPLE 29 <br><br> [[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-(4-pyrrolidin-l-yl-piperidin-l-yl)-methylene]-carbamic acid ethyl ester. MS, m/z 545 = M+l. <br><br> EXAMPLE 30 <br><br> {[1,4']Bipiperidinyl-1 '-yl-[ 1 -(4-cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-methylene}-carbamic acid ethyl ester. MS, m/z 559 = M+l. <br><br> 231 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> EXAMPLE 31 <br><br> [[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-(4-phenyl-piperazin-l-yl)-methylene]-carbaraic acid ethyl ester. MS, m/z 553 = M+1. <br><br> EXAMPLE 32 <br><br> [[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-(4-ethyl-piperazin-l-yl)-methylene]-carbamic acid ethyl ester. MS, m/z 505 = M+1. <br><br> EXAMPLE 33 <br><br> {(4-Acetyl-piperazin-l-yl)-[ 1 -(4-cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-methylene}-carbamic acid ethyl ester. MS, m/z 519 = M+l. <br><br> EXAMPLE 34 <br><br> 4- {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-ethoxycarbonylimino-methyl}-piperazine-l-carboxylic acid ethyl ester. MS, m/z 549 = M+l. <br><br> EXAMPLE 35 <br><br> [[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-(3,3,5 -trimethyl-6-aza-bicyclo[3.2.1]oct-6-yl)-methylene]-carbamic acid ethyl ester. MS, m/z 544 = M+l. <br><br> EXAMPLE 36 <br><br> 232 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> 2-(7-Fluoro-2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-yldeneamino)-5J5-dimethyl-hexanoic acid(4-cyano-1 -propyl-piperidin-4-yl)-aixiide. <br><br> To a stirred solution of aluminum chloride (7.13 g, 53.5mmol) in nitromethane (40 mL) at 0°C was added ethyl isothiocyanato formate (3.5 g, 26.8 mmol). The reaction was stirred at 0 °C for lh and then at room temperature for 48 h. The reaction mixture was 10 then poured over crushed ice and filtered to give 2.0 g of an orange solid. <br><br> The solid was dissolved in pyridine (20 mL) and heated at reflux for 4 h. The reaction was diluted with methylene chloride and washed with water. The organic fraction was dried over anhydrous sodium sulfate and evaporated on a rotary evaporator. The crude product was purified by flash column chromatography over silica gel using 25% EtOAc 15 and hexane to give 0.27 g of 7-fluoro-4-thioxo-3,4-dihydro-benzo[e][l,3]oxazin-2-one <br><br> To the above intermediate (0.135 g, 0.685 mmol) and 2-amino-5,5-dimethyl-hexanoic acid (4-cyano-l-propyl-piperidin-4-yl)-amide (0.251 g, 0.685 mmol) in dry THF(10 mL) <br><br> Desired product (minor) <br><br> By-product (major) <br><br> 5 <br><br> (5.1%). <br><br> 233 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> was added diisopropylethyl amine (0.36 mL, 2.06 mmol) and 2-chloro-l-methylpyridinium iodide(0.288g, 0.89 mmol). The reaction was stirred at room temperature for 48 h. Solvent was evaporated and the residue dissolved in methylene chloride, washed with water, dried over anhydrous sodium sulfate and evaporated. The crude product was purified initially by flash column chromatography over silica gel using 10% MeOH/methylene chloride (0.25 g, 79.8%). Final purification by HPLC afforded the title compound, 1HNMR and MS were consistent with the desired product; MS: 458 (M+l). <br><br> EXAMPLE 37 <br><br> N-(4-Cyano-1 -propyl-piperidin-4-yl)-3 -(4,4-dimethyl-cyclohexyl)-2-(2-oxo-2H-benzo[e] [ 1,3 ]oxazin-4-ylamino)-propionamide. <br><br> 234 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> t _ P <br><br> h3c ch3 pd cata|yst <br><br> To a solution of 4,4-dimethyl cyclohexanone (4.60 g, 36.5 mmol) in dry THF (82 mL) cooled in a dry ice/acetone bath, was added sodium bis (trimethylsilyl)amide (38 mL of a 1.0 M solution in THF, 38 mmol). The reaction mixture was stirred under an argon 5 atmosphere at -78 °C for 30 min. A solution of 2-(N,N-bis trifluoromethanesulfonyl)amino-5-chloropyridine (15g, 37.7 mmol) in dry THF (20 mL) was introduced via syringe and the resulting solution was warmed to room temperature and stirred overnight. The reaction mixture was washed with half saturated brine (60 mL) and the aqueous phase was extracted with diethyl ether. The combined organic 10 extracts were dried (MgSC&gt;4) and concentrated to provide a dark brown oil (23 g). <br><br> Chromatography over silica gel using petroleum ether as the eluant provided trifluoro-methane sulfonic acid 4,4-dimethyl-cyclohexyl-l-enyl ester as a colorless liquid (5.2 g, <br><br> 235 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> 56%). ]H NMR (400 MHz, CDC13) 8 0.98 (s, 6H), 1.53 (t, J = 6.5 Hz, 2H), 1.95-1.99 (m, 2H), 2.30-2.40 (m, 2H), 5.65-5.70 (m, IH). <br><br> A mixture of the above triflate ester (2.26 g, 8.75 mmol), Cbz dehydroalanine methyl 5 ester (2.10 g, 8.93 mmol), Pd (OAc)2 (160 mg, 0.71 mmol), and KOAc (3.42 g, 34.8 mmol) in dry DMF was stirred at room temperature for 24 h. The reaction mixture was diluted with water (400 mL) and extracted with EtOAc (2 x 150 mL). The combined, organic extracts were dried (MgS04) and concentrated. Chromatography of the resulting residue over silica gel using 1:20 EtOAc/ hexanes then 3:17 EtOAc/ hexanes provided 2-10 benzyloxycarbonylamino-3-(4,4-dimethyl-cyclohex-l-enyl)-acrylic acid methyl ester as a yellow oil (1.38 g, 46%). !H NMR (400 MHz, CDC13) 8 0.88 (s, 6H), 1.34 (t, J = 6.4 Hz, 2H), 1.95-2.00 (m, 2H), 2.23-2.30 (m, 2H), 3.74 (s, 3H), 5.15 (s, 2H), 5.90-6.10 (m, IH), 6.10-6.15 (m, IH), 7.0 (s, IH), 7.25-7.36 (m, 5H). m/z 382.4 (MK*). <br><br> 15 A suspension of the above acrylic acid ester (2.18 g, 6.35 mmol), Boc anhydride (1.52 g, 6.96 mmol), and 10% Pd/ C (300 mg) in MeOH was shaken on a Parr apparatus under 40 psi of hydrogen gas for 17 h. The reaction mixture was filtered through a pad of diatomaceous earth and concentrated to provide 2-tert-butoxycarbonylamino-3-(4,4-dimethyl-cyclohexyl)-propionic acid methyl ester as a yellow oil (1.87 g, 94%). XH NMR 20 (400 MHz, CDC13) 8 0.85 (s, 3H), 0.88 (s, 3H), 1.05-1.20 (m, 5H), 1.21-1.40 (m, 2H), 1.44 (s, 9H), 1.45-1.59 (m, m, 2H), 1.60-1.78 (m, 2H), 3.72 (broad s, 3H), 4.27-4.40 (m, IH), 4.82-4.96 (m, IH). <br><br> A suspension of the above methyl ester (1.87 g, 5.97 mmol) and lithium hydroxide 25 monohydrate (1.76 g, 41.9 mmol) in THF (18 mL), MeOH (6 mL), and water (6 mL) was stirred at room temperature for 4 h. The reaction mixture was acidified with 10% citric acid (aqueous) and extracted with diethyl ether (3 x 100 mL). The combined organic layers were dried (MgS04) and concentrated to provide a the corresponding carboxylic acid as a white foam (1.21 g, 68%). *H NMR (400 MHz, DMSO d6) 5 0.83 (s, 3H), 0.85 30 (s, 3H), 0.87-1.10 (m, 4H), 1.10-1.46 (m, 3H), 1.35 (s, 9H), 1.46-1.60 (m, 4H), 3.88-3.94 (m, IH), 7.0 (d, 8.2 Hz, IH), 11.7-12.9 (broad s, IH). <br><br> 236 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> Isobutyl chloroformate (0.55 mL, 4.24 mmol) was added dropwise to a solution of the above carboxylic acid (1.21 g, 4.04 mmol) and N-methyl morpholine (0.89 mL, 8.10 mmol) in dry THF cooled to 0 °C. The reaction mixture was stirred at 0 °C for lh. A 5 solution of 4-amino-l-propyl-piperidine-4-carbonitrile (780 mg, 4.65 mmol) in dry THF (5 mL) was added and the reaction mixture was allowed to warm to room temperature and stirred overnight. Volatiles were removed on a rotary evaporator and the resulting residue was dissolved in EtOAc (50 mL) and washed with saturated Na2C03 (50 mL). The organic phase was dried (MgS04) and concentrated. Chromatography of this crude 10 material over silica gel using a gradient of dichloromethane to 5% MeOH in dichloromethane provided [1 -(4-cyano-1 -propyl-piperidin-4-ylcarbamoyl)-2-(4,4-dimethyl-cyclohexyl)-ethyl]-carbamic acid tert-butyl ester as a white foam (1.17 g, 65%). *H NMR (400 MHz, CDC13) 5 0.85 (s, 3H), 0.88 (s, 3H), 0.89 (t, J = 7.3 Hz, 3H), 1.05-1.30 (m, 6H), 1.30-1.40 (m, 2H), 1.45 (s, 9H), 1.40-1.60 (m, 5H), 1.70-1.83 (m, 15 IH), 1.87-2.02 (m, 2H), 2.32-2.54 (m, 6H), 2.68-2.90 (m, 2H), 4.00-4.10 (m, IH), 4.80-5.00 (m, IH), 6.70-6.90 (m, IH); m/z 449.5 (M+H)+, 447.4 (M-H)\ <br><br> The above tert-butyl ester (1.17 g, 2.6 mmol) was dissolved in a solution of HC1 in 1,4-dioxane (10.0 mL of a 4.0 M solution, 40 mmol) and stirred under an active sweep of 20 argon gas for 10 min. The solution was concentrated on a rotary evaporator then taken up in CHCI3 (50 mL) and concentrated again to provide the amine dihydrochloride as a white powder (1.05 g, 95%). m/z = 349.5 (M+H)+. <br><br> A suspension of 4-chloro benzoxazin-2-one (500 mg, 2.69 mmol), the above amine salt 25 (400 mg, 0.95 mmol), and polystyrene supported diisopropylamine (2.40 g, 8.40 mmol) in dry acetonitrile was heated at 50 °C for 5 h. The reaction mixture was filtered through a pad of diatomaceous earth and the filtrate was concentrated. The resulting residue was chromatographed over silica gel using methylene chloride then 2.5% MeOH in methylene chloride and finally 10% MeOH in methylene chloride as the eluant to provide the title 30 compound as a white solid (45 mg, 10%). *H NMR (400 MHz, DMSO dg) 5 0.82 (t, J = 7.5 Hz, 3H), 0.83 (s, 3H), 0.84 (s, 3H), 1.00-1.20 (m, 5H), 1.25-1.42 (m, 5H), 1.48-1.58 <br><br> 237 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> (m, 2H), 1.60-1.70 (m, IH), 1.80-1.92 (m, 2H), 2.10-2.30 (m, 6H), 2.55-2.68 (m, 2H), 4.83-4.92 (m, IH), 7.29 (d, J = 8.3 Hz, IH), 7.36 (t, J = 7.7 Hz, IH), 7.73 (t, J = 7.3 Hz, IH), 8.36 (d, J= 8.1 Hz, IH), 8.73 (s, IH), 8.98-9.10 (ra, IH); m/z = 494.5 (M+H)+, 492.4 (M-H)". <br><br> EXAMPLE 38 <br><br> 10 <br><br> 4}4-Dimethyl-2-(l-methyl-2-oxo-l,2-dihydro-quinazolin-4-ylamino)-pentanoic acid (4-cyano-1 -propyl-piperidin-4-yl)-amide. <br><br> O <br><br> A. <br><br> HN N <br><br> 'CI <br><br> Mel <br><br> O <br><br> y <br><br> 'N"^N <br><br> SCI <br><br> 15 <br><br> A mixture of 4-chloro-l,2-dihydro-2-oxo-quinazoline (1.0 g, 5.5 mmol), iodomethane (0.86 mL, 2.5 equiv.) and potassium carbonate (1.91 g, 2.5 equiv.) in DMF (15mL)was heated at 80 °C for 90 min before the solvent was removed at reduced pressure at 80 °C. The residue was taken up in dichloromethane and filtered. The filtrate was concentrated <br><br> 238 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> and column chromatography on silica gel (eluent: EtOAc) gave the N-methyl analog <br><br> A mixture of the above intermediate (100 mg, 0.5 mmol), 2-amino-4,4-dimethylpentanoic acid (4-cyano-l-propyl-piperidin-4-yl)amide (151 mg, 0.5 mmol), Cu (powder, 66 mg, 1 mmol) and potassium carbonate (285 mg, 2 mmol) in NMP (3 mL) was heated at 150 °C for 16 h. After it was cooled to room temperature, it was filtered. The filtrate was diluted with water and extracted with dichloromethane. The organic phase was washed with brine, dried (sodium sulfate), concentrated and chromatographed on silica gel affording <br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl} -carbamic acid 2,2-dimethyl-propyl ester. <br><br> (0.21 g, 19.5%). <br><br> the title compound (101 mg, 44.6%); MS: 453 (M+l). <br><br> EXAMPLE 39 <br><br> O <br><br> AcN, reflux <br><br> NaNCS <br><br> 239 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> To a solution of sodium thiocyanate (4.46 g, 55 mmol) in 50 mL of acetonitrile was added neopentyl chloroformate (6.15 mL, 50 mmol). This mixture was heated at 80 °C for 2 h. After cooling to room temperature, the solid was removed by filtration and the 5 filtrate was used as a 1 M stock solution of neopentyl isothiocyanatoformate. <br><br> 2-Amino-iV-(4-cyano-1 -methyl-piperidin-4-yl)-3 -cyclohexyl-propionamide dihydrochloride salt (6.33 g, 17.32 mmol) was suspended in 50 mL of methylene chloride. Triethylamine (5.00 mL, 35.9 mL) was added. To this solution at 0 °C was 10 added the above solution (20 mL, 20 mmol). This mixture was stirred at 0 °C for 1 h. The solvent was removed in vacuo. The residue was purified by flash chromatography on silica gel eluting with 5% MeOH in ethyl ether (Rf = 0.2) to give the thiourea (4.76 g, 59%) as a yellow oil; MS: M+l = 466. <br><br> 15 The thiourea (4.67 g, 10.0 mmol) was dissolved in 30 mL of THF. Copper sulfate on silica gel (4.00 g, 10.0 mmol) was added followed by 1 mL of triethylamine. This mixture was stirred at room temperature for 30 min. Morpholine (1.25 mL, 20 mmol) was added. The reaction mixture was heated under reflux for 2 h.. Another 4 g of copper sulfate on silica gel and 1.25 mL of morpholine were added. The reaction mixture was 20 heated for an additional 2 h.. After cooling to room temperature, solids were removed by filtration and washed with acetonitrile. The filtrate was concentrated under reduced pressure and then purified by flash chromatography on silica gel, eluting with a mixture of ethyl ether, methylene chloride and MeOH (2:1:0.1) to give a yellow oil. This oil was crystalized from ethyl ether and hexane to give the title compound (1.81 g, 35%) as a 25 white solid; M+l = 519. <br><br> EXAMPLE 40 <br><br> 2-Amino-4,4,5-trimethyl-hexanoic acid (4-cyano-l-propyl-piperidin-4-yl)-amide bis-30 hydrochloride. <br><br> 240 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> 'O' <br><br> LDA <br><br> Mel <br><br> O' <br><br> LAH <br><br> O <br><br> H <br><br> _-.N C ' <br><br> O <br><br> O <br><br> KO-t-Bu <br><br> PtO: 50 psi H2 4 days <br><br> 6 N HCI <br><br> reflux HCI x <br><br> H2N <br><br> 4 N HCI in dioxane <br><br> OH <br><br> O <br><br> x 2 HCI O <br><br> Boc anhydride <br><br> 4 N NaOH (aq) dioxane <br><br> 10 <br><br> Lithium diisopropylamide (1.5 M solution in cyclohexane/THF/ethylbenzene) (113 mL, 169 mmol, 1.1 equiv) was syringed into a 1000 mL round-bottom flask under a blanket of Ar. Dry THF (150 mL) was added and the mixture was cooled to -78 °C with a dry-ice/acetone bath. 3-Methyl-butanoic acid ethyl ester (20 g, 23 mL, 154 mmol, 1.0 equiv) was added dropwise firom a syringe over a 10 min period followed by stirring at -78 °C for 1 h. Methyl iodide (10.5 mL, 169 mmol, 1.1 equiv) was added dropwise firom a syringe over a 10 min period and the creamy mixture was stirred for 1 h at -78 °C, resulting in a very thick mixture. The dry-ice bath was removed and replaced with an ice <br><br> 241 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> bath at 0 °C. Another 150 mL of dry THF was added followed by another addition of LDA (113 mL, 169 mmol, 1.1 equiv). The resulting mixture was stirred for 10 min and then the flask was re-immersed in a dry-ice/acetone bath Stirring was continued for another 50 min and then methyl iodide was added dropwise (10.5 mL, 169 mmol, 1.1 5 equiv) and the dry-ice/acetone bath was removed and the resulting mixture was stirred at ambient temperature for 14 h. The reaction mixture was quenched with 3 mL of conc. HCI and 2 N HCI was added until the pH was adjusted to &lt;1. The mixture was further diluted with 150 mL water and 500 mL Et20. The layers were separated and the organic layer was washed with 1 x 100 mL 2 N HCI, 1 x 100 mL saturated NaHCOs, and 1 x 200 10 mL brine. The organic layer was dried over Na2SC&gt;4 and then concentrated in vacuo to provide 2,2,3-trimethylbutanoic acid ethyl ester as an orange oil mixed with ethyl benzene (36.4 g of which 22.1 g was product by NMR). The mixture was used without further purification. <br><br> 15 A 500 mL round-bottom-flask equipped with a stir bar was flushed with Ar and charged with 50 mL dry THF and a 1 M solution of LAH in Et20 (87.5 mL, 87.5 mmol, 0.625 equiv). The solution was cooled to 0 °C with an ice bath and the above ethyl ester (22.1 <br><br> g, 140 mmol, 1.0 equiv) (approximately a 50% solution in ethylbenzene) was added dropwise at such a rate that the solution did not reflux (required 50 min). After addition <br><br> 20 of the ester, the reaction was stirred at 0 °C for 2 h and then at ambient temperature for 14 <br><br> h. The reaction solution was re-cooled to 0 °C and carefully quenched by addition of EtOAc. 1 N NaOH was added until a granular precipitate formed (7.5 mL). The mixture was filtered on a pad of diatomaceous earth which was then washed 3 x 100 mL Et20. The organics were combined and dried over Na2SC&gt;4. The solution was decanted and <br><br> 25 concentrated in vacuo to yield 2,2,3-trimethyl-biitanol 2,2,3-trimethyl-butanol as a nearly colorless oil (11.7 g of alcohol in 15.4 g of a mix with ethylbenzene). The crude product was used without further purification. <br><br> A 1000 mL round-bottom-flask was equipped with a stir bar, flushed with Ar and 30 charged with 300 mL dry CH2CI2 and oxalyl chloride (13.2 mL, 151 mmol, 1.5 equiv). The solution was cooled to -78 °C with a dry-ice/acetone bath. Dry DMSO (21.5 mL, <br><br> 242 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> 302 mmol, 3.0 equiv) was added dropwise over a 30 min period (vigorous gas evolution). The above alcohol (11.7 g, 100 mmol, 1.0 equiv) was added (with residual ethylbenzene) over a 10 min period. The resulting solution was stirred for 90 min. Triethylamine (56 mL, 403 mmol, 4.0 equiv) was added over 5 min and the cold-bath 5 was removed. The resulting creamy white mixture was stirred at room temperature over 1.5 h. The reaction mixture was carefully diluted with 200 mL water (more gas evolution). Layers were separated and the organic phase was washed with 1 x 100 mL 2 N HCI and 1 x 100 mL brine. The organic layer was dried over Na2SC&gt;4, decanted and concentrated in vacuo. The crude aldehyde was distilled fractionally through a 4 inch 10 Vigoreux column at 57-67 °C at 15 mm Hg to provide the 2,2,3-trimethyl-butanal (9.1 g) as a colorless oil. <br><br> A clean and dry 250 mL round-bottom flask was equipped with a stir bar and flushed with Ar. Dry THF was added (40 mL) followed by addition of a 1.0 M solution of ¥LQ-t-15 Bu (32.2 mL, 32.2 mmol, 1.05 equiv). The solution was cooled to -78 °C in a dry-ice/acetone bath. Ethyl isocyanoacetate (3.35 mL, 30.7 mmol, 1.0 equiv) was added dropwise over a 10 min period. The resulting mixture was stirred an additional 5 min followed by addition, via syringe, of 2,2,3-trimethyl-butanal (3.5 g, 30.7 mmol, 1.0 equiv). The cold-bath was removed and resulting mixture was stirred at room 20 temperature for 1 h. The reaction mixture was diluted by addition of a mix of 125 mL Et20,20 g ice, 2 mL AcOH. After the ice melted, 50 mL of water was added and the layers were mixed and separated. The organic layer was washed with 1 x 50 mL sat. NaHC03 and dried over Na2S04- The organic layer was decanted and concentrated. The crude enamide was purified by flash chromatography on silica gel using CH2CI2 to 4% 25 MeOH in CH2CI2 to provide 2-formylamino-4,4,5-trimethyl-hex-2-enoic acid ethyl ester as a thick oil (4.54 g); MS: 228 (M+l). <br><br> The above ethyl ester (4.54 g,.20 mmol, 1.0 equiv) was dissolved in 35 mL of MeOH in a Parr bottle followed by addition of PtC^ (1 g, 4.4 mmol, 0.22 equiv). The mixture was 30 shaken on a Parr hydrogenation apparatus for 4 days at which time MS showed consumption of the starting material; MS: 230 (M+l), 216 (M+l of methyl ester). The <br><br> 243 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> liquid was carefully decanted and the Pt was washed 3 x 20 mL MeOH followed each time by decantation, being careful not to allow the Pt to dry (if allowed to dry, the Pt may ignite). The MeOH solutions were combined and concentrated to a thick oil that was suspended in 25 mL of 6 N HCI and the mixture was refluxed for 4 h during which 5 time 5 mL of conc. HCI was added at the end of each of the first 3 h.. The mixture was cooled and the water and excess HCI were removed on a rotovap at a bath temperature of 70 °C. After about 50% concentration, a flaky crystalline solid formed. The mixture was cooled to 0 °C and the precipitate was collected by filtration. The filtrate was again concentrated by about 50% and cooled again to 0 °C to provide a second crop of crystals. 10 The crystals were combined and dried under high vacuum to provide 2-amino-4,4,5- <br><br> trimethyl-hexanoic acid hydrochloride as an off-white crystalline solid (2.32 g); MS: 174 (M-Cl+1). <br><br> The above amino acid salt (2.32 g, 11.1 mmol, 1.0 equiv) was dissolved in 100 mL of 15 50/50 dioxane/4 N NaOH. The solution was cooled to 0 °C and Boc anhydride (3.6 g, 16.6 mmol, 1.5 equiv) was added. The cold-bath was removed and the reaction stirred at ambient temperature for 16 h. The pH was carefully adjusted to 2 with cone. HCI, and the product was extracted with 3 x 100 mL CH2CI2. The organic layers were combined and dried over Na2S04. The solution was decanted and concentrated using 100 mL of 20 hexane as a chaser to provide a thick glass, which was triturated with 100 mL of hexane. After vigorous stirring for 4 h, a waxy solid resulted which was filtered and dried in air to provide 2-tert-butoxycarbonylamino-4,4,5-trimethyl-hexanoic acid (1.42 g). <br><br> The above carboxylic acid (0.400 g, 1.46 mmol, 1.0 equiv) was dissolved in 15 mL of 25 THF and cooled to 0 °C. iV-Methylmorpholine (0.338 mL, 3.07 mmol, 2.1 equiv) was added followed by dropwise addition, over 1 min, of isobutylchloroformate (0.19 mL, 1.0 equiv). A white precipitate immediately formed. The mixture was stirred for 30 min at which time a solution of 4-amino-4-cyano-l-propyl-piperidine (0.257 g, 1.54 mmol, 1.05 equiv) in 5 mL of THF was added. The resulting mixture was stirred for 16 h at room 30 temperature. The volatiles were removed on a rotovap and the resulting paste was triturated with 100 mL water with vigorous stirring to give a fluffy white solid which was <br><br> 244 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> collected by filtration. The solid was washed with 100 mL of water and dried under vacuum to yield the desired product as an off-white powder (0.521 g); MS: 423 (M+l). The Boc protecting group was removed by treatment of the solid under Ar with 20 mL of 4N HCI in dioxane for 1 h. The resulting paste was diluted with 40 mL of Et20 and the 5 solid was filtered under Ar. The resulting paste was washed 1 x 25 mL Et20 and dried in vacuo to yield the title compound as the dihydrochloride salt; MS: 323 (M+l). <br><br> EXAMPLE 41 <br><br> 10 2-/e?-/-Butoxycarbonylamino-5,5-dimethyl-hexanoic acid <br><br> O <br><br> DBU <br><br> H <br><br> Boc anhydride <br><br> Pd (carbon) MeOH 50 psi H2 <br><br> LiOH <br><br> H,0 <br><br> 7V-(Benzyloxycarbonyl)-a-phosphonoglycine trimethyl ester (2 g, 6.0 mmol, 1.0 equiv) was dissolved in dry THF (20 mL). tert-Butylacetaldehyde (0.758 mL, 6.0 mmol, 1.0 15 equiv) and DBU (0.903 mL, 6.0 mmol, 1.0 equiv) were added and the reaction mixture was stirred for 16 h. The solution was diluted with 100 mL of CH2CI2 and washed with 1 x 50 mL water, and 1 x 50 mL brine. The organic layer was dried over Na2S04, decanted and concentrated in vacuo to provide 2-benzyloxycarbonylamino-5,5-dimethyl-hex-2- <br><br> 245 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> enoic acid methyl ester as a thick oil (1.73 g, 94%) which was used without further purification; MS: 306 (M+l). <br><br> The above ester (1.73 g, 5.67 mmol, 1.0 equiv) was dissolved in a Parr bottle with Boc 5 anhydride (1.36 g, 6.23 mmol, 1.0 equiv) and MeOH (35 mL). Pd on carbon (Degussa type) (0.5g) was added. The mixture was shaken under 50 psi H2 fori 6 h. The mixture was filtered on diatomaceous earth followed by washing of the diatomaceous earth with 3 x 50 mL MeOH. The organics were combined and concentrated to provide 2-tert-butoxycarbonylamino-5,5-dimethyl-hexanoic acid methyl ester as a very thick oil which 10 was used without further purification. <br><br> The above ester (1.31 g, 4.79 mmol, 1.0 equiv) was dissolved in 50 mL of MeOH. 1 N LiOH (50 mL) was added and the mixture was stirred 16 h. Concentrated HCI was added carefully until the pH approached 2 at which time a bright white solid precipitated. The 15 solid was collected by filtration and washed 2 x 20 mL water and dried under vacuum to provide the title compound (1.05 g, 85%); MS: 258 (M-l). <br><br> 20 METHODS OF THERAPEUTIC USE <br><br> The compounds of the invention are useful in inhibiting the activity of cathepsin S, K, F, L and B. In doing so, these compounds are useful in blocking disease processes mediated by these cysteine proteases. <br><br> 25 <br><br> Compounds of this invention effectively block degradation of the invariant chain to CLIP by cathepsin S, and thus inhibit antigen presentation and antigen-specific immune responses. Control of antigen specific immune responses is an attractive means for treating autoimmune diseases and other undesirable T-cell mediated immune responses. 30 Thus, there is provided methods of treatment using the compounds of this invention for such conditions. These encompass autoimmune diseases and other diseases involving <br><br> 246 <br><br> WO 02/20485 <br><br> PCT/USO1/08084 <br><br> inappropriate antigen specific immune responses including, but not limited to, <br><br> rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, multiple sclerosis, Guillain-Barre syndrome, psoriasis, Grave's disease, myasthenia gravis, scleroderma, glomerulonephritis, dermatitis including contact and atopic 5 dermatitis, insulin-dependent diabetes mellitus and asthma including allergic asthma. The compounds of the invention can also be used to treat other disorders associated with extracellular proteolysis such as Alzheimer's disease and atherosclerosis. The compounds of the invention can also be used to treat other disorders associated with inappropriate autoimmune responses, T-cell mediated immune responses, or extracellular proteolysis 10 mediated by cathepsin S, unrelated to those listed above or discussed in the Background of the Invention. Therefore, the invention also provides methods of modulating an autoimmune disease comprising administering to a patient in need of such treatment a pharmaceutically effect amount of a compound according to the invention. <br><br> Compounds of the invention also inhibit cathepsin K. In doing so, they may block inappropriate degradation of bone collagen and other bone matrix proteases. Thus, there is provided a method for treating diseases where these processes play a role such as osteoporosis. Inhibition of cathepsins F, L, and B are also within the scope of the invention due to similarity of the active sites in cysteine proteases as described above. <br><br> For therapeutic use, the compounds of the invention may be administered in any conventional dosage form in any conventional manner. Routes of administration include, but are not limited to, intravenously, intramuscularly, subcutaneously, intrasynovially, by infusion, sublingually, transdermally, orally, topically or by inhalation. The preferred modes of administration are oral and intravenous. <br><br> The compounds of this invention may be administered alone or in combination with adjuvants that enhance stability of the inhibitors, facilitate administration of pharmaceutical compositions containing them in certain embodiments, provide increased 30 dissolution or dispersion, increase inhibitory activity, provide adjunct therapy, and the like, including other active ingredients. Advantageously, such combination therapies <br><br> 247 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> utilize lower dosages of the conventional therapeutics, thus avoiding possible toxicity and adverse side effects incurred when those agents are used as monotherapies. Compounds of the invention may be physically combined with the conventional therapeutics or other adjuvants into a single pharmaceutical composition. Advantageously, the compounds may then be administered together in a single dosage form. In some embodiments, the pharmaceutical compositions comprising such combinations of compounds contain at least about 15%, but more preferably at least about 20%, of a compound of the invention (w/w) or a combination thereof. Alternatively, the compounds may be administered separately (either serially or in parallel). Separate dosing allows for greater flexibility in the dosing regime. <br><br> As mentioned above, dosage forms of the compounds of this invention include pharmaceutically acceptable carriers and adjuvants known to those of ordinary skill in the art. These carriers and adjuvants include, for example, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, buffer substances, water, salts or electrolytes and cellulose-based substances. Preferred dosage forms include, tablet, capsule, caplet, liquid, solution, suspension, emulsion, lozenges, syrup, reconstitutable powder, granule, suppository and transdermal patch. Methods for preparing such dosage forms are known (see, for example, H.C. Ansel and N.G. Popovish, Pharmaceutical Dosage Forms and Drug Delivery Systems, 5th ed., Lea and Febiger (1990)). Dosage levels and requirements are well-recognized in the art and may be selected by those of ordinary skill in the art from available methods and techniques suitable for a particular patient In some embodiments, dosage levels range from about 10-1000 mg/dose for a 70 kg patient. Although one dose per day may be sufficient, up to 5 doses per day may be given. For oral doses, up to 2000 mg/day may be required. As the skilled artisan will appreciate, lower or higher doses may be required depending on particular factors. For instance, specific dosage and treatment regimens will depend on factors such as the patient's general health profile, the severity and course of the patient's disorder or disposition thereto, and the judgment of the treating physician. <br><br> 248 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> ASSESSMENT OF BIOLOGICAL PROPERTIES Expression and Purification of recombinant human Cathepsin S Cloning of human cathepsin S: <br><br> U937 RNA was subjected to reverse transcriptase / polymerase chain reaction with primer A (5'cacaatgaaacggctggtttg 3') and primer B (5'ctagatttctgggtaagaggg 3') <br><br> designed to specifically amplify the cathepsin S cDNA. The resulting 900 bp DNA fragment was subcloned into pGEM-T (Promega) and sequenced to confirm its identity. This construct was used for all subsequent manipulations. This procedure is typical for cloning of known genes and is established in its field. <br><br> Human Pre-Pro-Cat S was removed from pGem-T vector (Promega, 2800 Woods Hollow Rd, Madison, WI 53711) by digestion with restriction enzyme SacII, followed by treatment with T4 DNA polymerase to generate a blunt end, and a second restriction enzyme digest with Sail. It was subcloned into pFastBacl donor plasmid (GibcoBRL, 8717 Grovemont Cr., Gaithersburg, MD 20884) which had been cut with restriction enzyme BamHl and blunt-ended and then cut with restriction enzyme Sail. The ligation mixture was used to transform DH5a competent cells (GibcoBRL) and plated on LB plates containing lOOug/ml ampicillin. Colonies were grown in overnight cultures of LB media containing 50ug/ml Ampicillin, plasmid DNA isolated and correct insert confirmed by restriction enzyme digestion. Recombinant pFastBac donor plasmid was transformed into DHlOBac competent cells (GibcoBRL). Large white colonies were picked from LB plates containing 50ug/ml kanamycin, 7ug/ml gentamicin, lOug/ml tetracycline, lOOug/ml Bluo-gal, and 40ug/ml IPTG. DNA was isolated and used to transfect Sf9 insect cells using CellFECTIN reagent (GibcoBRL). Cells and supernatant were harvested after 72 hours. Viral supernatant was passaged twice and presence of Cat S confirmed by PCR of the supernatant. <br><br> 249 <br><br> WO 02/20485 <br><br> PCT/US01/08084 <br><br> SF9 cells were infected with recombinant baculovirus at a MOI of 5 for 48-72 hrs. Cell pellet was lysed and incubated in buffer at pH 4.5 at 37 for 2 hours to activate Cat S from pro-form to active mature form (Bromme, D &amp; McGrath, M., Protein Science. 1996, 5:789-791.) Presence of Cat S was confirmed by SDS-PAGE and Western blot using 5 rabbit anti-human proCat S. <br><br> Inhibition of Cathepsin S <br><br> Human recombinant cathepsin S expressed in Baculovirus is used at a final concentration 10 of 10 nM in buffer. Buffer is 50 mM Na acetate, pH 6.5, 2.5 mM EDTA, 2.5 mM TCEP. Enzyme is incubated with either compound or DMSO for 10 min at 37 °C. Substrate 7-amino-4-methylcoumarin, CBZ-L-valyl-L-valyl-L-arginineamide (custom synthesis by Molecular Probes) is diluted to 20 uM in water (final concentration of 5 M), added to assay and incubated for additional 10 minutes at 37 °C. Compound activity is measured 15 by diminished fluorescence compared to DMSO control when read at 360 nm excitation and 460 nm emission. <br><br> Examples listed above were evaluated for inhibition of cathepsin S in the above assay. All had IC50 values of 100 micromolar or below. <br><br> 20 <br><br> Inhibition of Cathepsin K, F, L and B: <br><br> Inhibition of these enzymes by particular compounds of the invention may be determined without undue experimentation by using art recognized methods as provided hereinbelow 25 each of which is incorporated herein by reference: <br><br> Cathepsin B, and L assays are to be found in the following references: <br><br> 1. Methods in Enzymology, Vol.244, Proteolytic Enzymes: Serine and Cysteine 30 Peptidases, Alan J. Barrett, ed. <br><br> Cathepsin K assay is to be found in the following reference: <br><br> 35 2. Bromme, D., Okamoto, K., Wang, B. B., and Biroc, S. (1996) J. Biol. Chem. 271, 2126-2132. <br><br> 250 <br><br></p> </div>

Claims (2)

<div class="application article clearfix printTableText" id="claims"> <p lang="en"> WO 02/20485<br><br> PCT/US01/08084<br><br> Cathepsin F assays are to be found in the following references:<br><br> 5 3. Wang, B., Shi, G.P., Yao, P.M., Li, Z., Chapman, H.A., and Bromme, D. (1998) J. Biol Chem. 273, 32000-32008.<br><br> 4. Santamaria, I., Velasco, G., Pendas, A.M., Paz, A., and Lopez-Otin, C (1999) J. Biol. Chem. 274, 13800-13809.<br><br> 10<br><br> Preferred compounds to be evaluated for inhibition of Cathepsin K, F, L and B in the above assays desirably have IC50 values of 100 micromolar or below.<br><br> 251<br><br> What is claimed is:<br><br> 1. A compound of the formula (la) or a tautomeric form thereof:<br><br> r,<br><br> 6\<br><br> f!1 "V /R3<br><br> .CN<br><br> R4<br><br> wherein for the Formula (la), the components<br><br> R6^ R2vyR3<br><br> f<br><br> R1^; R4 X and are chosen from any combination of A, B and C as follows:<br><br> N<br><br> (Het J-R5<br><br> A<br><br> R%<br><br> R1-^^<br><br> B<br><br> R2 R3 R4 X<br><br> C<br><br> R4<br><br> I ^-N<br><br> *N&gt;&lt;<br><br> (Het —j-R5<br><br> Al o<br><br> oK<br><br> O N<br><br> 6*.<br><br> B1<br><br> H O<br><br> ?<br><br> CI<br><br> tr<br><br> N<br><br> I<br><br> ?<br><br> A2<br><br> A<br><br> ?<br><br> B2<br><br> H O<br><br> y<br><br> C2<br><br> , H<br><br> N<br><br> k<br><br> 5<br><br> 252<br><br> ft -<br><br> J<br><br> WO 02/20485<br><br> PCT/US01/08084<br><br> A3<br><br> 0<br><br> h3cv A o*f ° p<br><br> B3<br><br> h 0<br><br> 5<br><br> C3<br><br> . h tf l-.<br><br> A4<br><br> 0<br><br> meo. ^0 A v* o^n s<br><br> B4<br><br> Me<br><br> &amp;<br><br> H 0<br><br> 9<br><br> C4<br><br> K<br><br> f<br><br> A5<br><br> o o<br><br> 11 11<br><br> i^c"^ o n<br><br> 0 Uy^<br><br> J<br><br> B5<br><br> rf-<br><br> h 0<br><br> 9<br><br> C5<br><br> 9<br><br> A6<br><br> X A<br><br> MeO o n<br><br> 9<br><br> B6<br><br> XfB<br><br> Vf£<br><br> h 0<br><br> 9<br><br> C6<br><br> 0\/\/\<br><br> 9<br><br> A7<br><br> 0<br><br> h,c^ A<br><br> 3 n n<br><br> 6*<br><br> j<br><br> B7<br><br> Me<br><br> Me&gt;C<br><br> h o<br><br> 3<br><br> C7<br><br> 4K"<br><br> W<br><br> j<br><br> A8<br><br> V 0<br><br> 0 A A<br><br> Sg^N &amp;■.<br><br> &gt;<br><br> B8<br><br> Me<br><br> Me&gt;L<br><br> h 0<br><br> 5<br><br> C8<br><br> , h ^.n<br><br> ¥ 1<br><br> j<br><br> A9<br><br> MeO—c^-0 0<br><br> V,<br><br> br*-.<br><br> &gt;<br><br> B9<br><br> Me me—<br><br> Vl*<br><br> h 0<br><br> 9<br><br> C9<br><br> &gt; h<br><br> Os/v'<br><br> j<br><br> 253<br><br> WO 02/20485<br><br> PCT/US01/08084<br><br> AlO<br><br> 0 ll<br><br> H,cin o<br><br> I j[<br><br> N N<br><br> »<br><br> BIO<br><br> «pO<br><br> H 0<br><br> 9<br><br> CIO<br><br> . H<br><br> *6<br><br> J<br><br> )<br><br> All o<br><br> V,<br><br> 6*<br><br> 9<br><br> Bll<br><br> Me<br><br> W<br><br> H 0<br><br> 9<br><br> Cll<br><br> 9<br><br> A12<br><br> O<br><br> V<br><br> B12<br><br> Me j J Me<br><br> VV<br><br> H 0<br><br> 9<br><br> C12<br><br> "tf<br><br> "~~o.<br><br> 9<br><br> A13<br><br> 0<br><br> V<br><br> 9<br><br> B13<br><br> &amp;<br><br> ^"T5-<br><br> HO.<br><br> C13<br><br> w&gt;.<br><br> 9<br><br> A14<br><br> O<br><br> r^sY^N'^v"N<br><br> Otf,<br><br> 9<br><br> B14<br><br> Me^e jCtV-<br><br> Me w<br><br> H 0<br><br> 9<br><br> C14<br><br> Ha'V^<br><br> t O<br><br> 9<br><br> A15<br><br> 0<br><br> t<br><br> B15<br><br> r$-<br><br> H 0<br><br> C15<br><br> 9<br><br> A16<br><br> O<br><br> &gt;<br><br> B16<br><br> H 0<br><br> s<br><br> C16<br><br> H2N\^<br><br> 9<br><br> 9<br><br> 254<br><br> WO 02/20485<br><br> PCT/US01/08084<br><br> A17<br><br> o<br><br> V.<br><br> 9<br><br> B17<br><br> Vv*<br><br> h 0<br><br> &gt;<br><br> C17<br><br> 0<br><br> »<br><br> A18<br><br> 0<br><br> oan<br><br> V<br><br> 9<br><br> B18<br><br> h 0<br><br> ?<br><br> C18<br><br> k^v^-nh2 0<br><br> A19<br><br> nA<br><br> q4<br><br> »<br><br> B19<br><br> /P<br><br> —Me h o<br><br> 9<br><br> C19<br><br> tf<br><br> 6.<br><br> A20<br><br> O-X<br><br> o*<br><br> j<br><br> B20<br><br> r-x^n'^oet h o<br><br> »<br><br> C2Q<br><br> i H<br><br> tf $<br><br> A21<br><br> XX<br><br> O4<br><br> 9<br><br> B21<br><br> .Me<br><br> P<br><br> h 0<br><br> 9<br><br> C21<br><br> &gt; H ^ *&amp;<br><br> &lt;^y^Qy ^ ,<br><br> A22<br><br> 0<br><br> °c^.<br><br> &gt;<br><br> B22<br><br> Me r3j-«.<br><br> Vs**<br><br> h 0<br><br> »<br><br> C22<br><br> tf<br><br> 6<br><br> 'A1*<br><br> o 0<br><br> 5<br><br> 255<br><br> WO 02/20485<br><br> PCT/US01/08084<br><br> A23<br><br> 9 o<br><br> II y H3C'jK ^0 N<br><br> )<br><br> B23<br><br> Me r&gt; VS*<br><br> H 0<br><br> 9<br><br> C23<br><br> i H<br><br> N H<br><br> 9<br><br> A24<br><br> 0<br><br> X<br><br> 9<br><br> B24<br><br> =V\?<br><br> H 0<br><br> 5<br><br> C24<br><br> &gt; H<br><br> Y)<br><br> I1<br><br> OH<br><br> 9<br><br> A25<br><br> Aa<br><br> &gt;<br><br> B25<br><br> V?<br><br> H 0<br><br> 5<br><br> C25<br><br> '—N H<br><br> }<br><br> A26<br><br> a0xp<br><br> &gt;<br><br> B26<br><br> H 0<br><br> »<br><br> C26<br><br> *zf<br><br> OH .<br><br> 9<br><br> A27<br><br> o<br><br> &lt;0<br><br> j<br><br> B27<br><br> Me<br><br> J0T"-<br><br> H 0<br><br> j<br><br> C27<br><br> V<br><br> N\<br><br> 9<br><br> A28<br><br> O<br><br> Y"°"\<br><br> o^J<br><br> 9<br><br> B28<br><br> APcMe<br><br> H 0<br><br> 9<br><br> C28<br><br> NV .<br><br> 9<br><br> A29<br><br> oA<br><br> u<br><br> 9<br><br> B29<br><br> v£&gt;<br><br> H 0<br><br> 9<br><br> C29<br><br> . H ^s-N<br><br> V<br><br> V^\<br><br> 9<br><br> A30<br><br> rc\<br><br> o-~y ^N-^<br><br> °^J<br><br> 9<br><br> B30<br><br> H 0<br><br> 9<br><br> C30<br><br> 9<br><br> 256<br><br> WO 02/20485<br><br> PCT/US01/08084<br><br> A31<br><br> CT°\<br><br> cr<br><br> 9<br><br> B31<br><br> v1?<br><br> H 0<br><br> j<br><br> C31<br><br> ^ /<br><br> »<br><br> A32<br><br> 0<br><br> .0^ X<br><br> »<br><br> B32<br><br> Vl<br><br> H C<br><br> 1^ ) .<br><br> 9<br><br> C32<br><br> b<br><br> 9<br><br> A33<br><br> f 0<br><br> F L<br><br> r^N<br><br> °J<br><br> 5<br><br> B33<br><br> vi<br><br> H 0 .<br><br> &gt;<br><br> C33<br><br> Q_o j<br><br> A34<br><br> O<br><br> rx^N'^N<br><br> °J<br><br> 9<br><br> B34<br><br> H 0 . -)<br><br> C34<br><br> Y&gt;<br><br> IZ.N '<br><br> A3 5<br><br> o<br><br> *^(AN<br><br> &gt;<br><br> B35<br><br> H O<br><br> j<br><br> C35<br><br> 9<br><br> A36<br><br> □.X<br><br> 0"^N<br><br> JL<br><br> 9<br><br> B35<br><br> VS<br><br> H C<br><br> I<br><br> )<br><br> C36<br><br> i H ^.N<br><br> 5<br><br> A3 7<br><br> 0<br><br> rr°Ai<br><br> N—S r^-N'^-<br><br> B37<br><br> H O .<br><br> 9<br><br> C37<br><br> &gt; H<br><br> 9<br><br> 257<br><br> WO 02/20485<br><br> PCT/US01/08084<br><br> 258<br><br> WO 02/20485<br><br> PCT/USO1/08084<br><br> A45<br><br> 0<br><br> XV.<br><br> 9<br><br> B45<br><br> h 0<br><br> &gt;<br><br> C45<br><br> 0<br><br> 9<br><br> A46<br><br> 0<br><br> n n<br><br> 6*.<br><br> B46<br><br> h 0<br><br> *<br><br> C46<br><br> '—n h<br><br> &gt;<br><br> A47<br><br> \<br><br> ^ °<br><br> n n<br><br> 6*.<br><br> i<br><br> B47<br><br> h 0 .<br><br> C47<br><br> 9<br><br> A48<br><br> o i I X<br><br> n<br><br> 9<br><br> B48<br><br> h 0 .<br><br> 9<br><br> C48<br><br> V<br><br> V.<br><br> &gt;<br><br> A49<br><br> &lt;X o<br><br> (^.<br><br> j<br><br> B49<br><br> V?<br><br> h 0<br><br> &gt;<br><br> A50<br><br> /r~~n'^v| o n n<br><br> 6*<br><br> *<br><br> A51<br><br> o v„<br><br> »<br><br> 259<br><br> WO 02/20485<br><br> PCT/US01/08084<br><br> A52<br><br> /^n^N o rA<br><br> A53<br><br> CXXx, O*<br><br> &gt;<br><br> A54<br><br> °<br><br> ' \a rA<br><br> »<br><br> A55<br><br> \<br><br> ✓ &gt; 0<br><br> SA,<br><br> ry^<br><br> j<br><br> A56<br><br> i<br><br> A57<br><br> Ti<br><br> N o rA<br><br> and the pharmaceutically acceptable derivatives thereof.<br><br> 260<br><br> WO 02/20485<br><br> PCT/US01/08084<br><br> 2. A compound chosen from:<br><br> {[ 1 -(3-Cyano- l-isobutyl-piperdin-3 -yl carbamoyl)-3,3-dimethyl-butylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester;<br><br> N-(2-Cyano-octahydro-quinolizin-2-yI)-3-cyclohexyI-2-( 1,1 -dioxo- IH-1 A,-benzo-3-ylamino)-propionamide;<br><br> {[ 1 -3 -Cyano-1 -methyl-piperidin-3-ylcarbamoyl)-3,3 -dimethyl-butylamino]-morpholin-4 yl-methylene}-carbamic acid ethyl ester;<br><br> {[l-(2-Cyano-octahydro-quinolizin-2-ylcarbamoyl)-3,3-dimethyl-butylamino]-morpholin-4-yl-methylene} -carbamic acid ethyl ester;<br><br> {[l-(4-Cyano-l-propyl-piperidin-4-ylcarbamoyl)-3-methyl-butylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester;<br><br> {[ 1 -(4-Cyano- l-cyclohexyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester;<br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene} -carbamic acid cyclohexylmethyl ester;<br><br> {[-1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid cyclobutyl ester;<br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid allyl ester;<br><br> N-(4-Cyano-l-propyl-piperidin-4-yl)-4-cyclohexyl-2-(2-oxo-2,3-dihydro-benzo [e] [ 1,3]oxazin-4-ylideneamino)-butyramide;<br><br> {[1 -(4-Cyano-1 -propyl-piperidin-4-ylcarbamoyl)-3-cyclohexyl-propylamino]-morpholin 4-yl-methylene}-carbamic acid ester;<br><br> {[ 1-(4-Cyano-1-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid tetrahydro-furan-3ylmethyl ester;<br><br> {[ 1 -(4-Cyano-1 -methy-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethyl aminoj-morpholin-4-yl-methylene}-carbamic acid tetrahydro-furan-2-yhnethyl ester;<br><br> iVL(4-Cyano-1 -methyl-piperidin-4-yl)-3 -cyclohexyl-2-(5,6-difluoro-3 -oxo-2,3-dihydro-isoindol-1 -ylideneamino)-propionamide;<br><br> 261<br><br> WO 02/20485<br><br> PCT/US01/08084<br><br> 2-(5,6-Difluoro-3-oxo-2,3-dihydro-isoindol-l-ylideneamino)-4,4-dimethyl-pentanoic acid (4-cyano-l-propyl-piperidm-4-yl)-amide;<br><br> 2-(6-Fhioro-3-oxo-2,3-dihydro-isoindoI-l-ylideneamino)-4,4-dimethyl-pentanoic acid (4-cyano-1 -propyl-piperidin-4-yl)-amide;<br><br> iV-(4-Cyano-1 -methyl-piperidin-4-yl)-3 -cyclohexyl-2-(6-fluoro-3 -oxo-2,3 -dihydro-isoindol- 1 -ylideneamino)-propionamide;<br><br> {[l-(4-Cyano-l-propyl-piperidin-4-ylcarbamoyl)-3,3-dimethyl-butylimino]-morpholm-4-yl-methyl}-carbamic acid methyl ester;<br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl} -carbamic acid methyl ester;<br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid 2,2-dimethyl-propyl ester,<br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-3,3-dimethyl-butylimino]-morpholin-4-yl-methyl}-carbamic acid methyl ester;<br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid benzyl ester;<br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid isobutyl ester;<br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid propyl ester;<br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid hexyl ester;<br><br> {[1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-moipholin-4-yl-methyl}-carbamic acid cyclobutylmethyl ester;<br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid 3,3,3-trifluoro-propyl ester;<br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morphoIin-4-yl-methyl} -carbamic acid 2-methoxy-ethyl ester;<br><br> 5,5-Dimethyl-2-(2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-hexanoic acid (4-cyano-1 -propyl-piperidin-4-yl)-amide;<br><br> 262<br><br> WO 02/20485<br><br> PCT/USO1/08084<br><br> {[l-(4-Cyano-l-propyl-piperidin-4-ylcarbamoyl)-4,4-dimethyI-pentylimino]-morpholin-4-yl-methyl}-carbamic acid ethyl ester;<br><br> {[1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-moxpholin-4-yl-methyl}-carbamic acid 2-isopropoxy-ethyl ester;<br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid 3-methoxy-butyl ester;<br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid 2-isobutoxy-ethyl ester;<br><br> {[ 1 -(4-Cyano-1 -propyl-piperidin-4-ylcarbamoyl)-3,3-dimethyl-butylimino]-morpholin-4-yl-methyl}-carbamic acid 2-methoxy-ethyl ester;<br><br> N-(4-Cyano-1 -methyl-piperidin-4-yl)-4-cyclohexyl-2-(6-methoxy-2-oxo-2,3 -dihydro-benzo[e] [ 1,3]oxazin-4-ylideneamino)-butyramide;<br><br> N-(4-Cyano-l-methyl-piperidin-4-yl)-4-cyclohexyl-2-(6-fluoro-2-oxo-2,3-dihydro-benzo[e] [1,3]oxazin-4-ylideneamino)-butyramide;<br><br> N-(4-Cyano-l-methyl-piperidin-4-yl)-4-cyclohexyl-2-(7-fluoro-2-oxo-2,3-dihydro-benzo [e] [ 1,3]oxazin-4-ylideneamino)-butyramide;<br><br> 2-(7-Fluoro-2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-yldeneamino)-5,5-dimethyl-hexanoic acid(4-cyano-1 -propyl-piperidin-4-yl)-amide;<br><br> N-(4-Cyano-l-methyl-piperidin-4-yl)-4-cyclohexyl-2-(7-methoxy-2-oxo-2,3-dihydro-benzo[e] [ 1 }3]oxazin-4-ylideneamino)-butyramide;<br><br> 2-(7-Methoxy-2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-yldeneamino)-5!5-dimethyl-hexanoic acid(4-cyano-1 -propyl-piperidin-4-yl)-amide;<br><br> {[ 1 -(4-Cyano-1 -propyl-piperidin-4-ylcarbamoyl)-5-methyl-hexylimino]-morpholin-4-yl-methyl}-carbamic acid ethyl ester;<br><br> 2-[(iV-Benzyl-morpholine-4-carboximidoyl)-amino]-iV-(4-cyano-l-methyl-piperidin-4-yl)-3-cyclohexyl-propionamide;<br><br> A^-(4-Cyano-l-methyl-piperidin-4-yl)-3-cyclohexyl-2-(2-oxo-2,3-dihydro-benzo[e] [ 1,3]oxazin-4-ylideneamino)-propionamide;<br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-pyrrolidin-1 -yl-methyl}-carbamic acid ethyl ester;<br><br> 263<br><br> WO 02/20485<br><br> PCT/US01/08084<br><br> {[I -(4-Cyano-1 -methyl-piperidia-4-ylcarbamoyl)-2-cyclohexyI-ethylimino]-piperidin-1 -yl-methyl}-carbamic acid ethyl ester;<br><br> {Azepan-1 -yl-[ 1 -(4-cyano-1 -methyl-piperidin-4-y lcarbamoyl)-2-cyclohexyl-ethylimino]-methyl}-carbamic acid ethyl ester;<br><br> {Azocan- l-yl-[ 1 -(4-cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino] -methyl}-carbamic acid ethyl ester;<br><br> 1 - {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-ethoxycarbonylamino-methyl}-piperidine-4-carboxylic acid ethyl ester;<br><br> l-{[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-ethoxycarbonylamino-methyl}-piperidine-3-carboxylic acid ethyl ester;<br><br> [[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-(4-pyrrolidin-l-yl-piperidin-l-yl)-methyl]-carbamic acid ethyl ester;<br><br> {[ 1,4']Bipiperidinyl-1 -yl- [ 1 -(4-cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-methyl}-carbamic acid ethyl ester;<br><br> [[1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-(4-phenyl-piperazin-l-yl)-methyl]-carbamic acid ethyl ester;<br><br> [[1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-(4-ethyl-piperazin-l-yl)-methyl]-carbamic acid ethyl ester;<br><br> {(4-Acetyl-piperazin- l-yl)-[ 1 -(4-cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-methyl}-carbamic acid ethyl ester;<br><br> 4- {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-ethoxycarbonylamino-methyl}-piperazine-l-carboxylic acid ethyl ester;<br><br> [[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-(3,3,5-trimethyl-6-aza-bicyclo[3.2.1]oct-6-yl)-methyl]-carbamic acid ethyl ester;<br><br> {(3-Acetylamino-pyrrolidm-1 -yl)-[l -(4-cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-methyl}-carbamic acid ethyl ester;<br><br> {(3-Acetylamino-pyrrolidin- l-yl)-[ 1 -(4-cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-methyl}-carbamic acid ethyl ester;<br><br> {(3-Azapent-3-yl)-[l-(4-cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethyhmino]-methyl}-carbamic acid ethyl ester;<br><br> 264<br><br> WO 02/20485<br><br> PCT/US01/08084<br><br> {(1 -Methoxy-3 -azapent-3-yl)-[l -(4-cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-methyl}-carbamic acid ethyl ester;<br><br> [[1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino] -(3 -oxo-piperazin-l-yl)-methyl]-carbamic acid ethyl ester;<br><br> {(1,5-Dimethoxy-3 -azapent-3-yI)-[l -(4-cyano-1 -methyI-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-methyl}-carbamic acid ethyl ester;<br><br> 4,4-Dimethyl-2-(2-oxo-2!3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-pentanoic acid (4-cyano-1 -propyl-piperidin-4-yl)-amide;<br><br> {(4-Carbamoyl-piperidin-1 -yl)-[ 1 -(4-cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-methyl}-carbamic acid ethyl ester;<br><br> [ [ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino] -(2-methoxymethyl-morpholin-4-yI)-methyl]-carbamic acid ethyl ester;<br><br> (4- {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-ethoxycarbonylamino-methyl}-piperazin-l-yl)-acetic acid ethyl ester;<br><br> [[1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino] -(2,6-dimethyl-morpholin-4-yl)-methyl]-carbamic acid ethyl ester;<br><br> [[1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-(2,6-dimethyl-morpholin-4-yl)-methyl]-carbamic acid ethyl ester;<br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin~4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-thiomorpholin-4-yl-methyl}-carbamic acid ethyl ester;<br><br> 4,4-Dimethyl-2-(6-methyl-2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-pentanoic acid (4-cyano-l-propyl-piperidin-4-yl)-amide;<br><br> 2-(6-Chloro-2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-4,4-dimethyl-pentanoic acid (4-cyano-l-propyl-piperidin-4-yl)-amide;<br><br> 4!4-Dimethyl-2-(2-oxo-2,3-dihydro-li7-quinazolin-4-ylideneamino)-pentanoic acid (4-cyano-1 -propyl-piperidin-4-yl)-amide;<br><br> 2-(7-Chloro-2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-4,4-dimethyl-pentanoic acid (4-cyano-l-propyl-piperidin-4-yl)-amide;<br><br> 5-Methyl-2-(2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-hexanoic acid (4-cyano-1 -propyl-piperidin-4-yl)-amide;<br><br> 265<br><br> WO 02/20485<br><br> PCT/USO1/08084<br><br> 4,4-Dimethyl-2-(l-methyl-2-oxo-l,2-dihydro-quinazolin-4-ylamino)-pentanoic acid (4-cyano-1 -propyl-piperidin-4-yl)-amide;<br><br> 3-fer*-Butylsulfanyl-iV"-(4-cyano-l-propyl-piperidin-4-yl)-2-(2-oxo-253-dihydro-benzo[e][l;3]oxazin-4-ylideneamino)-propionamide;<br><br> {[2-tert-Butylsulfanyl-1 -(4-cyano-1 -propyl-piperidin-4-ylcarbamoyl)-ethyhmino]-morpholin-4-yl-methyl}-carbamic acid ethyl ester;<br><br> 3-Benzylsulfanyl-7V-(4-cyano-l-propyl-piperidin-4-yl)-2-(2-oxo-2,3-dihydro-benzo[e] [ 1,3]oxazin-4-ylideneamino)-propionamide;<br><br> {[2-Benzylsulfanyl-1 -(4-cyano-1 -propyl-piperidin-4-ylcarbamoyl)-ethylimino] -morpholin-4-yl-methyl}-carbamic acid ethyl ester;<br><br> Ar-(4-Cyano-l-propyl-piperidin-4-yl)-3-cyclooctyl-2-(2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-propionamide;<br><br> iV-(4-Cyano-l-propyl-piperidin-4-yl)-3-cycloheptyl-2-(2-oxo-2,3-dihydro-benzofe] [ 1,3]oxazin-4-ylideneamino)-propionamide;<br><br> {[l-(4-Cyano-l-propyl-piperidin-4-ylcarbamoyl)-2-cycloheptyl-ethylimino]-morpholin-<br><br> 4-yl-methyl}-carbamic acid ethyl ester;<br><br> {[1 -(4-Cyano-1 -propyl-piperidin-4-ylcarbamoyl)-2-cyclooctyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid ethyl ester;<br><br> {[l-(4-Cyano-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid isobutyl ester;<br><br> ({1 - [4-Cyano-1 -(2-morpholin-4-yl-ethyl)-piperidin-4-ylcarbamoyl]-2-cyclohexyl-ethylamino}-morpholin-4-yl-methylene)-carbamic acid isobutyl ester;<br><br> ({1 -[ 1 -2-Carbamoyl-ethyl)-4-cyano-piperidin-4-ylcarbamoyl] -2-cyclohexyl-ethylamino}-morpholin-4-yl-methylene)-carbamic acid isobutyl ester;<br><br> [(l-{4-Cyano-l-[2-(2-methoxyl-ethoxy)-ethyl]-piperidin-4-ylcarbamoyl}-2-cyclohexyl-ethylamino)-morpholm-4-yl-methylene]-carbamic acid isobutyl ester;<br><br> [(l-{4-Cyano-I-[3-(2-methoxyl-ethoxy)-propyl]-piperidin-4-ylcarbamoyl}-2-cyclohexyl-ethylamino)-morpholin-4-yl-methylene]-carbamic acid isobutyl ester;<br><br> {[2-tert-Butoxy-l-(4-cyano-l-propyl-piperidin-4-ylcarbamoly)-ethylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester;<br><br> 266<br><br> WO 02/20485<br><br> PCT/US01/08084<br><br> N-(4-Cyano-l-methyl-piperidin-4-yl)-3-cyclohexyl-2-{[diethyl-carbamoylimino)-morpholin-4-yl-methyl] -amino} -propionamide;<br><br> {[l-(4-Cyano-l-propyl-piperidin-4-ylcarbamoyl)-2-(3,3,5,5-tetramethyl-cyclohexyl)-ethylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester;<br><br> {[ 1 -(4-Cyano-1 -propyl-piperidin-4-ylcarbamoyl)-2-(4,4-dipropyl-cyclohexyl)-ethylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester;<br><br> {[ 1 -(4-Cyano-1 -isopropyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester;<br><br> {[ I -(4-Cyano-1 -phenethyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester;<br><br> {[ 1 -(4-Cyano-1 -ethyl-piperidin-4-ylcarbarnoyl)-2-cyclohexyl- ethylamino] -morpholin-4-yl-methylene}-carbamic acid ethyl ester;<br><br> {[l-(l-Benzyl-4-cyano-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester;<br><br> 4-Cyano-4-{3-cyclohexyl-2-[(ethoxycarbonylimino-morpholin-4-yl-methyl)-amino]-propionylamino}-piperidine-l-carboxylic acid benzyl ester;<br><br> {[ 1 -(1 -Benzyl-4-cy ano-piperidin-4-ylcarbamoyl)-3,3 -dimethyl-butylamino] -morpholin-4-yl-methylene}-carbamic acid ethyl ester;<br><br> {[1 -(4-Cyano-1 -phenethyl-piperidin-4-ylcarbamoyl)-3,3-dimethyl-butylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester;<br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][l ,3]oxazin-4-ylamino)-pentanoic acid (l-benzyl-4-cyano-piperidin-4-yl)-amide;<br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][ 1,3 ]oxazin-4-ylamino)-pentanoic acid [4-cyano-1 -(5-methyl-thiophen-2-ylmethyl)-piperidin-4-yl]-amide;<br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e] [ 1,3]oxazin-4-ylamino)-pentanoic acid [4-cyano-1 -(4-fluoro-benzyl)-piperidin-4-yl]-amide;<br><br> 4s4-Dimethyl-2-(2-oxo-2H-benzo[e][l ,3]oxazin-4-ylamino)-pentanoic acid (4-cyano-l-ethyl-piperidin-4-yl)-amide;<br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][ 1 ;3]oxazin-4-ylamino)-pentanoic acid (4-cyano-1 -methyl-piperidin-4-yl)-amide;<br><br> 267<br><br> WO 02/20485<br><br> PCT/US01/08084<br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][l ,3]oxazin-4-ylamino)-pentanoic acid (4-cyano-piperidin-4-yl)-amide;<br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e] [1,3] oxazin-4-ylamino)-pentanoic acid (4-cyano-1 -phenethyl-piperidin-4-yl)-amide;<br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e] [1,3]oxazin-4-ylamino)-pentanoic acid [4-cyano-1-(2,2-dimethyl-propyl) -piperidin-4-yl]-amide;<br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-pentanoic acid [4-cyano-1-(3,3-dimethyl-butyl)-piperidin-4-yl]-amide;<br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][l ,3]oxazin-4-ylamino)-pentanoic acid (4-cyano-l-pentyl-piperidin-4-yl)-amide;<br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-pentanoic acid (l-butyl-4-cyano-piperidin-4-yl)-amide;<br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e] [ 1,3]oxazin-4-ylamino)-pentanoic acid [4-cyano-1 -(3,3,3-trifluoro-propyl)-piperidin-4-yl]-amide;<br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-pentanoic acid (4-cyano-l-cyclohexylmethyl-piperidin-4-yl)-amide;<br><br> N-(4-Cyano-1 -propyl-piperidin-4-yl)-3 -(4,4-dimethyl-cyclohexyl)-2-(2-oxo-2H-benzo[e] [ 1,3]oxazin-4-ylamino)-propionamide;<br><br> N-(4-Cyano-l-propyl-piperidin-4-yl)-3-(4,4-dipropyl-cyclohexyl)-2-(2-oxo-2H-benzo[e][l,3Joxazin-4-ylamino)-propionamide;<br><br> N-(4-Cyano-1 -propyl-piperidin-4-yl)-3 -(4-tert-butyl-cyclohexyl)-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-propionamide;<br><br> N-(4-Cyano-l-propyl-piperidin-4-yl)-3-(3,3,5,5-tetramethyl-cyclohexyl)-2-(2-oxo-2H-benzo[e] [1,3] oxazin-4-ylamino)-propionamide;<br><br> {[l-(3-Cyano-l-ethyl-pyrrolidin-3-ylcarbamoyl)-2-cyclohexyl-etliylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester;<br><br> 2-[(Methanesulfonylimino-moipholin-4-yl-methyl)-amino]-4,4-dimethyl-pentanoic acid (4-cyano-1 -propyl-piperidin-4-yl)-amide;<br><br> {[l-(3-Cyano-l-propyl-pyrrolidin-3-ylcarbamoyl)-3,3-dimethyl-butylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester;<br><br> 268<br><br> ({1 -[3 -Cyano-l-(4,4-dimethyl-cyclohexyl)-pyrrolidin-3-ylcarbamoyl]-3,3-dimethyl-butylamino}-morpholin-4-yl-methylene)-carbamic acid ethyl ester,<br><br> {[1-(3-Cyano-1-ethyl-5,5-dimethyl-pyrrolidin-3-ylcarbamoyl)-3,3-dimethyl-butylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester,<br><br> N-(4-Cyano-l-methyl-piperidin-4-yl)-3-cyclohexyl-2-(7,8-difluoro-2-oxo-2H-b enzo [e] [ 1,3 ]oxazin-4-ylamino)-propionamide;<br><br> {[l-(4-Cyano-l-cyclohexylmethyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester;<br><br> 3-Cyano-3-[4,4-dimethyl-2-(2-oxo-2//-benzo[e][l,3]oxazin-4-ylamino)-pentanoylamino]-azepane-1-carboxylie acid benzyl ester,<br><br> 4,4-Dimethyl-2-(2-oxo-2/7-benzo [e][l,3 ]oxazin-4-ylamino)-pentanoic acid (3 -cyano-1 -propyl-azepan-3-yl)-amide;<br><br> 4,4-Dimethyl-2-(2-oxo-2#-benzo[e][l,3]oxazin-4-ylamino)-pentanoic acid (4-cyano-l-propyl-azepan-4-yl)-amide;<br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid 4-methoxy-cyclohexylmethyl ester;<br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid cyclohexyl ester;<br><br> {[1 -(4 -Cyano-1 -propyl-piperidin-4-ylcarbamoyl)-3,3 -dimethyl-butylamino]-phenyl-methylene}-carbamic acid ethyl ester;<br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-phenyl-methylene}-carbamic acid ethyl ester,<br><br> 2-{[N-(4-Cyano-phenyl)-morpholine-4-carboximidoyl]-amino}-4,4-dimethyl-pentanoic acid (4-cyano-l-propyl-piperidin-4-yl)-amide;<br><br> 4,4-Dimethyl-2-{[N-(4-trifluoromethyl-phenyl)-morpholine-4-carboximidoyl]-amino}-pentanoic acid (4-cyano-l-propyl-piperidin-4-yl)-amide and all the tautomeric forms of any thereof;<br><br> and the pharmaceutically acceptable derivatives of any thereof.<br><br> [■ _ " &gt;■<br><br> 269<br><br> WO 02/20485<br><br> PCT/USO1/08084<br><br> 3. The compound according to claim 2 wherein the compound is chosen from<br><br> {[ 1 -(3-Cyano-1 -isobutyl-piperdin-3 -yl carbamoyl)-3,3-dimethyl-butylaminoj-morpholin-4-yl-methylene}-carbamic acid ethyl ester;<br><br> {[ 1 -(4-Cyano-1 -cyclohexyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino] -morpholin-4-yl-methylene}-carbamic acid ethyl ester;<br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino] -morpholin-4yl-methylene}-carbamic acid cyclohexylmethyl ester;<br><br> {[-l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-moipholin-4-yl-methylene}-carbamic acid cyclobutyl ester;<br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylaxnino]-moipholin-4-yl-methylene}-carbamic acid allyl ester;<br><br> N-(4-Cyano-l-propyl-piperidin-4-yl)-4-cyclohexyl-2-(2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-bu1yramide;<br><br> {[ 1-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpiholin-4-yl-methylene}-carbamic acid tetrahydro-furan-3ylmethyl ester;<br><br> {[l-(4-Cyano-l-methy-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethyl amino]-morpholin-4-yl-methylene}-carbamic acid tetrahydro-furan-2-ylmethyl ester;<br><br> JV-(4-Cyano-l-methyl-piperidin-4-yl)-3-cyclohexyl-2-(5,6-difluoro-3-oxo-2,3-dihydro-isoindol-1 -ylideneamino)-propionamide;<br><br> 2-(5,6-Difluoro-3-oxo-2,3-dihydro-isoindol-l-ylideneamino)-4,4-dimethyl-pentanoic acid (4-cyano-1 -propyl-piperidin-4-yl)-amide;<br><br> 2-(6-Fhioro-3-oxo-2,3-dihydro-isoindol-l-ylideneamino)-4,4-dimethyl-pentanoic acid (4-cyano-1 -propyl-piperidin-4~yl)-amide;<br><br> A^-(4-Cyano-l-methyl-piperidin-4-yl)-3-cyclohexyl-2-(6-fIuoro-3-oxo-2,3-dihydro-isoindol-1 -ylideneamino)-propionamide;<br><br> {[ 1 -(4-Cyano-1 -propyl-piperidin-4-ylcarbamoyl)-3,3 -dimethyl-butyIimino]-moipholm-4-yl-methyl} -carbamic acid methyl ester;<br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid methyl ester;<br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid 2,2-dimethyl-propyl ester;<br><br> 270<br><br> WO 02/20485<br><br> PCT7US01/08084<br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-3,3 -dimethyl-butylimino] -morpholin-4-yl-methyl}-carbamic acid methyl ester;<br><br> {[l-(4-Cyano-l-methyI-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid benzyl ester;<br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid isobutyl ester;<br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino] -morpholin-4-yl-methyl}-carbamic acid propyl ester;<br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid hexyl ester;<br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid cyclobutylmethyl ester;<br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid 3,3,3-trifluoro-propyl ester;<br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid 2-methoxy-ethyl ester;<br><br> 5,5-Dimethyl-2-(2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamzno)-hexanoic acid (4-cyano-1 -propyl-piperidin-4-yl)-amide;<br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid 2-isopropoxy-ethyl ester;<br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethyhmino]-morpholin-4-yl-methyl}-carbamic acid 3-methoxy-butyl ester;<br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid 2-isobutoxy-ethyl ester;<br><br> {[ 1 -(4-Cyano-1 -propyl-piperidin-4-ylcarbamoyl)-3,3 -dimethyl-butylimino] -morpholin-4-yl-methyl}-carbamic acid 2-methoxy-ethyl ester;<br><br> N-(4-Cyano-l-methyl-piperidin-4-yl)-4-cyclohexyl-2-(6-methoxy-2-oxo-2,3-dihydro-benzo[e] [1,3]oxazin-4-ylideneamino)-butyramide;<br><br> N-(4-Cyano-l-methyl-piperidin-4-yl)-4-cyclohexyl-2-(6-fluoro-2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-butyramide;<br><br> 271<br><br> WO 02/20485<br><br> PCT/US01/08084<br><br> N-(4-Cyano-l-methyl-piperidin-4-yl)-4-cyclohexyl-2-(7-fluoro-2-oxo-2:3-dihydro-benzo[e] [1,3]oxazin-4-ylideneamino)-butyramide;<br><br> 2-(7-Fhioro-2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-yldeneamino)-535-dimethyl-hexanoic acid(4-cyano-l-propyl-piperidin-4-yl)-amide;<br><br> N-(4-Cyano-l-methyl-piperidin-4-yl)-4-cyclohexyl-2-(7-methoxy-2-oxo-2,3-dihydro-benzo[e] [ 1,3]oxazin-4-ylideneamino)-butyramide;<br><br> 2-(7-Methoxy-2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-yldeneammo)-5!,5-dimethyl-hexanoic acid(4-cyano-1 -propyl-piperidin-4-yl)-amide;<br><br> AL(4-Cyano-1 -methyl-piperidin-4-yl)-3 -cyclohexyl-2-(2-oxo-2,3 -dihy dro-benzo [e] [ 1,3]oxazin-4-ylideneamino)-propionamide;<br><br> {[ 1 -(4-Cyano-1 -metkyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino] -pyrrolidin-1 -yl-methyl}-carbamic acid ethyl ester;<br><br> {[l-(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-piperidin-1 -yl-methyl}-carbamic acid ethyl ester;<br><br> {Azepan-1 -yl-[ 1 -(4-cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-methyl}-carbamic acid ethyl ester;<br><br> {Azocan-1 -yl-[ 1 -(4-cyano-l -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-methyl}-carbamic acid ethyl ester;<br><br> 1 - {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-ethoxycarbonylamino-methyl}-piperidine-4-carboxylic acid ethyl ester;<br><br>
1 - {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-ethoxycarbonylamino-methyl}-piperidine-3-carboxylic acid ethyl ester;<br><br> [[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-(4-phenyl-piperazin-l-yl)-methyl]-carbamic acid ethyl ester;<br><br> [[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-(4-ethyl-piperazin-l-yl)-methyl]-carbamic acid ethyl ester;<br><br> {(4-Acetyl-piperazin-1 -yl)-[ 1 -(4-cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-elhyliminoj-methyl}-carbamic acid ethyl ester;<br><br> 4- {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino] -ethoxycarbonylamino-methyl}-piperazine-l-carboxylic acid ethyl ester;<br><br> [[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-(3,3=5-trimethyl-6-aza-bicyclo[3.2.1]oct-6-yl)-methyl]-carbamic acid ethyl ester;<br><br> 272<br><br> WO 02/20485<br><br> PCT/USO1/08084<br><br> {(3-Acetylamino-pyrrolidin-l-yl)-[l-(4-cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-methyl}-carbamic acid ethyl ester;<br><br> {(3-Acetylamino-pyrrolidin-1 -yl)-[ 1 -(4-cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-methyl}-carbamic acid ethyl ester;<br><br> {(3-Azapent-3-yl)-[ 1 -(4-cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethyliminoj-methyl} -carbamic acid ethyl ester;<br><br> {(l-Methoxy-3-azapent-3-yl)-[l-(4-cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-methyl}-carbamic acid ethyl ester;<br><br> [[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-(3-oxo-piperazin-l-yl)-methyl]-carbamic acid ethyl ester;<br><br> {(1,5 -Dimethoxy-3 -azapent-3 -yl)-[ 1 -(4-cyano-1 -methyl-piperidin-4-ylcaxbamoyl)-2-cyclohexyl-ethylimino]-methyl}-carbamic acid ethyl ester;<br><br> 4,4-Dimethyl-2-(2-oxo-2,3-dihydro-benzo[e] [1,3] oxazin-4-ylideneamino)-pentanoic acid (4-cyano-1 -propyl-piperidin-4-yl)-amide;<br><br> {(4-Carbamoyl-piperidin-1 -yl)-[ 1 -(4-cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-methyl}-carbamic acid ethyl ester;<br><br> [[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-(2-methoxymethyl-morpholin-4-yl)-methyl]-carbamic acid ethyl ester;<br><br> (4- {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-ethoxycarbonylamino-methyl}-piperazin-l-yl)-acetic acid ethyl ester;<br><br> [[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-(2,6-dimethyl-morpholin-4-yl)-methyl]-carbamic acid ethyl ester;<br><br> [[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-(2,6-dimethyl-morpholin-4-yl)-methyl]-carbamic acid ethyl ester;<br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-thiomorpholin-4-yl-methyl}-carbamic acid ethyl ester;<br><br> 4,4-Dimethyl-2-(6-methyl-2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-pentanoic acid (4-cyano-l-propyl-piperidin-4-yl)-amide;<br><br> 2-(6-Chloro-2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-4,4-dimethyl-pentanoic acid (4-cyano- l-propyl-piperidin-4-yl)-amide;<br><br> 273<br><br> WO 02/20485<br><br> PCT/US01/08084<br><br> 4,4-Dimethyl-2-(2-oxo-2,3-dihydro- lJfT-quinazolin-4-ylideneamino)-pentanoic acid (4-cyano-1 -propyl-piperidin-4-yl)-amide;<br><br> 2-(7-Chloro-2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-4,4-dimethyl-pentanoic acid (4-cyano-l-propyl-piperidin-4-yl)-amide;<br><br> 5-Methyl-2-(2-oxo-2)3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-hexanoic acid (4-cyano-1 -propy l-piperidin-4-yl)-amide;<br><br> 4,4-Dimethyl-2-( 1 -methyl-2-oxo-1,2-dihydro-quinazolin-4-ylamino)-pentanoic acid (4-cyano-1 -propyl-piperidin-4-yl)-amide;<br><br> 3-ferf-Butylsulfanyl-7V-(4-cyano-l-propyl-piperidin-4-yl)-2-(2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-propionamide;<br><br> 3-Benzylsulfanyl-7V-(4-cyano-l-propyl-piperidin-4-yl)-2-(2-oxo-2;3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-propionamide;<br><br> {[2-Benzylsulfanyl-l-(4-cyano-l-propyl-piperidin-4-ylcarbamoyl)-ethylimino]-morpholin-4-yl-methyl} -carbamic acid ethyl ester;<br><br> N-(4-Cyano-l-propyl-piperidin-4-yl)-3-cyclooctyl-2-(2-oxo-2,3-dihydro-benzo[e] [1,3]oxazin-4-ylideneamino)-propionamide;<br><br> iV-(4-Cyano-1 -propyl-piperidin-4-yl)-3-cycloheptyl-2-(2-oxo-2,3-dihydro-benzo[e] [ 1,3]oxazin-4-ylideneamino)-propionamide;<br><br> {[ 1 -(4-Cyano-1 -propyl-piperidin-4-ylcarbamoyl)-2-cycloheptyl-ethylimino]-morpholin-<br><br> 4-yl-methyl}-carbamic acid ethyl ester;<br><br> {[ 1 -(4-Cyano-1 -propyl-piperidin-4-ylcarbamoyl)-2-cyclooctyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid ethyl ester;<br><br> {[l-(4-Cyano-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid isobutyl ester;<br><br> ({1 -[4-Cyano-1 -(2-morpholin-4-yl-ethyl)-piperidin-4-ylcarbamoy 1] -2-cyclohexyl-ethylamino}-morpholin-4-yl-methylene)-carbamic acid isobutyl ester;<br><br> ( {l-[ 1 -2-Carbamoyl-ethyl)-4-cyano-piperidm-4-ylcarbamoyl]-2-cycIohexyl-ethylamino}-morpholin-4-yl-methylene)-carbamic acid isobutyl ester;<br><br> [(1 - {4-Cyano-1 -[2-(2-methoxyl-ethoxy)-ethyl] -piperidin-4-ylcarbamoyl} -2-cyclohexyl-ethylamino)-morpholin-4-yl-methylene]-carbamic acid isobutyl ester;<br><br> 274<br><br> WO 02/20485<br><br> PCT/US01/08084<br><br> [(1 - {4-Cyano-l -[3-(2-methoxyl-ethoxy)-propyl]-piperidin-4-ylcarbamoyl} -2-cyclohexyl-ethylamino)-morpholin-4-yl-rnethylene]-carbarnic acid isobutyl ester;<br><br> {[2-tert-Butoxy-1 -(4-cyano-1 -propy l-piperidin-4-ylcarbamoly)-ethylamino] -morpholin-4-yl-methylene}-carbamic acid ethyl ester;<br><br> N-(4-Cyano-1 -methyl-piperidin-4-yl)-3 -cyclohexyl-2- {[diethyl-carbamoylimino)-morpholin-4-yl-methyl] -amino} -propionamide;<br><br> {[ 1 -(4-Cyano-1 -propyl-piperidin-4-ylcarbamoyl)-2-(3,3,5,5-tetramethyl-cyclohexyl)-ethylamino]-moipholin-4-yl-methylene}-carbamic acid ethyl ester;<br><br> {[l-(4-Cyano-l-propyl-piperidin-4-ylcarbamoyl)-2-(4,4-dipropyl-cyclohexyl)-ethylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester;<br><br> {[ 1 -(4-Cyano-1 -isopropyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester;<br><br> {[ 1 -(4-Cyano-1 ~phenethyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester;<br><br> {[ 1 -(4-Cyano-1 -ethyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester;<br><br> {[ 1 -(1 -Benzyl-4-cyano-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethyIamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester;<br><br> 4-Cyano-4-{3-cyclohexyl-2-[(ethoxycarbonylimino-morpholin-4-yl-methyl)-amino]-propionylamino}-piperidine-l-carboxylie acid benzyl ester;<br><br> {[l-(l-Benzyl-4-cyano-piperidin-4-ylcarbamoyl)-3,3-dimethyl-butylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester;<br><br> {[1 -(4-Cyano-1 -phenethyl-piperidin-4-ylcarbamoyl)-3,3-dimethyl-butylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester;<br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-pentanoic acid (l-benzyl-4-cyano-piperidin-4-yl)-amide;<br><br> 4}4-Dimethyl-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-pentanoic acid [4-cyano-l-(5-methyl-thiophen-2-ylmethyl)-piperidin-4-yl]-amide;<br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-pentanoic acid [4-cyano-l-(4-fluoro-benzyl)-piperidin-4-yl]-amide;<br><br> 275<br><br> WO 02/20485<br><br> PCT/USO1/08084<br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-pentanoicacid (4-cyano-l-ethyl-piperidin-4-yl)-amide;<br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][ 1,3]oxazin-4-ylamino)-pentanoic acid (4-cyano-1 -methyl-piperidin-4-yl)-amide;<br><br> 4,4-DimethyI-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-pentanoic acid (4-cyano-piperidin-4-yl)-amide;<br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-pentanoic acid (4-cyano-l-phenethyl-piperidin-4-yl)-amide;<br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-pentanoic acid [4-cyano-l-(2,2-dimethyl-propyl)-piperidin-4-yl]-amide;<br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-pentanoic acid [4-cyano-l-(3,3 -dimethyl-butyl)-piperidin-4-yl]~amide;<br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][ 1,3]oxazin-4-ylamino)-pentanoic acid (4-cyano-1 -pentyl-piperidin-4-yl)-amide;<br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e] [1,3]oxazin-4-ylamino)-pentanoic acid (l-butyl-4-cyano-piperidin-4-yl)-amide;<br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e] [1,3] oxazin-4-ylamino)-pentanoic acid [4-cyano-1 -(3,3,3-trifluoro-propyl)-piperidin-4-yl]-amide;<br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][l ,3]oxazin-4-ylamino)-pentanoic acid (4-cyano-l-cyclohexylmethyl-piperidin-4-yl)-amide;<br><br> N-(4-Cyano-l-propyl-piperidin-4-yl)-3-(4,4-dimethyl-cyclohexyl)-2-(2-oxo-2H-benzo[e] [ 1,3 ]oxazin-4-ylamino)-propionamide;<br><br> N-(4-Cyano-l-propyl-piperidin-4-yl)-3-(4,4-dipropyl-cycIohexyl)-2-(2-oxo-2H-b enzo [e] [ 1,3]oxazin-4-ylamino)-propionamide;<br><br> N-(4-Cyano-1 -propyl-piperidin-4-yl)-3 -(4-tert-bntyl-cyclohexyl)-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-propionamide;<br><br> N-(4-Cyano~l-propyl-piperidin-4-yl)-3-(3,3,5,5-tetrametbyl-cyclohexyl)-2-(2-oxo-2H-benzo [e] [ 1,3 ] oxazin-4-ylamino)-propionamide;<br><br> {[ 1 -(3-Cyano-1 -ethyl-pyrrolidin-3-yIcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester;<br><br> 276<br><br> {[l-(3-Cyano-l-propyl-pyrrolidin-3-ylcarbamoyl)-3,3-dimethyl-butylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester,<br><br> ({1 -[3 -Cyano-1 -(4,4-dimethyl-cyclohexyl)-pyrrolidin-3 -ylcarb amoyl]-3,3 -dimethyl-butylamino}-morpholin-4-yl-methylene)-carbamic acid ethyl ester,<br><br> N-(4-Cyano-l-methyl-piperidin-4-yl)-3-cyclohexyl-2-(7,8-difluoro-2-oxo-2H-benzo[e][l ,3 ]oxazin-4-ylamino)-propionamide;<br><br> {[l-(4-Cyano-l-cyclohexylmethyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-m ethylene}-carbamic acid ethyl ester,<br><br> 3-Cyano-3-[4,4-dimethyl-2-(2-oxo-2i/-benzo[e][l,3]oxazin-4-ylamino)-pentanoylammo]-azepane-1 -carboxylic acid benzyl ester;<br><br> 4,4-Dimethyl-2-(2-oxo-2//-benzo[e][l,3]oxazm-4-ylamino)-pentanoic acid (3-cyano-l-propyl-azepan-3-yl)-amide;<br><br> 4,4-Dimethyl-2-(2-oxo-2/7-benzo[e][l ,3]oxazin-4-ylamino)-pentanoic acid (4-cyano-l-propyl-azepan-4-yl)-amide;<br><br> {[1 -(4-Cyano-1 -methyl-piperidin-4-ylcarb amoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid 4-methoxy-cyclohexylmethyl ester;<br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid cyclohexyl ester;<br><br> {[l-(4-Cyano-l-propyl-piperidin-4-ylcarbamoyl)-3,3-dimethyl-butylamino]-phenyl-methylene}-carbamic acid ethyl ester;<br><br> and<br><br> {[ 1-(4-Cyano-l-methyl-piperidin-4-ylcarb amoyl)-2-cyclohexyl-ethylamino]-phenyl-methylene}-carbamic acid ethyl ester;<br><br> and all tautomeric forms of any thereof.<br><br> 4. The compound according to claim 3 wherein the compound is chosen from:<br><br> {[1 -(4-Cy ano-l -cyclohexyl-piperidin-4-ylcarb amoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester;<br><br> 277<br><br> WO 02/20485<br><br> PCT/US01/08084<br><br> {[l-(4-cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid cyclohexylmethyl ester;<br><br> {[-l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid cyclobutyl ester;<br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid allyl ester;<br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl) -2-cyclohexyl-ethylamino] -morpholin-4-yl-methylene}-carbamic acid tetrahydro-furan-3ylmethyl ester;<br><br> {[l-(4-Cyano-l-methy-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethyl amino]-morpholin-4-yl-methylene}-carbamic acid tetrahydro-furan-2-ylmethyl ester;<br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino] -morpholin-4-yl-methyl}-carbamic acid methyl ester;<br><br> {[ l-(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino] -morpholin-4-yl-methyl}-carbamic acid 2,2-dimethyl-propyl ester;<br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino] -morpholin-4-yl-methyl}-carbamic acid benzyl ester;<br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino] -morpholin-4-yl-methyl}-carbamic acid isobutyl ester;<br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethyliimno]-morpholin-4-yl-methyl}-carbamic acid propyl ester;<br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimmo]-morpholin-4-yl-methyl}-carbamic acid hexyl ester;<br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid cyclobutylmethyl ester;<br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid 3,3,3-trifluoro-propyl ester;<br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid 2-methoxy-ethyl ester;<br><br> 5,5-Dimethyl-2-(2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-hexanoic acid (4-cyano-l-propyl-piperidin-4-yl)-amide;<br><br> 278<br><br> WO 02/20485<br><br> PCT/US01/08084<br><br> {[ 1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cycIohexyl-ethyhmino]-morpholin-4-yl-methyl}-carbamic acid 2-isopropoxy-ethyl ester;<br><br> {[1 -(4-Cyano-1 -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethyhmino] -morpholin-4-yl-methyl}-carbamic acid 3-methoxy-butyl ester;<br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid 2-isobutoxy-ethyl ester;<br><br> N-(4-Cyano-l-methyl-piperidin-4-yl)-4-cyclohexyl-2-(7-fluoro-2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneaxnino)-butyramide;<br><br> 2-(7-Fluoro-2-oxo-2,3-dihydro-benzo[e][l,3]oxazm-4-yldeneamino)-5,5-dimethyl-hexanoic acid(4-cyano-l -propyl-piperidin-4-yl)-amide;<br><br> N-(4-Cyano-l-methyl-piperidin-4-yl)-4-cyclohexyl-2-(7-methoxy-2-oxo-2,3-dihydro-benzo[e] [ 1,3] oxazin-4-ylideneamino)-butyramide;<br><br> 2-(7-Methoxy-2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-yldeneamino)-5,5-dimethyl-hexanoic acid(4-cyano-l -propyl-piperidin-4-yl)-amide;<br><br> iV-(4-Cyano-1 -methyl-piperidin-4-yl)-3 -cy clohexyl-2-(2-oxo-2,3 -dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-propionamide;<br><br> 4,4-Dimethyl-2-(2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-pentanoic acid (4-cyano-1 -propyl-piperidin-4-yl)-amide;<br><br> 4,4-Dimethyl-2-(2-oxo-2,3-dihydro- liJ-quinazolin-4-ylideneamino)-pentanoic acid (4-cyano-1 -propyl-piperidin-4-yl)-amide;<br><br> 2-(7-Chloro-2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-4,4-dimethyl-pentanoic acid (4-cyano-l-propyl-piperidin-4-yl)-amide;<br><br> 4,4-Dimethyl-2-( 1 -methyl-2-oxo-1,2-dihydro-quinazolin-4-ylamino)-pentanoic acid (4-cyano-1 -propyl-piperidin-4-yl)-amide;<br><br> N-(4-Cy ano-1 -propyl-piperidin-4-yl)-3 -cyclooctyl-2-(2-oxo-2,3 -dihydro-benzo [e] [ 1,3 ]oxazin-4-ylideneamino)-propionamide;<br><br> iV-(4-Cyano-l-propyl-piperidin-4-yl)-3-cycloheptyl-2-(2-oxo-2,3-dihydro-benzo[e][l,3]oxazin-4-ylideneamino)-propionamide;<br><br> {[ 1 -(4-Cyano-1 -propyl-piperidin-4-ylcarbamoyl)-2-cycloheptyl-ethylimino] -morpholin-4-yl-methyl}-carbamic acid ethyl ester;<br><br> 279<br><br> WO
02/20485<br><br> PCT/US01/08084<br><br> {[ 1 -(4-Cyano-l-propyl-piperidin-4-ylcarbamoyl)-2-cyclooctyl-ethylimino]-morpholin-4-yl-methyl}-carbamic acid ethyl ester;<br><br> ({1 -[ 1 -2-Carbamoyl-ethyl)-4-cyano-piperidin-4-ylcarbamoyl]-2-cyclohexyl-ethylamiiio}-morpholin-4-yl-methylene)-carbamic acid isobutyl ester;<br><br> [(1 - {4-Cyano-1 -[2-(2-methoxyl-ethoxy)-ethyl]-piperidin-4-ylcarbamoyl} -2-cycIohexyl-ethylamino)-morpholin-4-yl-methylene]-carbamic acid isobutyl ester;<br><br> [(1 - {4-Cyano-1 -[3-(2-methoxyl-ethoxy)-propyl] -piperidin-4-ylcarbamoyl} -2-cyclohexyl-ethylamino)-morpholin-4-yl-methylene]-carbamic acid isobutyl ester;<br><br> {[ 1 -(4-Cyano-1 -isopropyl-piperidin-4-ylcarbamoy l)-2-cyclohexyl-ethy iamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester;<br><br> {[ 1 -(4-Cyano-1 -phenethyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino] -morpholin-4-yl-methylene}-carbamic acid ethyl ester;<br><br> {[l-(4-Cyano-1 -ethyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester;<br><br> {[ 1 -(1 -Benzyl-4-cyano-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylaxnino] -morpholin-4-yl-methylene}-carbamic acid ethyl ester;<br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e] [1,3]oxazin-4-ylamino)-pentanoic acid (1 -benzyl-4-cyano-piperidin-4-yI)-amide;<br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e] [1,3] oxazin-4-ylamino)-pentanoic acid [4-cyano-1 -(5-methyl-thiophen-2-yhnethyl)-piperidin-4-yl]-amide;<br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e] [ 1,3] oxazin-4-ylamino)-pentanoic acid [4-cyano-1 -(4-fluoro-benzyl)-piperidin-4-yl]-amide;<br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e] [ 1,3]oxazin-4-ylamino)-pentanoic acid (4-cyano-1 -ethyl-piperidin-4-yl)-amide;<br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-pentanoic acid (4-cyano-1-methyl-piperidin-4-yl)-amide;<br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e] [ 1,3]oxazin-4-ylamino)-pentanoic acid (4-cyano-1 -phenethyl-piperidin-4-yl)-amide;<br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-pentanoic acid [4-cyano-l-(2,2-dimethyl-propyl)-piperidin-4-yl]-amide;<br><br> 280<br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][ 1,3]oxazin-4-ylamino)-pentanoic acid [4-cyano-1 -(3,3 -dimethyl-butyl)-piperidin-4-yl]-amide;<br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-pentanoic acid (4-cyano-l-pentyl-piperidin-4-yl)-amide;<br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-pentaiioic acid (1 -butyl-4-cyano-piperidin-4-yl)-amide;<br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-pentanoic acid [4-cyano-l-(3,3,3-trifluoro-propyl)-piperidin-4-yl]-amide;<br><br> 4,4-Dimethyl-2-(2-oxo-2H-benzo[e][ 1,3]oxazin-4-ylamino)-pentanoic acid (4-cyano-1 -cyclohexylmethyl-piperidin-4-yl)-amide;<br><br> N-(4-Cyano-l-propyl-piperidin-4-yl)-3-(4,4-dimethyl-cyclohexyl)-2-(2-oxo-2H-benzo[e][l ,3]oxazin-4-ylamino)-propionamide;<br><br> {[ 1-(3-Cyano-1-ethyl-pyrrolidin-3-ylcarb amoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester;<br><br> N-(4-Cyano-1 -methyl-piperidin-4-yl)-3-cyclohexyl-2-(7,8-difluoro-2 -oxo-2H-benzo[e][l,3]oxazin-4-ylamino)-propionamide;<br><br> {[ 1 -(4-Cyano-1 -cyclohexylmethyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid ethyl ester;<br><br> {[l-(4-Cyano-l-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid 4-methoxy-cyclohexylmethyl ester;<br><br> {[ 1 -(4-Cyano-l -methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethylamino]-morpholin-4-yl-methylene}-carbamic acid cyclohexyl ester;<br><br> {[ 1 -(4-Cyano-1 -propyl-piperidin-4-ylcarbamoyl)-3,3 -dimethyl-butylaminoj-phenyl-methylene}-carbamic acid ethyl ester;<br><br> and<br><br> {[ 1 -(4-Cyano-l -methyl-piperidin-4-ylcarb amoyl)-2-cyclohexyl-ethylamino]-phenyl-methylene}-carbamic acid ethyl ester;<br><br> and all tautomeric forms of any thereof.<br><br> 281<br><br> 5. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound according to claims 1 or 2.<br><br> 6. A compound as defined in claim 1 or claim 2 for the treatment of an autoimmune disease.<br><br> 7. A compound as defined in claim 1 or claim 2 for the treatment of rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, multiple sclerosis, Guillain-Barre syndrome, psoriasis, Grave's disease, myasthenia gravis, scleroderma, glomerulonephritis, dermatitis, endometriosis or insulin-dependent diabetes mellitus.<br><br> 8. A compound as defined in claim 1 or claim 2 for the treatment of Alzheimer's disease.<br><br> 9. A compound as defined in claim 1 or claim 2 for the treatment of atherosclerosis.<br><br> 10. A compound as defined in claim 1 or claim 2 for the treatment of osteoporosis.<br><br> 11. A compound as defined in claim 1 or claim 2 for the treatment of asthma.<br><br> 12. Use of a compound as claimed in claim 1 or claim 2 for the manufacture of a medicament for the treatment of an autoimmune disease.<br><br> 13. Use of a compound as claimed in claim 1 or claim 2 for the manufacture of a medicament for the treatment of rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, multiple sclerosis, Guillain-Barre syndrome, psoriasis, Grave's disease,<br><br> 282<br><br> myasthenia gravis, scleroderma, glomerulonephritis, dermatitis, endometriosis or insulin-dependent diabetes mellitus.<br><br> 14. Use of a compound as claimed in claim 1 or claim 2 for the manufacture of a medicament for the treatment of Alzheimer's disease.<br><br> 15. Use of a compound as claimed in claim 1 or claim 2 for the manufacture of a medicament for the treatment of astherosclerosis.<br><br> 16. Use of a compound as claimed in claim 1 or claim 2 for the manufacture of a medicament for the treatment of osteoporosis.<br><br> 17. Use of a compound as claimed in claim 1 or claim 2 for the manufacture of a medicament for the treatment of asthma.<br><br> 18. A compound as claimed in any one of claims 1 -4 substantially as described herein with reference to the Examples.<br><br> 19. A pharmaceutical composition as claimed in claim 5 substantially as described herein with reference to the Examples.<br><br> 283<br><br> 20. Process for the manufacture of a compound as claimed in claim 1 or 2 wherein a) a dipeptide nitrile intermediate (HI), wherein R2, R3, R4 and R5 and Het are all as defined 5 in claim 1<br><br> R2 R3 R4<br><br> ,NL XN<br><br> 10<br><br> HN"<br><br> R4 X nHet^-R5<br><br> m or a basic salt thereof, is allowed to react with compound (VIII), wherein RI and R6 are as defined in claim 1<br><br> 15<br><br> Rgftv<br><br> N<br><br> 20<br><br> Rf S<br><br> (vnt)<br><br> in the presence of a suitable coupling agent to provide the desired product of formula 1(a) N R R R4<br><br> 11 2\ / 3 | 4<br><br> .CN<br><br> -,-Vvx*<br><br> R4 X ^Hety-Rs<br><br> 30<br><br> (la)<br><br> as defined in claim 1 or one of its tautomeric forms; or<br><br> 35<br><br> rs<br><br> 40<br><br> 284<br><br> 5<br><br> b) a dipeptide nitrile intermediate (HI), or a basic salt thereof, is allowed to react with (IX), wherein RI and R6 are as defined in claim 1 and R is an alkyl or aryl group<br><br> 10<br><br> 15<br><br> 40<br><br> N<br><br> Rf OR (IX)<br><br> with or without an added base such as triethylamine, to provide the desired product of formula (la) as defined in claim 1 or one of its tautomeric forms; or<br><br> 20 c) a dipeptide nitrile intermediate (UT), or a basic salt thereof, is allowed to react with intermediate (X) wherein RI and R6 are as defined in claim 1 and X is a halogen or other suitable leaving group<br><br> 25 fVvN<br><br> Rf X'<br><br> 30 (X)<br><br> with or without an added base such as triethylamine, to provide the desired product of formula (la) as defined in claim 1 or one of its tautomeric forms; or d) a carbodiimide (XI) derivative of (HI)<br><br> R2 R3 R4<br><br> N..CN<br><br> VHet-)-<br><br> XI<br><br> R6— N=c=W ^<br><br> X l&gt;leH"R5'<br><br> wherein R2, R3, R4, R5 and R6 are all as defined in claim 1 is allowed to react with an amine RI as defined in claim 1 to provide the desired guanidine product of formula (la) of 45 claim 1 or one of its tautomeric forms.<br><br> END OF CLAIMS<br><br> 2oj<br><br> - r<br><br> </p> </div>
NZ525169A 2000-09-08 2001-03-14 Spiroheterocyclic nitriles (amidino and guanidino peptidyl compounds) useful as reversible inhibitors of cysteine proteases NZ525169A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/655,351 US6420364B1 (en) 1999-09-13 2000-09-08 Compound useful as reversible inhibitors of cysteine proteases
PCT/US2001/008084 WO2002020485A1 (en) 2000-09-08 2001-03-14 Spiroheterocyclic nitriles useful as reversible inhibitors of cysteine proteases

Publications (1)

Publication Number Publication Date
NZ525169A true NZ525169A (en) 2004-11-26

Family

ID=24628539

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ525169A NZ525169A (en) 2000-09-08 2001-03-14 Spiroheterocyclic nitriles (amidino and guanidino peptidyl compounds) useful as reversible inhibitors of cysteine proteases

Country Status (25)

Country Link
US (10) US6420364B1 (en)
EP (1) EP1322613A1 (en)
JP (1) JP2004508356A (en)
KR (1) KR20030051644A (en)
CN (1) CN1303067C (en)
AU (1) AU2001245694A1 (en)
BG (1) BG107585A (en)
BR (1) BR0113740A (en)
CA (1) CA2417177A1 (en)
CZ (1) CZ2003603A3 (en)
EA (1) EA005203B1 (en)
EE (1) EE200300093A (en)
HK (1) HK1060565A1 (en)
HR (1) HRP20030163A2 (en)
HU (1) HUP0303934A2 (en)
IL (1) IL154080A0 (en)
MX (1) MXPA03001947A (en)
NO (1) NO20031065D0 (en)
NZ (1) NZ525169A (en)
PL (1) PL361038A1 (en)
SK (1) SK2862003A3 (en)
UA (1) UA73378C2 (en)
WO (1) WO2002020485A1 (en)
YU (1) YU17003A (en)
ZA (1) ZA200301032B (en)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9723407D0 (en) * 1997-11-05 1998-01-07 Ciba Geigy Ag Organic compounds
AU3731400A (en) * 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Methods and compositions useful in inhibiting apoptosis
US6420364B1 (en) * 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
US6773704B1 (en) * 1999-10-28 2004-08-10 The Brigham And Women's Hospital, Inc. Methods of treating vascular disease associated with cystatin C deficiency
GB0003111D0 (en) * 2000-02-10 2000-03-29 Novartis Ag Organic compounds
US7064123B1 (en) 2000-12-22 2006-06-20 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
CA2439415C (en) * 2001-03-02 2011-09-20 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
US6982263B2 (en) * 2001-06-08 2006-01-03 Boehringer Ingelheim Pharmaceuticals, Inc. Nitriles useful as reversible inhibitors of cysteine proteases
DE10141650C1 (en) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Safe transdermal therapeutic system for administration of fentanyl or analogous analgesics, having matrix layer of carboxy group-free polyacrylate adhesive providing high permeation rate
IL160819A0 (en) 2001-09-14 2004-08-31 Aventis Pharma Inc Novel compounds and compositions as cathepsin inhibitors
EP1434769A2 (en) * 2001-10-02 2004-07-07 Boehringer Ingelheim Pharmaceuticals Inc. Compounds useful as reversible inhibitors of cysteine proteases
WO2003037892A1 (en) * 2001-10-29 2003-05-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cysteine proteases
US6977256B2 (en) 2001-11-14 2005-12-20 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin S inhibitors
AU2003256305A1 (en) * 2002-06-24 2004-01-06 Axys Pharmaceuticals, Inc. Peptidic compounds as cysteine protease inhibitors
US7326690B2 (en) * 2002-10-30 2008-02-05 Bach Pharma, Inc. Modulation of cell fates and activities by phthalazinediones
US7465745B2 (en) * 2003-03-13 2008-12-16 Boehringer Ingelheim Pharmaceuticals, Inc. Cathepsin S inhibitors
US7326719B2 (en) * 2003-03-13 2008-02-05 Boehringer Ingelheim Pharmaceuticals, Inc. Cathepsin S inhibitors
US7109243B2 (en) * 2003-03-24 2006-09-19 Irm Llc Inhibitors of cathepsin S
US7384970B2 (en) * 2003-03-24 2008-06-10 Irm Llc Inhibitors of cathepsin S
WO2004089395A2 (en) * 2003-04-01 2004-10-21 Aventis Pharmaceuticals Inc. Use of an inhibitor of cathepsin-s or -b to treat or prevent chronic obstructive pulmonary disease
US7662849B2 (en) * 2003-06-04 2010-02-16 Virobay, Inc. Amidino compounds as cysteine protease inhibitors
US7173051B2 (en) * 2003-06-13 2007-02-06 Irm, Llc Inhibitors of cathepsin S
US7256207B2 (en) 2003-08-20 2007-08-14 Irm Llc Inhibitors of cathepsin S
KR20060079143A (en) * 2003-09-18 2006-07-05 액시스 파마슈티컬스 인코포레이티드 Haloalkyl containing compounds as cysteine protease inhibitors
CA2543884A1 (en) * 2003-10-30 2005-05-19 Boehringer Ingelheim Pharmaceuticals, Inc. Dipeptide-analogue synthesis
UY28645A1 (en) * 2003-12-03 2005-06-30 Glaxo Group Ltd NEW ANTAGONISTS OF THE M3 ACETILCOLINE MUSCARINIC RECEPTOR
EP1694357A1 (en) * 2003-12-11 2006-08-30 Axys Pharmaceuticals, Inc. Use of cathepsin s inhibitors for treating an immune response caused by administration of a small molecule therapeutic or biologic
CA2548600A1 (en) * 2003-12-12 2005-06-23 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
EP1697355A2 (en) * 2003-12-23 2006-09-06 Axys Pharmaceuticals, Inc. Amidino compounds as cysteine protease inhibitors
WO2006060810A1 (en) * 2004-12-02 2006-06-08 Schering Aktiengesellschaft Sulfonamide compounds as cysteine protease inhibitors
WO2006076797A1 (en) * 2005-01-19 2006-07-27 Merck Frosst Canada Ltd. Cathepsin k inhibitors and atherosclerosis
EP1865940B1 (en) 2005-03-21 2013-02-13 Virobay, Inc. Alpha ketoamide compounds as cysteine protease inhibitors
CA2602112A1 (en) * 2005-03-22 2006-09-28 Celera Genomics Sulfonyl containing compounds as cysteine protease inhibitors
US7282964B2 (en) * 2005-05-25 2007-10-16 Texas Instruments Incorporated Circuit for detecting transitions on either of two signal lines referenced at different power supply levels
KR20080028881A (en) * 2005-06-14 2008-04-02 쉐링 코포레이션 Heterocyclic aspartyl protease inhibitors, preparation and use thereof
US8067415B2 (en) * 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
WO2007053498A1 (en) * 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
WO2007053495A2 (en) * 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
EP1951706A1 (en) 2005-11-01 2008-08-06 Janssen Pharmaceutica N.V. Dihydroisoindolones as allosteric modulators of glucokinase
SG172661A1 (en) * 2006-06-01 2011-07-28 Sanofi Aventis Spirocyclic nitriles as protease inhibitors
US8652844B2 (en) 2006-06-13 2014-02-18 The Curators Of The University Of Missouri Methods for the cryopreservation of animal cells that contain high levels of intracellular lipids
US8063082B2 (en) * 2006-08-02 2011-11-22 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US8071625B2 (en) * 2006-08-02 2011-12-06 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
EA022130B1 (en) * 2006-10-04 2015-11-30 Вайробей, Инк. Di-fluoro containing compounds as cysteine protease inhibitors
US7893112B2 (en) 2006-10-04 2011-02-22 Virobay, Inc. Di-fluoro containing compounds as cysteine protease inhibitors
KR100877394B1 (en) 2007-07-11 2009-01-07 한국화학연구원 Pharmaceutical composition for treating or preventing osteoporosis and gingivitis comprising carbonitrile compounds
AU2008276512A1 (en) * 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of PKB
JP2010533715A (en) 2007-07-17 2010-10-28 アムジエン・インコーポレーテツド Heterocyclic PKB regulator
MX2010001692A (en) 2007-08-15 2010-04-22 Cytokinetics Inc Certain chemical entities, compositions, and methods.
EP2222636B1 (en) 2007-12-21 2013-04-10 Ligand Pharmaceuticals Inc. Selective androgen receptor modulators (sarms) and uses thereof
WO2009087379A2 (en) 2008-01-09 2009-07-16 Amura Therapeutics Limited Tetrahydrofuro (3, 2 -b) pyrrol- 3 -one derivatives as inhibitors of cysteine proteinases
MY156789A (en) * 2008-09-05 2016-03-31 Celgene Avilomics Res Inc Algorithm for designing irreversible inhibitors
US20120088791A1 (en) * 2009-02-19 2012-04-12 Vanderbilt University Amidobipiperidinecarboxylate m1 allosteric agonists, analogs and derivatives thereof, and methods of making and using same
US8324417B2 (en) 2009-08-19 2012-12-04 Virobay, Inc. Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof
SG179172A1 (en) 2009-09-16 2012-04-27 Avila Therapeutics Inc Protein kinase conjugates and inhibitors
SG181965A1 (en) 2009-12-30 2012-08-30 Avila Therapeutics Inc Ligand-directed covalent modification of protein
US8680152B2 (en) 2011-05-02 2014-03-25 Virobay, Inc. Cathepsin inhibitors for the treatment of bone cancer and bone cancer pain
EP2719693B1 (en) 2011-06-07 2016-08-10 Kureha Corporation Method for manufacturing oxetane compound, method for manufacturing azolylmethylcyclopentanol compound, and intermediate compound
EP2537532A1 (en) 2011-06-22 2012-12-26 J. Stefan Institute Cathepsin-binding compounds bound to a nanodevice and their diagnostic and therapeutic use
CA2856076C (en) 2011-11-18 2020-02-25 Heptares Therapeutics Limited Muscarinic m1 receptor agonists
WO2014111113A1 (en) 2013-01-15 2014-07-24 Merck Patent Gmbh Acylguanidines for treating osteoarthritis
US10441567B2 (en) 2014-01-17 2019-10-15 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
US10259787B2 (en) * 2016-10-14 2019-04-16 Heptares Therapeutics Limited Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
CN111943848B (en) * 2020-08-19 2023-05-05 苏州旺山旺水生物医药有限公司 Preparation method and application of elexacator intermediate

Family Cites Families (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3467691A (en) 1964-04-22 1969-09-16 Tsutomu Irikura N-(n-acylaminoacyl)-aminoacetonitriles
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
JPS4310619Y1 (en) 1967-02-16 1968-05-09
EP0115472A3 (en) 1983-01-27 1985-10-02 Ciba-Geigy Ag Pyrrolidinon derivatives and process for their preparation
US4767202A (en) * 1984-01-20 1988-08-30 Minolta Camera Kabushiki Kaisha Objective lens system for optical recording type disks
JPS61502124A (en) * 1984-05-09 1986-09-25 ジ　オ−ストラリアン　ナシヨナル　ユニヴア−シテイ− How to modulate the immune response
US4797202A (en) 1984-09-13 1989-01-10 The Dow Chemical Company Froth flotation method
US4737425A (en) * 1986-06-10 1988-04-12 International Business Machines Corporation Patterned resist and process
JPS6358346A (en) 1986-08-29 1988-03-14 Fuji Photo Film Co Ltd Color photographic developing solution composition and method for processing silver halide photographic sensitive material
US4734425A (en) 1986-10-17 1988-03-29 E. R. Squibb & Sons, Inc. 7-oxabicycloheptane substituted hydroxamic acid prostaglandin analogs
US4749715A (en) 1987-03-02 1988-06-07 E. R. Squibb & Sons, Inc. 7-oxabicycloheptane substituted amino prostaglandin analogs
FR2615104B1 (en) 1987-05-14 1989-08-18 Centre Nat Rech Scient NOVEL PLASMODIUM FALCIPARUM PROTEASE, ANTIBODIES AGAINST THIS PROTEASE, PEPTIDE SUBSTRATES SPECIFIC TO SAID PROTEASE, AND THEIR USE AS MEDICAMENTS AGAINST MALARIA
JPS63301868A (en) 1987-06-01 1988-12-08 Nippon Kayaku Co Ltd N-(2-chloroisonicotinoyl)amino acid derivative and agricultural and horticultural fungicide comprising said derivative as active ingredient
DE3719226A1 (en) 1987-06-09 1988-12-22 Bayer Ag (2-CYAN-2-OXIMINOACETYL) AMINO ACID DERIVATIVES
US4971978A (en) 1987-09-21 1990-11-20 Nadzan Alex M Derivatives of D-glutamic acid and D-aspartic acid
WO1989003841A1 (en) 1987-10-26 1989-05-05 Warner-Lambert Company Renin inhibitors, processes for preparing them, methods for using them, and compositions containing them
US4962117A (en) 1987-11-25 1990-10-09 Merck Frosst Canada, Inc. Heterazole dialkanoic acids
US4957932A (en) 1987-11-25 1990-09-18 Merck Frosst Canada, Inc. Benzoheterazoles
CA1322004C (en) 1987-11-25 1993-09-07 Merck Frosst Canada Incorporated Pyridyl styrene dialkanoic acids
JPH03503650A (en) 1988-04-05 1991-08-15 アボツト・ラボラトリーズ Tryptophan derivatives as CCK antagonists
US5346907A (en) 1988-04-05 1994-09-13 Abbott Laboratories Amino acid analog CCK antagonists
AU3570089A (en) 1988-05-03 1989-11-29 Upjohn Company, The Renin inhibitory peptides containing a substituted phenoxyacetyle group
DE3827727A1 (en) 1988-08-16 1990-02-22 Boehringer Ingelheim Kg ANALYZED TETRAHYDROPYRIDINE IGNESE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE OF SUCH CONNECTIONS FOR CARDIRO PROTECTION
EP0374098A3 (en) 1988-12-15 1991-05-02 Ciba-Geigy Ag Inhibitors of retroviral proteases
US5270302A (en) 1988-12-21 1993-12-14 Abbott Laboratories Derivatives of tetrapeptides as CCK agonists
GB8909836D0 (en) 1989-04-28 1989-06-14 Boots Co Plc Therapeutic agent
DE3915755A1 (en) 1989-05-13 1990-11-29 Bayer Ag FUNGICIDAL AGENTS AND SUBSTITUTED AMINO ACID DERIVATIVES AND THE PRODUCTION THEREOF
US5504109A (en) 1989-05-13 1996-04-02 Bayer Aktiengesellschaft Susbstituted amino acid amide derivatives their preparation and use
US5196291A (en) 1989-05-24 1993-03-23 Fuji Photo Film Co., Ltd. Silver halide photographic material
JP2658004B2 (en) 1989-05-31 1997-09-30 キヤノン株式会社 Electrophotographic photoreceptor
JPH0462788A (en) 1990-06-30 1992-02-27 Toshiba Corp Microwave oven
FR2665159B1 (en) 1990-07-24 1992-11-13 Rhone Poulenc Sante NEW PYRIDINE AND QUINOLEIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
JPH06145173A (en) 1990-08-21 1994-05-24 Fujisawa Pharmaceut Co Ltd 1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid compound
JPH0511439A (en) 1990-09-13 1993-01-22 Fuji Photo Film Co Ltd Photopolymerizable composition
DE4035961A1 (en) 1990-11-02 1992-05-07 Thomae Gmbh Dr K CYCLIC IMINODERIVATES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
AU9042191A (en) 1990-12-07 1992-07-08 Dyno Industrier A.S. System for utilization of wave energy
DE4104257A1 (en) 1991-02-13 1992-08-20 Boehringer Ingelheim Kg USE OF ANALYZED TETRAHYDROPYRIDINE IGNESE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL ILLNESSES
US5206249A (en) 1991-03-27 1993-04-27 Du Pont Merck Pharmaceutical Company Bis-naphthalimides containing amino-acid derived linkers as anticancer agents
US5461176A (en) 1991-03-27 1995-10-24 The Du Pont Merck Pharmaceutical Company Processes for preparing bis-naphthalimides containing amino-acid derived linkers
US5190922A (en) 1991-06-04 1993-03-02 Abbott Laboratories Terminally modified tri-, tetra- and pentapeptide anaphylatoxin receptor ligands
EP0668870A1 (en) 1991-06-14 1995-08-30 Chiron Corporation Inhibitors of picornavirus proteases
US5250732A (en) 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
US5298377A (en) 1991-08-28 1994-03-29 Eastman Kodak Company Photographic element with 2-equivalent magenta dye-forming coupler and filter dye
US5215876A (en) 1991-08-29 1993-06-01 Eastman Kodak Company Radiographic element with uv absorbation compound in polyester support
US5204349A (en) 1991-09-16 1993-04-20 Merck & Co., Inc. Amide-substituted derivatives of spiroindanylcamphorsulfonyl oxytocin antagonists
JP2947539B2 (en) 1991-11-12 1999-09-13 コニカ株式会社 Silver halide photographic material
WO1993012075A1 (en) 1991-12-10 1993-06-24 Shionogi & Co., Ltd. Hydroxamic acid derivative based on aromatic sulfonamide
EP0547699A1 (en) 1991-12-19 1993-06-23 Merck & Co. Inc. Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme
GB9200209D0 (en) 1992-01-07 1992-02-26 British Bio Technology Compounds
US5218123A (en) 1992-02-18 1993-06-08 Warner-Lambert Company Didehydrotryptophan derivatives and pharmaceutical use thereof
US5831002A (en) 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
JPH063787A (en) 1992-06-18 1994-01-14 Konica Corp Solid color developing agent for silver halide photographic sensitive material and processing method using that solid color developing agent
WO1994000435A1 (en) 1992-06-22 1994-01-06 Boehringer Ingelheim Kg Ring-closed dihydropyridines and their use in the preparation of pharmaceutical compositions
FR2694006A1 (en) 1992-07-22 1994-01-28 Esteve Labor Dr New amide derivs. of benzo-hetero cyclic cpds. - for treating gastrointestinal disorders, including ulcers and gastric hypersecretion
DE4225487A1 (en) 1992-07-30 1994-02-03 Schering Ag New bi:cyclooctane carbacyclin analogues - useful as thromboxane-A2 and prostaglandin H2 antagonists
JPH0651451A (en) 1992-07-31 1994-02-25 Konica Corp Solid treating agent for silver halide photographic sensitive material
JP3168547B2 (en) 1992-08-18 2001-05-21 日本製粉株式会社 Mix for potato dough, method for producing potato dough, and fried food using potato dough
JP3283114B2 (en) 1992-09-07 2002-05-20 クミアイ化学工業株式会社 Condensed heterocyclic derivatives and agricultural and horticultural fungicides
US5389682A (en) 1992-09-18 1995-02-14 Warner-Lambert Company Agents acting at cholecystokinin receptors
DE4232505A1 (en) 1992-09-29 1994-03-31 Degussa Process for the reduction of carboxylic acids or carboxylic acid derivatives and new compounds
ES2150933T3 (en) 1992-12-22 2000-12-16 Lilly Co Eli HIV PROTEASE INHIBITORS USEFUL FOR THE TREATMENT OF AIDS.
DE4303145A1 (en) 1993-01-30 1994-08-04 Schering Ag New phenylene-substd. 2-oxa-bicyclo(2.2.1)heptane TXA2 antagonists
JP2848232B2 (en) 1993-02-19 1999-01-20 武田薬品工業株式会社 Aldehyde derivatives
WO1994021657A1 (en) 1993-03-18 1994-09-29 Pfizer Inc. Antibacterial 16-membered ring macrolides containing olefins at c-20
AU6697694A (en) 1993-03-29 1994-10-24 Du Pont Merck Pharmaceutical Company, The A process and intermediate compounds useful for the preparation of platelet glycoprotein IIb/IIIa inhibitors containing N alpha--methylarginine
JPH06340643A (en) 1993-04-04 1994-12-13 Nippon Nohyaku Co Ltd Oxazole or thiazole derivative, its production and herbicide
JP3165760B2 (en) 1993-04-12 2001-05-14 株式会社トクヤマ New compound
US5658885A (en) 1993-04-27 1997-08-19 The Dupont Merck Pharmaceutical Company Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes
RU2128186C1 (en) 1993-04-28 1999-03-27 Кумиай Кемикал Индастри Ко., Лтд. Amino acid amide derivatives, method of preparing fungicidal composition for agriculture or horticulture
JPH0789951A (en) 1993-06-03 1995-04-04 Sterling Winthrop Inc Interleukin-1 beta transfer enzyme inhibitor
DE4321897A1 (en) 1993-07-01 1995-01-12 Hoechst Schering Agrevo Gmbh Substituted amino acid derivatives, processes for their preparation, compositions comprising them, and their use
US5514778A (en) 1993-07-01 1996-05-07 Eli Lilly And Company Anti-picornaviral agents
DE4322067A1 (en) 1993-07-02 1995-01-12 Hoechst Schering Agrevo Gmbh Acylated aminophenylsulfonylureas; Representation and use as herbicides and growth regulators
CH686479A5 (en) 1993-08-11 1996-04-15 Nestle Sa food product has fast rehydration and process for its preparation.
US5554753A (en) 1993-08-25 1996-09-10 Indiana University Foundation Catalytic enantioselective synthesis of α-amino acid derivatives by phase-transfer catalysis
JPH07101959A (en) 1993-09-30 1995-04-18 Sankyo Co Ltd 1-methylcarbapenem derivative
HU221629B1 (en) 1993-10-01 2002-12-28 Merrell Pharmaceuticals Inc. Peptides as inhibitors of beta-amyloid protein production, process for their preparation and pharmaceutical compositions comprising thereof
IT1270882B (en) 1993-10-05 1997-05-13 Isagro Srl FUNGICIDE-BASED OLIGOPEPTIDES
JP3075657B2 (en) 1993-10-15 2000-08-14 富士写真フイルム株式会社 Photographic processing composition and processing method
AU691201B2 (en) 1993-11-01 1998-05-14 Japat Ltd. Endothelin receptor antagonists
US5486623A (en) 1993-12-08 1996-01-23 Prototek, Inc. Cysteine protease inhibitors containing heterocyclic leaving groups
DE4343528A1 (en) 1993-12-16 1995-06-22 Schering Ag New di-heterocyclyl-benzene or pyridine derivs.
IL112759A0 (en) 1994-02-25 1995-05-26 Khepri Pharmaceuticals Inc Novel cysteine protease inhibitors
ATE195933T1 (en) 1994-03-10 2000-09-15 Searle & Co L-N6-(1-IMINOETHYL)LYSINE DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS
ES2108504T3 (en) 1994-03-19 1997-12-16 Basf Ag AMIDES OF THE CARBAMOILOXIMCARBOXILICO ACID FUNGICIDES.
JPH07285931A (en) 1994-04-19 1995-10-31 Tokuyama Corp New compound
DE4415049A1 (en) 1994-04-29 1995-11-02 Hoechst Schering Agrevo Gmbh Acylated aminophenylsulfonylureas, process for their preparation and use as herbicides and growth regulators
DE4419517A1 (en) 1994-06-03 1995-12-07 Basf Ag Substituted 3-phenylpyrazoles
US5847135A (en) 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
DE4431467A1 (en) 1994-09-03 1996-03-07 Basf Ag Caramoylcarboxamides
KR970706242A (en) 1994-10-04 1997-11-03 후지야마 아키라 Urea derivatives and their use as ACAT-inhibitors (Urea derivatives and their use as ACAT-inhibitors)
ATE204277T1 (en) 1994-10-26 2001-09-15 Upjohn Co PHENYLOXAZOLIDINONE WITH ANTIMICROBIAL EFFECT
CA2163325A1 (en) 1994-11-21 1996-05-22 Kaneyoshi Kato Amine compounds, their production and use
US5869501A (en) 1994-12-02 1999-02-09 Yamanouchi Pharmaceutical Co. Ltd Amidinonaphthyl derivative or salt thereof
US6017887A (en) 1995-01-06 2000-01-25 Sibia Neurosciences, Inc. Peptide, peptide analog and amino acid analog protease inhibitors
US5804560A (en) 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US5691368A (en) 1995-01-11 1997-11-25 Hoechst Marion Roussel, Inc. Substituted oxazolidine calpain and/or cathepsin B inhibitors
DE19501841A1 (en) 1995-01-23 1996-07-25 Bayer Ag Amino acid amides
DE19505932B4 (en) 1995-02-21 2005-06-23 Degussa Ag Process for the preparation of oxazolidinones, new oxazolidinones and use of oxazolidinones
US5710129A (en) 1995-02-23 1998-01-20 Ariad Pharmaceuticals, Inc. Inhibitors of SH2-mediated processes
JPH08248579A (en) 1995-03-14 1996-09-27 Mitsubishi Paper Mills Ltd Silver halide photographic sensitive material and its processing method
US5776718A (en) * 1995-03-24 1998-07-07 Arris Pharmaceutical Corporation Reversible protease inhibitors
JPH11503417A (en) 1995-03-24 1999-03-26 アリス・ファーマシューティカル・コーポレイション Reversible protease inhibitor
IL117940A (en) 1995-04-19 2003-06-24 Kumiai Chemical Industry Co Benzylsulfide derivatives, process for their production and insecticide compositions containing them
GB9508195D0 (en) 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
EP0821670A1 (en) 1995-04-21 1998-02-04 Novartis AG N-aroylamino acid amides as endothelin inhibitors
JPH08319291A (en) 1995-05-25 1996-12-03 Meiji Seika Kaisha Ltd New cephem derivative
MX9709875A (en) 1995-06-06 1998-03-31 Pfizer Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors.
US5756528A (en) 1995-06-06 1998-05-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5827866A (en) 1995-06-07 1998-10-27 Ortho Pharmaceutical Corporation Peptidyl heterocycles useful in the treatment of thrombin related disorders
WO1996040753A1 (en) 1995-06-07 1996-12-19 G.D. Searle & Co. Pipecolic acid derivatives of proline threonine amides useful for the treatment of rheumatoid arthritis
TW438591B (en) * 1995-06-07 2001-06-07 Arris Pharm Corp Reversible cysteine protease inhibitors
US6069130A (en) 1995-06-07 2000-05-30 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
US5827860A (en) 1995-06-07 1998-10-27 Ortho Pharmaceutical Corporation Peptidyl heterocycles useful in the treatment of thrombin related disorders
EP0836383A1 (en) 1995-06-29 1998-04-22 Merck & Co., Inc. Combinations of inhibitors of farnesyl-protein transferase
WO1997003093A1 (en) 1995-07-07 1997-01-30 Sagami Chemical Research Center Peptide derivatives and angiotensin iv receptor agonist
GB9518552D0 (en) 1995-09-11 1995-11-08 Fujisawa Pharmaceutical Co New heterocyclic compounds
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
AU7710596A (en) 1995-11-29 1997-06-19 Nihon Nohyaku Co., Ltd. Phenylalanine derivatives, optically active substances, salts or coordination compounds thereof, and their use as fungicides
TW474946B (en) 1995-12-15 2002-02-01 Basf Ag Novel compounds, the preparation and use thereof
US5843904A (en) 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
NZ331104A (en) 1995-12-29 2000-03-27 Boehringer Ingelheim Ca Ltd Phenyl thiazole derivatives that inhibit herpes replication by inhibiting the herpes helicase primase enzyme complex
US6008372A (en) 1996-01-16 1999-12-28 Warner-Lambert Company Substituted dinaphthylmethyl and diheteroarylmethylacetyl histidine inhibitors of protein farnesyltransferase
WO1997027200A1 (en) 1996-01-26 1997-07-31 Smithkline Beecham Plc Thienoxazinone derivatives useful as antiviral agents
US6288037B1 (en) 1996-01-29 2001-09-11 Basf Aktiengesellschaft Substrates and inhibitors for cysteine protease ICH-1
WO1997031016A2 (en) 1996-02-23 1997-08-28 Ariad Pharmaceuticals, Inc. New inhibitors of sh2-mediated processes
DE19609955A1 (en) 1996-03-14 1997-09-18 Basf Ag Amido-nitrile derivatives
CA2204082A1 (en) 1996-05-03 1997-11-03 Michael William John Urquhart Pharmaceutical compounds
DE19621483A1 (en) 1996-05-29 1997-12-04 Hoechst Ag Substituted 2-naphthoylguanidines, processes for their preparation, their use as medicaments or diagnostic agents and medicaments containing them
DE19621522A1 (en) 1996-05-29 1997-12-04 Hoechst Schering Agrevo Gmbh New N-acylsulfonamides, new mixtures of herbicides and antidots and their use
US6124345A (en) 1996-05-31 2000-09-26 Basf Aktiengesellschaft Carbamoyl carboxylic acid amide oximes
DE19629717C1 (en) 1996-07-25 1998-02-12 Hoechst Ag Process for the catalytic production of N-acylglycine derivatives
US5939527A (en) 1996-07-30 1999-08-17 Basf Aktiengesellschaft Tetrapeptides as antitumor agents
DE69732780T2 (en) 1996-10-02 2006-04-06 Novartis Ag PYRIMIDERIVATES AND METHOD FOR THE PRODUCTION THEREOF
PL194025B1 (en) 1996-10-18 2007-04-30 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
EP0844248B1 (en) 1996-10-28 2002-07-10 Rolic AG Crosslinkable, photoactive silane derivatives
WO1998021199A2 (en) 1996-11-12 1998-05-22 Novartis Ag Pyrazole derivatives useful as herbicides
ID22499A (en) 1996-11-22 1999-10-21 Elan Pharmaceuticals Inc Cs AMINO N-AMIDA (ARIL / HETEROARIL / ALCILACETYL) AMINO, PHARMACY COMPOSITION CONSISTING FROM AMINO ACID AMIDO, AND METHODS TO RESPOND TO THE B-AMILOID PEPTIDES AND / OR THE MAKING OF THESE PEOPLE.
US5952322A (en) 1996-12-05 1999-09-14 Pfizer Inc. Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
AU5522498A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
WO1998026654A2 (en) 1996-12-19 1998-06-25 Isagro S.P.A. Fungicidal compositions based on (n-phenylacetyl-n-2,6-xylyl)methyl alaninate
DE19653647A1 (en) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin receptor antagonists, their preparation and their use
CA2275796A1 (en) 1996-12-23 1998-07-02 Donald Joseph Phillip Pinto Nitrogen containing heteroaromatics as factor xa inhibitors
AR011164A1 (en) 1997-02-28 2000-08-02 Lilly Co Eli HETEROCICLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM, AND METHODS TO INHIBIT THE RELEASE OF THE BETA-AMYLOID PEPTIDE AND / OR ITS SYNTHESIS THROUGH THE USE OF SUCH COMPOUNDS
FR2762315B1 (en) 1997-04-22 1999-05-28 Logeais Labor Jacques AMINO ACID DERIVATIVES INHIBITOR OF EXTRACELLULAR MATRIX METALLOPROTEASES AND TNF ALPHA RELEASE
AU7726898A (en) 1997-05-22 1998-12-11 G.D. Searle & Co. Pyrazole derivatives as p38 kinase inhibitors
CA2291065C (en) 1997-05-23 2010-02-09 Bayer Corporation Raf kinase inhibitors
PT1019040E (en) 1997-05-23 2005-01-31 Bayer Pharmaceuticals Corp INHIBITION OF THE ACTIVITY OF P38-KINASE BY MEANS OF ARILUREIAS
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
ES2239806T3 (en) 1997-06-19 2005-10-01 Bristol-Myers Squibb Pharma Company XA FACTOR INHIBITORS WITH A P1 NEUTRAL SPECIFICITY GROUP.
EP0897908A1 (en) 1997-08-19 1999-02-24 Roche Diagnostics GmbH 3-Aryl-succinamido-hydroxamic acids, process for their preparation and medicaments containing them
JP3002872B2 (en) 1997-09-05 2000-01-24 ヒエン電工株式会社 Threading device for helical support for cable suspension
JPH11100373A (en) 1997-09-26 1999-04-13 Eisai Co Ltd New phenothiazine derivative and its medicine
US5872122A (en) 1997-10-16 1999-02-16 Monsanto Company Pyrimidinylamidino β-amino acid derivatives useful as inhibitors of platelet aggregation
DK1027328T3 (en) 1997-10-31 2006-11-13 Aventis Pharma Ltd Substituted anilides
JP4450988B2 (en) 1997-11-05 2010-04-14 ノバルティス アーゲー Dipeptide nitrile
KR100571588B1 (en) 1997-12-22 2006-04-17 바이엘 코포레이션 Inhibition of RAF Kinase with Substituted Heterocyclic Urea
UA67763C2 (en) 1997-12-22 2004-07-15 Байер Фармасьютікалс Корпорейшн Compound and method for inhibition of raf kinase with use of aryl and heteroaryl substituted heterocyclic urea compounds
HUP0101963A3 (en) 1998-05-05 2003-07-28 Basf Ag Succinamide inhibitors of interleukin-1betha converting enzyme
CA2360740A1 (en) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
SK12882001A3 (en) 1999-03-15 2002-04-04 Axys Pharmaceuticals, Inc. N-cyanomethylamides as protease inhibitors
EP1136575A4 (en) * 1999-08-10 2008-04-23 Jfe Steel Corp Method of producing cold rolled steel sheet
JP2003529546A (en) * 1999-09-13 2003-10-07 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Novel spiroheterocycles useful as reversible inhibitors of cysteine proteases
US6420364B1 (en) * 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
WO2001020051A1 (en) * 1999-09-16 2001-03-22 Nkk Corporation Steel thin plate having high strength and method for production thereof
WO2001023632A1 (en) * 1999-09-28 2001-04-05 Nkk Corporation Hot-rolled steel sheet having high tensile strength and method for production thereof
KR100430987B1 (en) * 1999-09-29 2004-05-12 제이에프이 엔지니어링 가부시키가이샤 Steel sheet and method therefor
WO2001023624A1 (en) * 1999-09-29 2001-04-05 Nkk Corporation Sheet steel and method for producing sheet steel
CN1331183A (en) 2000-06-28 2002-01-16 上海博德基因开发有限公司 Polypeptide-human DNA repair protein 10.23 and polynucleotide for coding it

Also Published As

Publication number Publication date
US20030216383A1 (en) 2003-11-20
CN1471511A (en) 2004-01-28
BR0113740A (en) 2003-06-24
CN1303067C (en) 2007-03-07
YU17003A (en) 2006-03-03
US20040006078A1 (en) 2004-01-08
US6420364B1 (en) 2002-07-16
WO2002020485A1 (en) 2002-03-14
CA2417177A1 (en) 2002-03-14
EE200300093A (en) 2005-02-15
AU2001245694A1 (en) 2002-03-22
JP2004508356A (en) 2004-03-18
EA005203B1 (en) 2004-12-30
US7279472B2 (en) 2007-10-09
US6858623B2 (en) 2005-02-22
KR20030051644A (en) 2003-06-25
EP1322613A1 (en) 2003-07-02
US20030225270A1 (en) 2003-12-04
US6787540B2 (en) 2004-09-07
PL361038A1 (en) 2004-09-20
US6756372B2 (en) 2004-06-29
US6720319B2 (en) 2004-04-13
NO20031065L (en) 2003-03-07
US7265132B2 (en) 2007-09-04
BG107585A (en) 2003-11-28
HK1060565A1 (en) 2004-08-13
NO20031065D0 (en) 2003-03-07
US20030225271A1 (en) 2003-12-04
HUP0303934A2 (en) 2004-04-28
HRP20030163A2 (en) 2005-04-30
US20020058809A1 (en) 2002-05-16
MXPA03001947A (en) 2003-06-24
US6525052B2 (en) 2003-02-25
UA73378C2 (en) 2005-07-15
US20020137932A1 (en) 2002-09-26
SK2862003A3 (en) 2003-08-05
EA200300348A1 (en) 2003-08-28
US7056915B2 (en) 2006-06-06
US20030232826A1 (en) 2003-12-18
US6982272B2 (en) 2006-01-03
US20050032772A1 (en) 2005-02-10
US20050032792A1 (en) 2005-02-10
IL154080A0 (en) 2003-07-31
CZ2003603A3 (en) 2003-06-18
ZA200301032B (en) 2004-04-21

Similar Documents

Publication Publication Date Title
US6525052B2 (en) Compounds useful as reversible inhibitors of cysteine proteases
AU782246B2 (en) Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases
JP4309251B2 (en) A novel nitrile effective as a reversible inhibitor of cysteine protease
EP1434769A2 (en) Compounds useful as reversible inhibitors of cysteine proteases

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)